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Abstract 
 
 
Introduction of antimicrobial chemotherapy in the 20th century was an invaluable 
achievement of medicine. The efficacy of currently available antibiotics, however, is 
decreasing due to the global spread of antibiotic-resistant strains of pathogens. 
Especially Gram-negative bacteria pose a serious threat as there are fewer possible 
treatment options. The innovation gap in antibiotics discovery severely reduced the 
number of novel antibacterial drug candidates. 
 
Penicillin-binding proteins (PBPs) are enzymes responsible for the final steps of cell 
wall synthesis in bacteria. Due to their uniqueness, essentiality and interspecific 
conservation, they are important drug targets, yet there is only one class of compounds 
in clinical use that can directly inhibit them. As the need for new antibiotics increases, 
alternative approaches to penicillin-binding proteins’ inhibition should be scrutinised.  
 
The aim of this thesis was to investigate new biochemical methods to monitor 
enzymatic activities of class A penicillin-binding proteins, in particular E. coli PBP1b, 
and their amenability to the high-throughput drug screening. Two distinct assays were 
developed and optimised for target-based drug screening in a high-throughput 
manner. The assays complement each other as they are designed to measure two 
different activities of the same enzyme. The methods rely on the use of tailored 
substrates in the presence of the natural PBP1b cofactor, lipoprotein B. 
 
The assays were tested against chemical libraries of over 150,000 diverse compounds 
yielding over 2,700 primary hits. The post-screening selection process has decreased 
the number of compounds, and now 11 of them are available for further investigation. 
The assay development process provided additional insight into the PBP1b biology 
and natural products inhibiting its activity. Supplementary applications were found for 
the bespoke substrate used in the assay. The methods presented in the thesis can 
become the foundation of a cell wall inhibitors discovery platform and identify new 
chemical matter for medicinal chemistry.  
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CHAPTER 1: Introduction 
 
 
 
1.1 Antimicrobial resistance 
 
No other class of medicines has saved more lives than antibiotics (Blaskovich et al., 
2017). Salvarsan produced in the early twentieth century to treat syphilis and a range 
of sulphonamides developed in the 1930s were the first single-agent products used 
for targeted treatment of bacterial infections. In an age when medicine was often 
defenceless against pathogenic microorganisms, these drugs were considered 
‘wonder-bullets’. But it was Sir Alexander Fleming’s discovery of penicillin that 
initiated the golden age of antibiotics development (Museum of the History of 
Science, 2016). In the next 30 years, 11 classes of antibiotics were introduced giving 
physicians a plentiful weaponry to combat life-threatening infections. Plummeting 
morbidity and mortality rates led to the belief that the war against pathogenic 
microorganisms can be deemed accomplished and won. The 1960s saw a steep 
decline in research and development of new antimicrobial agents and the golden age 
of antibiotics discovery was followed by a 40-years long innovation gap (Walsh & 
Wencewicz, 2014). 
 
In his 1945 Nobel Prize lecture Fleming accurately predicted: “The time may come 
when penicillin can be bought by anyone in the shops. Then there is the danger that 
the ignorant man may easily underdose himself and by exposing his microbes to 
non-lethal quantities of the drug make them resistant”. He was aware that the 
emergence of strains resistant to any antibiotic is more of a question of when rather 
than if. Resistance to antibiotics, although it is a natural process, is further 
accelerated by misuse and overuse of these drugs. Indeed, under selective pressure of 
antibiotics, an emergence of resistance is inevitable (see table 1.1). The rapid spread 
of resistant bacteria and in particular the rise of multi-drug resistant (MDR) strains 
has, in recent years, become one of the major challenges that medicine has to face 
(Lewis, 2013).  
	 2 
O’Neil report estimates that about 700,000 people die every year from resistant 
strains of bacteria, viruses and parasites yet the real number is likely to be higher. 
Worryingly, according to the long term prognosis, the annual global death toll might 
reach 10 million by 2050. If left unaddressed, the problem of multi-drug resistance 
might cause a cumulative cost of $100 trillion to the global economy (O’Neill, 2015). 
Gram-positive pathogens like vancomycin-resistant enterococci (VRE) and 
methicillin-resistant Staphylococcus aureus (MRSA) have received attention in the 
recent years, and new treatment strategies have been proposed. The Gram-negative 
infectious bacteria, especially Klebsiella pneumoniae, Acinetobacter baumanii, 
Pseudomonas aeruginosa and Enterobacter species consistently prove to be more 
challenging to tackle (Walsh & Wencewicz, 2014). The 2013 Center for Disease 
Control and Prevention (CDC) report classify them as urgent or serious threats.  
 
 
1.1.1 Mechanisms of antibiotics action and antimicrobial resistance  
 
Antibiotics are designed to inhibit cellular processes absent in eukaryotic cells or take 
advantage of fine structural differences between enzymatic machineries of bacteria 
and humans. For instance, penicillins inhibit synthesis of peptidoglycan, a bacteria-
exclusive cell wall component while chloramphenicol stops protein synthesis by 
binding to the 23s ribosomal RNA present only in bacteria. Generally, antibiotics 
exhibit following mechanisms of action: 
• Inhibition of cell wall synthesis, 
• Inhibition of protein synthesis, 
• Inhibition of nucleic acid synthesis, 
• Alteration of cell membranes, 
• Antimetabolite activity (Kochanski et al., 2010).  
 
As already mentioned, selective pressure can render bacteria resistant to antibiotics. 
Mechanistically, this can be achieved in several ways: 
• Prevention of antibiotic access to the target by reduced permeability or 
increased efflux, 
• Mutation of the target protein, 
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• Chemical modification of the target, 
• Antibiotic inactivation by hydrolysis or addition of a chemical group (Dever 
& Dermody, 1991; Blair et al., 2015). 
 
Table 1.1 summarises the history of antibiotic development and emergence of 
resistance. Notably, clinical resistance to some antibiotics was reported almost 
instantaneously after their deployment. Since most of the antibiotics were derived 
from naturally occurring, antibiotic-producing microorganisms, resistance 
mechanisms can be present in bacterial communities for millions of years (Blair et al., 
2015). Understanding of resistance mechanisms, their regulation and interspecific 
transfer might help to circumvent the loss of antibiotic efficacy in the future. 
 
 
Antibiotic Molecular target Year deployed Clinical resistance 
observed 
Sulfonamides Folic acid synthesis 1930s 1940s 
Penicillin Cell wall 1943 1946 
Streptomycin Protein synthesis 1943 1959 
Chloramphenicol Protein synthesis 1947 1959 
Tetracycline Protein synthesis 1948 1953 
Erythromycin Protein synthesis 1952 1988 
Vancomycin Cell wall 1956 1988 
Methicillin Cell wall 1960 1961 
Ampicillin Cell wall 1960 1973 
Cephalosporins Cell wall 1960s Late 1960s 
Nalidixic acid DNA replication 1962 1962 
Fluoroquinolones DNA replication 1980s 1980s 
Linezolid Protein synthesis 1999 1999 
Daptomycin Cell membrane 2003 2003 
Retapamulin Protein synthesis 2007 2007 
Fidaxomicin RNA synthesis 2011 2011 
Bedaquiline ATP synthase 2013 ? 
 
 
  
Table 1.1: Discovery of antibiotics and emergence of resistance strains. Modified from Walsh and 
Wencewicz, 2014 
 
 
1.2 Bacterial envelopes 
 
All living organisms are made of cells; the fundamental building units separated from 
one another with a clear boundary of a cell membrane. Essentially, anything found 
outside biological membranes is non-living. Unlike cells of higher organisms that 
often benefit from a homeostatic environment, bacteria must endure chemically 
	 4 
dynamic and generally hostile conditions. To survive, bacterial cells have developed 
complex cell envelopes that protect their content yet allow a selective exchange of 
chemicals with the environment (Alberts et al., 2015). 
 
In 1884 Christian Gram developed a staining procedure allowing to categorise 
almost all bacteria into two large groups, depending on their colour upon treatment 
with the dye (Kaplan & Kaplan, 1933; Bartholomew & Mittwer, 1952). Scientific 
progress in the 20th century led to the explanation of that phenomenon. With the aid 
of electron microscopy, it was found that the envelope of Gram-negative bacteria is 
made of two layers of a membrane with a layer of cell wall between them. The two 
membranes enclose a spherical compartment called the periplasm. Gram-positive 
bacteria lack the outer membrane, but their cell wall is usually many times thicker 
than in Gram-negative species (Figure 1.1) (Glauert & Thornley, 1969; Osborn & 
Rick, 1979). 
 
Apart from membranes and a layer of cell wall, bacterial envelopes contain multiple 
proteins, membrane-bound or dissolved in the periplasm (Heppel, 1967; Dramsi et 
al., 2008). Gram-positive envelopes are enriched with teichoic acids, anionic 
polymers threading through the cell wall. Gram-negative outer membrane may also 
be decorated with a layer of lipopolysaccharides (Shilavy et al., 2010). 
 
 
 
Figure 1.1: Schematic composition of Gram-negative (A) and Gram-positive (B) cell envelopes.  
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1.2.1 Cell wall composition and properties 
 
The common constituent of the cell envelopes of virtually all bacteria species, 
excluding Mycoplasma and Planctomyces, is a cell wall containing peptidoglycan 
(murein). The primary function of bacterial sacculi is to protect the cell from effects 
of the osmotic pressure. Peptidoglycan also poses a structural scaffold, tethering 
proteins and teichoic acid. Moreover, peptidoglycan maintains defined bacteria 
shape and is directly involved in its growth and division. Inhibition of cell wall 
biosynthesis leads to cell cycle arrest at the stage of division, morphology alterations, 
and often cell lysis. In Gram-negative bacteria, murein also serves as a base for the 
outer membrane (Scheffers & Pinho, 2005; Vollmer et al., 2005; Yao et al., 2013).  
 
Bacterial cell wall has unique, bacteria-specific structure and composition. 
Peptidoglycan is made of linear glycan strands of alternately arranged residues of N-
acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc), linked by β1-4 
bonds (Desmarais et al., 2013). The strands of glycan are created by oligomerisation 
of monomeric units of GlcNAc-MurNAc-peptide complexes attached to the lipid 
carrier (undecaprenyl diphosphate) known as lipid II that are tethered to the plasma 
membrane. This process is performed by membrane-bound enzymes presenting 
transglycosylation activity. Glycan strands can be subjected to secondary 
modifications such as N-deacetylation, O-acetylation and N-glycolylation (van 
Heijenoort, 2001; Vollmer et al., 2005). 
 
The length of separate glycan strands may vary a great deal both interspecific and 
within species. Depending on the research method and studied species, glycan 
strands were found to be between 3 and 250 disaccharide units long, with the 
average range in Gram-negative bacteria between 20 and 40 units (Tuomanen et al., 
1989; Quintela et al., 1995; Vollmer et al., 2008). For improved rigidity and 
integrity, glycan strands are crosslinked by short stem peptides. The linking peptide 
attached to GlcNAc-MurNAc disaccharide has a distinct composition, usually L-
Ala-D-Glu-[L-Lys/A2pm (2,6-diaminopimelic acid)]-D-Ala-D-Ala and is bound 
through the D-lactoyl group of MurNAc residue. Cross-linking of two parallel 
glycan strands occurs between the second or third amino acid of one glycan unit and 
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D-Ala residue at position 4 of the other after hydrolysis of the last peptide bond in 
the latter (Rogers et al., 1980; Sauvage et al., 2008). Due to the different activities of 
Mur ligases and potential post-synthesis modifications, cross-linking stem peptides 
composition is also a subject of variations (Vollmer, 2008). 
 
Bacterial sacculi need to demonstrate some paradoxical biophysical properties. Dense 
cross-linking enables bacteria to withstand osmotic pressure up to 25 atmospheres 
but on the other hand, cell wall remains flexible, allowing for shrinking and 
expansion. Due to presence of relatively large pores, peptidoglycan is also permeable 
for diffusing molecules (Vollmer et al., 2008).  
 
The thickness of the sacculus varies depending on growth phase and conditions, 
bacteria species and technique applied for measurements. In Gram-negative bacteria 
such as Escherichia coli and Pseudomonas aeruginosa, peptidoglycan layer is 6.35±0.53 
nm and 2.41±0.54 nm thick, respectively. The thickness of it in selected Gram-
positive bacteria (Staphylococcus aureus, Bacillus subtilis, Streptococcus gordonii, 
Enterococcus gallinarum) was determined to be between 15 and 30 nm. E. coli cells 
subjected to changes of osmotic pressure could shrink by 33% and swell by 23%, as 
measured by cell surface area (Matias et al., 2003; Matias & Beveridge, 2006; 
Baldwin et al., 1988). 
 
 Bacterial sacculi were proven to be more flexible in the direction of the long cell axis 
than in the direction of the perpendicular one (Yao et al., 1999). In spite of 
differences in thickness, peptidoglycan pores in Gram-positive and Gram-negative 
sizes were determined to be of similar average sizes. Calculations based on the pores’ 
radius suggest that globular, uncharged proteins of 22-24 kDa molecular weight 
should be able to penetrate through the peptidoglycan in relaxed state. Cell wall 
stretching should theoretically make pores accessible for 50 kDa or bigger globular 
proteins (Demchick & Koch, 1996, Vollmer et al., 2008). A three-dimensional 
peptidoglycan model basing on a NMR-resolved structure of lipid II estimates the 
pores in a continuous cell wall to have a diameter of 70 Å which allows 
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accommodating, for example, an outer membrane channel protein, TolC (Meroueh 
et al., 2006). 
 
 
1.2.2 Peptidoglycan intermediates biosynthesis 
 
The biosynthesis of peptidoglycan is a multi-step process taking place both in cytosol 
and periplasm. Initial steps consist of the synthesis of soluble nucleotide precursors 
of N-acetyl muramic acid and N-acetylglucosamine coupled with pentapeptides (see 
Figure 1.2). The process can be divided into four major stages taking place in the 
cytoplasm: 1: formation of UDP-GlcNAc from fructose-6-phosphate, 2: formation 
of UDP-MurNAc from UDP-GlcNAc, 3: synthesis of the peptide stem leading to 
UDP-MurNAc-pentapeptide and 4: formation of D-alanyl-D-alanine (Bugg & 
Walsh, 1992). 
 
UDP-GlcNAc obtained due to Glm enzymes activity can be utilised for synthesis of 
UDP-MurNAc. This part of the pathway is performed by MurA and MurB 
proteins. The activity of the former is a rare biochemical process: it transfers the 
enolpyruvate moiety of phosphoenolpyruvate (PEP) to the 3’-hydroxyl of UDP-
GlcNAc releasing inorganic phosphate (Pi). Mur B catalyses reduction of UDP-
GlcNAc-enolpyruvate to its lactyl ether form. Both, Mur A and Mur B were studied 
as potential targets for antimicrobials. Numerous inhibitors were found in screening 
studies but their application seemed questionable due to low target specificity 
(Barreteau et al., 2008). 
 
Addition of the peptide moiety is performed by the group of Mur ligases which are 
responsible for stepwise addition of L-alanine, D-glutamic acid, meso-
diaminopimelic acid or L-lysine, and D-alanyl-D-alanine. The Mur ligases are 
capable of formation of an amide or peptide bonds with simultaneous hydrolysis of 
ATP to ADP and Pi (Mengin-Lecreulx et al., 1982). These enzymes share several 
common characteristics: their activity depends on presence of a divalent cation, Mg2+ 
or Mn2+, they have the same reaction mechanism, their ATP-binding consensus 
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sequence is invariable, they have highly similar structure, as shown by crystallography 
studies (Kouidmi et al., 2014). 
 
When the phospho-MurNAc-pentapeptide complex reaches the cell membrane, 
MraY transferase binds it with membrane acceptor undecaprenyl phosphate, yielding 
so-called lipid I. After coupling lipid I with GlcNAc moiety, carried out by MurG 
transferase, the complex of undecaprenyl-pyrophosphoryl-MurNAc-pentapeptide-
GlcNAc (lipid II) is ready for incorporation into growing peptidoglycan. To achieve 
that, lipid II must be first passed across the plasma membrane by, debatedly, either 
MurJ, FtsW or AmJ (Ruiz, 2015; Meeske et al., 2015).  
 
 
Figure 1.2: Cytoplasmic steps of peptidoglycan synthesis. Adapted from an unpublished figure by Dr 
Vita Godec. Formation of UDP-GlcNAc from fructose-6-phosphate was omitted for clarity. 
 
 
1.2.3 Cell wall assembly 
 
In Gram-negative bacteria, final steps of cell wall assembly take place in the 
periplasm (see Figure 1.3). At first GlcNAc-MurNAc-pentapeptide units are used to 
elongate peptidoglycan by transglycosylation-capable enzymes (TG-ases). This 
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process is carried out by either monofunctional transglycosylases or class A, 
bifunctional penicillin-binding proteins (PBPs). Transglycosylases of family 51 
(GT51) are bound to the cell membrane through the presence of the transmembrane 
domain. A crystal structure of Staphylococcus aureus PBP2 suggested that the growing 
peptidoglycan chain acts as a donor while a monomeric, membrane-embedded lipid 
II is an acceptor (Lovering et al., 2007). The activity of most characterised 
peptidoglycan transglycosylases was dependent on the presence of divalent metal ions 
(Schwartz et al. 2002; Zawadzka-Skomiał et al., 2006). The process leads to release 
of the undecaprenyl (C55) tail from the donor that can be then recycled by MraY. 
 
In the last step of cell was assembly, peptide cross-linking is made between separate 
glycan strands due to catalytic activity of class A or B penicillin-binding proteins 
(Sauvage et al., 2008). The process is known as transpeptidation (TP). The reaction 
follows a three-step mechanisms: 1- formation of a noncovalent complex between 
the enzyme and a pentapeptide of peptidoglycan, 2- formation of an acyl-enzyme 
intermediate by the attack of the active site serine on the carbonyl group of the D-
Ala-D-Ala peptide bond leading to the release of the C-terminal D-Ala, 3- 
formation of the cross-link with another peptidoglycan stem peptide. The final step 
may also consist of hydrolysis that leads to shortening of the stem peptide but no 
cross link is formed (carboxypeptidation).  
 
In bifunctional PBPs, the last two steps of peptidoglycan synthesis can co-occur. 
Moreover, transglycosylation can occur while the transpeptidation domain is 
inhibited or dysfunctional. Transpeptidation domain, instead, remains inactive when 
transglycosylation is inhibited (Terrak et al., 1999; Born et al., 2006). 
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Figure 1.3: Final steps of peptidoglycan synthesis. Adapted from an unpublished figure by Dr Vita 
Godec. 
 
 
1.3 Peptidoglycan synthases: penicillin-binding proteins and transglycosylases 
 
As mentioned above, the two final steps of cell wall synthesis are catalysed by 
penicillin-binding proteins and monofunctional transglycosylases. PBPs are divided 
into two major classes, depending on their molecular weight: high molecular mass 
(HMM, >60kDa) and low molecular mass (LMM, <60 kDa). HMM PBPs belong 
to either class A, consisting of bifunctional enzymes endowed with both 
transglycosylase and peptidase catalytic function, or class B that lacks the TG 
domain. LMM, or class C PBPs, are considered to be involved in cell separation, cell 
wall maturation and recycling. They exhibit carboxypeptidase or endopeptidase 
activities, therefore, are not involved in de novo synthesis of peptidoglycan. The focus 
of this work is laid upon class A, bifunctional PBPs, in particular, E. coli PBP1b that 
serves as a model protein for assay development and a molecular target for chemical 
library screening. 
 
 
1.3.1 Cell wall related enzymes as therapeutic targets 
 
 
1.3.1.1 Mur ligases inhibitors 
 
In E. coli enzymes involved in synthesis of peptidoglycan, intermediates need to 
provide substrate for cell wall synthesis at both divisome and elongasome. As 
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described in paragraph 1.2.2, Mur-family enzymes together with MraY synthesise 
lipid II. This pathway is exclusive to prokaryotes and thus considered a promising 
target for antibiotics. The proteins are well-studied and were used in inhibitor 
development projects, yielding many high-affinity molecules. Unfortunately, many 
of them lack antimicrobial properties in vivo or demonstrate insufficient specificity 
(den Blaauwen et al., 2014). 
 
A notable example of an antibiotic in clinical use that acts on cell wall intermediates 
synthesis is fosfomycin. Extracted from Streptomyces bacteria in the 1960s, 
fosfomycin is a broad spectrum antibiotic used nowadays mostly in treatment of 
urinary tract infections. Being a phosphoenolpyruvate analogue, fosfomycin inhibits 
MurA and, in effect, formation of N-Acetylmuramic acid. Some bacteria, however, 
like Mycobacterium tuberculosis or Chlamydia trachomatis are insusceptible to 
fosfomycin. Additionally, emergence of resistance mechanisms has been described. 
(Michalopoulos et al., 2011; Hrast et al., 2014) 
 
 
1.3.1.2 Transglycosylases as antibiotic targets 
 
GT51 family enzymes, whether monofunctional or coupled with transpeptidases in 
class A PBPs, share some invariant amino acids forming characteristic structural 
motifs surrounding the catalytic site. Figure 1.4 shows partial sequence alignment of 
10 selected bacterial transglycosylases. Motifs surrounding active site glutamate form 
a jaw and a head subdomains responsible for binding of the reaction acceptor, 
monomeric lipid II. High level of conservation and uniqueness of GT51 proteins 
make them viable, yet still underexploited antibiotics targets (van Heijenoort, 2001). 
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Figure 1.4: Partial sequence alignment of E. coli PBP1b and nine selected GT51 enzymes. Rectangles 
indicate conserved motifs of the ‘jaw’ (blue rectangles) and ‘head’ (red rectangle) subdomains. Active 
site position highlighted in yellow. 
 
The only natural product antibiotics showed to directly bind to transglycosylases 
active sites are moenomycins, represented here by moenomycin A (Figure 1.5 A). It 
is a highly potent inhibitor of some Gram-positive bacteria but Gram-negative 
species are much less sensitive due to the presence of the outer membrane. 
Moenomycin was thought to compete for the binding site with lipid II but closer 
analysis revealed that it mimics dimerised lipid II, the first product of 
transglycosylation (Ritzeler et al., 1997). Cocrystallisation with GT51 proteins 
showed that moenomycin interacts with residues critical for their catalytic activity.  
 
Although the antibiotic has been extensively used as a growth promoter in farming, 
incidence of moenomycin resistance remains low. Moenomycin is not suitable for 
use in humans due to its poor pharmacokinetic properties, mostly low bioavailability 
and long serum half-life (van Heijenoort, 2001; Ostash & Walker, 2010; Galley et 
al., 2014). Moenomycin A and lipid II served as blueprints for development of 
synthetic transglycosylation inhibitors (Figure 1.5 B and C). Recently Zuegg and 
colleagues developed a library of disaccharide molecules mimicking the moenomycin 
pharmacophore. Compounds showed good antibacterial properties but their activity 
was diminished in the presence of serum. In the same study, monosaccharide 
compounds were tested. They showed good potency against Gram-positive species 
and bactericidal activity in a mouse infection model (Zuegg et al., 2015). In another 
study, a library of 250 disaccharides was synthesised, yet only two of bactericidal 
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compounds were demonstrated to bind the S. aureus MGT specifically (Mesleh et 
al., 2015). 
 
Figure 1.5: Skeletal formula of moenomycin A (A) and synthetic TG inhibitors based on mono- or 
disaccharide scaffolds. Figure B shows examples of compounds developed by Zeugg et al. and figure 
C shows compounds from the Mesleh et al., 2015 study. 
 
Over the decades, some biochemical assays have been developed to study 
transglycosylation in vitro (Terrak et al., 1999; Schwartz et al., 2002; Terrak et al., 
2008; Dumbre et al., 2012). Due to difficulties in obtaining high amounts of lipid II, 
they were used as basic research tools or in low-throughput drug testing. In the last 
ten years, however, due to an increased interest in transglycosylases and 
advancements in peptidoglycan intermediates synthesis, high-throughput drug 
screening for TG inhibitors became more feasible.  
 
Huang and colleagues in their 2013 study demonstrated the use of doubly modified 
lipid II analogue in development of a high-throughput screening assay. Addition of a 
fluorescent coumarin group to the position three of the stem pentapeptide and a 
dabsyl moiety, serving as its molecular quencher, to the lipid tail, allowed them to 
develop a functional FRET assay. As the transglycosylation occurred, the quencher 
was released leading to the increase of coumarin fluorescence. The screen of 120,000 
compounds revealed 25 primary hits (Huang et al. 2013) including compound 4 
shown in figure 1.6. This was the first reported use of a continuous functional 
transglycosylation assay in high-throughput drug discovery. Another example is 
described in chapters 4 and 5 of this thesis.  
A
B
C
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Figure 1.6: Examples of small-molecule transglycosylation inhibitors. Discovery of shown 
compounds was described in following publications: 1-3: Cheng et al., 2008; 4: Huang et al., 2013; 5-
8: Cheng et al., 2010; 9: Gampe et al., 2013; 10: Wang et al., 2014; 11: Derouaux et al., 2011; 12: 
Sosič et al., 2015. Figure adapted from Sauvage & Terrak, 2016. 
 
Other studies reported identification of transglycosylation inhibitors within chemical 
libraries with the aid of methods based on moenomycin displacement (Cheng et al., 
2010; Gampe et al., 2013). Fluorescently labelled moenomycin analogues were 
synthesised to probe binding sites of GT51 enzymes used in experiments. Tested 
compounds compete for the binding site of the enzyme and moenomycin 
displacement can be measured by fluorescence anisotropy. Described protocols do 
not depend on lipid II and they are solely ligand binding rather than functional 
assays. Compounds 5-9 presented in figure 1.6 are examples of hits identified in 
screening campaign using moenomycin competition methods. Despite continuous 
efforts, clinically applicable transglycosylation inhibitors are still to be found.  
 
 
1.3.1.3 Transpeptidases as antibiotic targets 
 
Penicillin-binding domains of HMM and LMM PBPs proteins do not have high 
sequence homology; nevertheless, their overall architecture is highly similar. It 
includes two subdomains. One is composed of three α-helices and a five-stranded β-
sheet while the other is all helical (Figure 1.7). The active site serine residue is 
1 2 3 4
5 6 7 8
9 10 11 12
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positioned at the beginning of a highly conserved motif SXXK. Another two 
conserved motifs and a glycine residue surround the catalytic site (Sauvage et al., 
2008). 
 
 
 
Figure 1.7: Transpeptidation domain of E. coli PBP1b in apo state. General architecture (A) and 
vicinity of the catalytic site (B). Conserved motifs were highlighted in green and the active site serine 
510 was coloured red. Crystal structure by Sung et al. (PDB ID: 3VMA). 
 
Transpeptidases carry out the final step of peptidoglycan synthesis following a 
mechanism described in paragraph 1.2.3. Their activity can be inhibited by β-
lactams due to their structural resemblance to D-alanine-D-alanyl moiety of lipid II 
stem pentapeptide. The core of β-lactams, a four-membered ring is essentially 
peptidomimetic (see Figure 1.8, top row). Acylation of the active site serine of PBPs 
by β-lactams prevents the enzyme from performing its regular catalytic function. The 
reaction between antibiotics and the enzyme is reversible, but usually deacylation rate 
is much slower and the enzyme remains inactive. The lethal effect for the bacterium 
results from the loss of the cell wall integrity (Waxman & Strominger, 1983). 
According to the widely accepted model, treatment with β-lactams induces 
imbalance between peptidoglycan synthases and hydrolases. Decreased or inhibited 
activity of transpeptidases combined with ongoing peptidoglycan hydrolysis cause 
cell wall damage leading to cell lysis. 
 
Beta lactams are arguably the most successful antibiotics ever used in clinical 
practice. They normally exhibit a broad spectrum of antibacterial activity yet their 
affinities to certain PBPs vary due to fine structural differences. Their extensive use, 
A B
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however, led to selection of insusceptible strains of bacteria that have adapted variety 
of resistance mechanisms including acquisition of β-lactamases and alterations of 
target proteins. 
 
To counteract decreasing efficacy of β-lactams, alternative solutions are being 
developed (see Figure 1.8, bottom row). Non-β-lactams PBP inhibitors include 
boronic acid derivatives (Zervosen et al., 2012a). Additionally, cyclic boronates were 
demonstrated to act as efficient β-lactamases inhibitors and some derivatives can also 
inhibit nonessential PBPs (Brem et al., 2016). Discovered in 1986, lactivicin was the 
first non-β-lactam inhibitor of penicillin-binding proteins. Lactivicin, just like β-
lactam antibiotic binds covalently to the active site serine of PBPs. It is potent 
against a wide range of both Gram-positive and Gram-negative bacteria yet due to 
relatively high toxicity it requires further chemical modifications (Zervosen et al., 
2012b).  
 
 
 
Figure 1.8: Examples of transpeptidation inhibitors. The top row shows four major classes of β-
lactams. Structures of other inhibitors obtained from the following publications: Lactivicin- Sauvage 
& Terrak, 2016; Boronic acid- Zervosen et al., 2012; Cyclic boronate- Bren et al., 2016; Oxadiazole- 
O’Daniel et al., 2014.  
 
Additionally, small-molecule, noncovalent inhibitors of PBPs were recently reported 
to be found with the aid of in silico and high-throughput screening. O’Daniel and 
colleagues screened 1.2 million molecules deposited in the ZINC database by virtual 
docking into the crystal structure of S. aureus PBP2a. Their study led to discovery of 
oxadiazoles that proved to be active against methicillin-resistant S. aureus and a panel 
of Gram-positive bacteria (O’Daniel et al., 2014). In another study, a fluorescent 
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derivative of penicillin, bocillin FL, was used to develop a fluorescence anisotropy-
based ligand binding assay. Over 50,000 compounds were tested for their affinity to 
Neisseria gonorrhoea PBP2. From the initial 580 identified perturbants, 18 were 
tested for anti-gonococcal properties. The study showed 7 compounds to be active 
against β-lactams resistant N. gonorrhoea (Fedarovich et al., 2012). 
 
 
1.3.1.4 Inhibition of cell wall synthesis by lipid II binding substances 
 
β-lactams, as most of the nature-derived antibiotics, are produced by 
microorganisms to outcompete other species in their environment. Combating 
competitors by disrupting their cellular envelope is a popular strategy in the Bacteria 
domain. Direct suppression of peptidoglycan synthases, however, is not the only way 
of weakening bacterial cell walls. Another successful approach relies on binding and 
sequestering the ultimate cell wall intermediate, lipid II. This mechanism has been 
adapted not only by bacteria. It is thought that lipid II, structurally conserved yet 
exclusive to bacteria, poses a prominent target for antibiotics (Oppedijk et al., 2016). 
 
Lipid II-binding properties are exhibited by molecules belonging to several distinct 
classes, i.e. glycopeptides, lantibiotics, depsipeptides and defensins that are 
structurally diverse. Their action is not only limited to sole sequestration of the cell 
wall substrate. Additional effects may include pore forming and disruption of the cell 
membrane or interference with the multi-protein complexes involved in cell wall 
synthesis (Müller et al., 2017) 
 
Clinical examples of lipid II-binding antibiotics are vancomycin and teicoplanin. 
These natural products selectively bind D-Ala-D-Ala terminus of the stem 
pentapeptide. Although highly potent against Gram-positive pathogens, they are 
considered last resort therapeutic choices due to their adverse effects. Teicoplanin 
was shown to be more potent than vancomycin which was attributed to higher 
lipophilicity. This observation inspired the design of semi-synthetic glycopeptide 
antibiotics: telavancin, dalbavancin and oritavancin that were approved for human 
use in the recent years. 
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Another class, lantibitoics, are characterised by the presence of the polycyclic amino 
acid lanthionine. Lantibiotics primarily bind lipid II by caging its pyrophosphate 
moiety. Mechanistically, they disrupt Gram-positive envelopes either by sole lipid II 
binding or have an additional pore-forming properties (Müller et al., 2017). The 
former mechanism is adapted by actagardines, in particular deoxyactagardine B, that 
has passed its early development testing and reached phase I clinical trials (data from 
2013), (Butler et al., 2013). The latter mechanism is exhibited by nisin. Lipid II 
binding and the subsequent structural rearrangement leads to forming a pore in the 
cell membrane (Breukink & de Kruijff, 2006). Although potent antimicrobial agent, 
nisin has not found use in clinical practice and is used as a preservative in dairy 
industry. 
 
A common downside of the most of lipid II-binding natural products is their lack or 
low potency against Gram-negative pathogens. There are, however, exceptions to 
this rule. Defensins are host defence peptides found in higher organisms from plants 
to vertebrates. It is known that 17 defensins expressed in various human tissues 
exhibit activity against Gram-positive and –negative bacteria as well as 
Mycobacteria, viruses and fungi (Jarczak et al., 2013). Human neutrophil defensin I 
and β-defensin 3, that was shown to inhibit S. aureus and Burkholderia cepacia 
growth, are thought to interact with lipid II. Additionally, plectasin and eurocin, two 
fungal defensins, were demonstrated to have the same property (Oppedijk et al., 
2016). Medical applications of antimicrobial peptides might be limited, mostly due 
to their susceptibility to proteolysis. Nevertheless, synthetic analogues of defensisns 
are in trials for topical use against skin and mucous infections (Jarczak et al., 2013). 
 
 
1.3.2 E. coli PBP1b 
 
In Escherichia coli two major peptidoglycan synthases are class A penicillin-binding 
proteins, PBP1a and PBP1b. Despite their close homology, two enzymes seem to 
play distinct roles in cell cycle and morphogenesis. PBP1a is thought to be involved 
predominantly in cell elongation while PBP1b is responsible mostly for cell division 
(Typas et al., 2012). Although, when isolated, both proteins on their own 
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demonstrate activity in vitro, inside the cell, they participate in formation of 
functional protein complexes (Szwedziak & Löwe, 2013). As the particular focus of 
this thesis is laid upon PBP1b, this protein will be characterised in the next section. 
 
 
1.3.2.1 E. coli PBP1b architecture 
 
E. coli PBP1b is encoded by the mrcB gene, situated in locus b0149. It encodes a 
polypeptide of 844 amino acid residues (isoform alpha), having a molecular weight of 
94.3 kDa. Another isoform, gamma, lacks 45 N-terminal residues. Two other 
isoforms, beta and delta, are thought to be artifactual truncations of alpha and 
gamma, respectively. Existing crystal structures usually show the enzyme without 40-
50 residues at both ends, therefore, are more representative for the gamma isoform.  
 
The protein consists of 5 domains: cytoplasmic tail and a transmembrane (TM) 
element at the N-terminus, UvrB 2 homolog domain (UB2H), transglycosylation 
(TG) domain, a linker region connecting two catalytic domains and, towards the C-
terminus, transpeptidation (TP) domain (Sung et al., 2009; King et al., 2016). Figure 
1.9 depicts tertiary structure (A) and spatial arrangement of domains (B).  
 
 
 
Figure 1.9: Architecture of E. coli PBP1b. A crystal structure (PDB ID: 3VMA) by Sung et al. was 
used to illustrate tertiary structure (A) and extent of particular domains (B). On figure A helices were 
coloured yellow, strands were coloured blue and coils were coloured red. Moenomycin A visible on 
both images as a skeletal model. Images generated with UCSF Chimera. 
TP	domain
UB2H	domain
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TG	domain
TM	domain
A B
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1.3.2.2 Cellular localisation and regulation of E. coli PBP1b 
 
PBP1b localises at cell poles, along the cylindrical part of the cell but is enriched at 
the cell septum. Septal localisation of the protein is dependent on presence of PBP3 
and is particularly pronounced during cell division (Bertsche et al., 2006; Derouaux et 
al., 2008; King et al., 2014). 
 
The enzyme was shown to interact with PBP3, FtsN, MipA, LpoB and CpoB. It 
can also form homodimers (Vollmer et al., 1999; Typas et al., 2012; Bertsche et al., 
2006; Derouaux et al., 2008; Gray et al., 2015). PBP3, a monofunctional 
transpeptidase, tethers PBP1b in the divisome complex, promoting septal 
localisation. Dimer formation, presence of TolA, interaction with FtsN and LpoB 
stimulate catalytic activities of PBP1b. LpoB, a lipoprotein anchored in the outer 
membrane, enhances transglycosylation rate and cross-linking frequency but it also 
promotes synthesis of shorter peptidoglycan strands. CpoB partially reduces 
stimulatory effect of lipoprotein B and is thought to coordinate peptidoglycan 
synthesis with cell constriction during the division (Gray et al., 2015). Discovery of 
PBP1b interaction with these two cofactors helped to explain the function of the 
noncatalytic UB2H domain that is now proposed to play the regulatory role (King et 
al., 2014). In vitro activity of PBP1b is also dependent on presence of bivalent metal 
ions and affected by low pH (Schwartz et al., 2002; Egan & Vollmer, 2013).  
 
 
1.3.2.3 Inhibitors of PBP1b activities 
 
To resolve the structure of PBP1b shown above, the protein has been co-crystallised 
with moenomycin A (Sung et al., 2009). This antibiotic isolated in the 1960s from 
Streptomyces bacteria remain the only natural product to directly inhibit catalytic 
site of GT51 enzymes. Although it binds to E. coli PBP1b and inhibits its activity in 
vitro, moenomycin efficacy against Gram-negative bacteria is low due to presence of 
the outer membrane. 
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PBP1b, like all other penicillin-binding proteins, is a target for ß-lactam antibiotics.  
E. coli PBP1a and b are reported to be particularly sensitive to cefsulodin (Yao & 
Kishony, 2013; Lee et al., 2016) and PBP1b showed high susceptibility to 
cephaloridine. DrugBank names 14 other antibiotics inhibiting PBP1b (Spratt, 
1975; Kong et al., 2016).  
 
 
1.3.2.4 Essentiality of PBP1b in E. coli 
 
Deletion of mrcA and mrcB genes encoding two class A pencillin-binding proteins in 
E. coli has shed light on the essentiality of these major peptidoglycan synthases.  
Although PBP1a and PBP1b are proposed to play different roles in the E. coli cell, 
being involved in elongasome and divisome, respectively, they can substitute one 
another. Depletion of either of the proteins leads to viable phenotypes but a double 
mutation is lethal (Yousif et al., 1985). The same holds true for their cognate 
lipoprotein cofactors. They are required for PBP activity in vivo; therefore, 
inactivation of both of the lpo genes results in cell lysis. For growth, E. coli requires at 
least one complete class A PBP-Lpo complex (Typas et al., 2010; Paradis-Bleau et 
al., 2010).  
 
 
1.4 Challenges in antibiotics discovery 
 
 
1.4.1 A mismatch between molecular and cellular effects of potential antimicrobial 
compounds 
 
The serendipitous discovery of penicillin in Penicillium spp. inspired more systematic 
screening for substances of antimicrobial properties. A method introduced by 
Selman Waksman based on culturing soil-derived Streptomyces bacteria and testing 
them against human pathogens. The “Waksman discovery platform” yielded 
streptomycin and, when widely adopted by pharmaceutical industry, many other 
classes of antibiotics. Their discovery was solely based on inhibition of growth and 
often mode of action was determined much later (Lewis, 2013).  
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Advancements in molecular biology and recombinant protein expression brought a 
revolutionary approach to the field of drug discovery. A better understanding of 
essentiality and interspecific conservation of molecular processes in bacteria allowed 
for careful selection of targets and development of target-based biochemical screens. 
This approach, although very successful in identification of enzyme inhibitors, did 
not produce any new antibiotics (Payne et al., 2007; Tommasi et al., 2015). Unlike 
compounds identified this way for the eukaryotic targets, hits shown to inhibit 
bacterial enzymes in vitro seldom demonstrated sufficient cellular effect. A 
significant mismatch between results of cell-free and cell-based assays indicates how 
important for bacteria survival are their envelopes. This observation is often an 
argument in favour of phenotypic rather than target-based screening (Silver, 2011; 
Singh, 2014). 
 
 
1.4.2 Limitations of chemical libraries 
 
Regardless of the screening approach, antibiotic discovery is also affected by the 
insufficient diversity or biased designs of the existing chemical libraries. The 
landmark publication of Lipinski and colleagues defining physicochemical properties 
increasing the likelihood of oral bioavailability of drug candidates had a very strong 
impact on the design of chemical libraries (Lipinski et al., 1997). Lipinski property 
filters favour lipophilic drugs. Such compounds, however, are rather unlikely to 
penetrate through the prokaryotic envelopes. A study by O’Shea and Moser 
highlights major differences between compounds suitable for eukaryotic and 
prokaryotic cells (O’Shea & Moser; 2007). Arguably, existing chemical libraries are 
also short of chemical diversity. Collections owned by big pharmaceutical companies 
often include millions of compounds. Although impressive, the number of 
compounds deposited in these collections is still just a fraction of all possibilities. It 
has been estimated that 1060 molecules of size and composition similar to existing 
drugs could be made (Bohacek et al., 1996).  
 
 
 
 
	 23 
1.4.3 Profitability of antibiotics research and development 
 
The number of big pharmaceutical companies actively involved in discovery and 
development of antibiotics fell from 18 to 4 between 1990 and 2013 (Butler et al., 
2013). The major reason for industry withdrawing from this therapeutic area is a 
lower financial incentive when compared to other classes of medicines. Most widely 
used antibiotics are cheap and offer very low revenue. Since antimicrobial therapy is 
usually short, even more advanced and expensive drugs cost only hundreds of dollars 
per treatment compared to sums well in excess of 10,000 dollars spent on, for 
instance, anticancer agents. Industry prefers to allocate their resources to 
development of drugs for chronic therapies or medicines offering much higher 
monetary returns. The shift in research and development (R&D) efforts is well 
reflected by the numbers of medicines in the pipeline. In 2014 there were almost 800 
oncology-related agents in the development pipelines, with 80% being potentially 
first in class. At the same time, there were fewer than 50 new antibiotics being 
developed. 
 
Although the current state situation of AMR is of high urgency, this is generally not 
reflected in investments in the field (O’Neill, 2016). Being less profitable than other 
classes of drugs, development of antibiotics does not attract private capital. Between 
2003 and 2013, only 4.7% of the venture capital allocated to pharmaceutical research 
and development was for antimicrobial development. The underinvested industry of 
antimicrobial R&D needs changes in its funding structure. One of the proposed 
solutions is bigger participation of public capital in accelerating anti-AMR 
innovations.  
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1.5 Thesis aims 
 
 
β-lactams, inhibitors of peptidoglycan cross-linking, play a prodigious role in the 
control of infectious diseases. Nowadays, they account for over 40% of all antibiotics 
prescribed in the United Kingdom, but their efficiency is dropping due to the 
emergence and spread of resistant strains of bacteria. Nevertheless, penicillin-
binding proteins, especially bifunctional, class A enzymes, remain very attractive 
targets for antibiotics development as they are essential, unique and well conserved in 
Bacteria. 
 
The overarching objective of this doctoral thesis is to enable the discovery of non-β-
lactam inhibitors of bifunctional penicillin-binding proteins. The main aim of this 
work is to develop high-throughput, target-based, biochemical assays characterising 
enzymatic activities of class A PBPs. Such tools could aid the identification of novel 
chemical matter of potentially antimicrobial properties. This task is addressed by: 
 
• Adaptation of an existing low-throughput, spectrophotometric 
transpeptidation assay into a high-throughput, fluorometric method. This 
work, as well as, screening of a 120,000-compounds chemical library is 
described in chapter 3. 
 
• Development of a novel, FRET-based transglycosylation assay described in 
chapter 4. The thesis also presents further applications of the bespoke 
chemistry used in assay development. 
 
• High-throughput screening of another diverse chemical library against the 
optimised, FRET-based transglycosylation assay. This part is a subject of 
chapter 5. 
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CHAPTER 2: Materials and methods 
 
 
 
2.1  Buffers and solutions 
 
All buffers were made with ultrapure water (MiliQ type I). Buffers used for 
chromatography and intended for long-term storage were filtered using 0.22 µm 
membrane filter. Buffers pH was adjusted using a WPA pH meter CD720 by Hanna 
Instruments, with pH 4.0, pH 7.0 and pH 10.0 buffer standards.  
 
 
2.2  Maintenance of E. coli cells 
 
 
2.2.1 E. coli strains used in the project 
 
E. coli cell line (strain) Genotype 
TOP-10 F
- mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 ΔlacX74 recA1 
araD139 Δ(ara leu) 7697 galU galK rpsL (StrR) endA1 nupG 
BL21 (λDE3) 
F- ompT gal dcm lon hsdSB(rB–mB–) λ(DE3 [lacI lacUV5-
T7p07 ind1 sam7 nin5]) [malB+]K-12(λS) 
 
BL21 Rosetta (λDE3) F- ompT hsdSB(rB- mB-) gal dcm (DE3) pRARE (CamR) 
C41 (λDE3) F- ompT hsdSB (rB- mB-) gal dcm (DE3) 
C43 (λDE3) F - ompT hsdSB (rB- mB-) gal dcm (DE3) 
 
Table 2.1 Bacterial strains used for plasmid amplification and protein expression 
 
 
2.2.2 Growth media 
 
• Lysogeny broth (LB) 
1% (w/v) tryptone, 0.5% (w/v) NaCl, 0.5% (w/v) yeast extract. Sterilised by 
autoclaving. 
• LB-agar plates 
LB media with 1.5% (w/v) agar were sterilised by autoclaving, cooled to 50°C before 
adding the appropriate antibiotics, and 20 mL poured into sterile Petri dishes. 
Prepared plates were stored at 4°C.  
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2.2.3 Glycerol stocks 
 
Glycerol stocks of bacteria were made from a single colony grown overnight in 5 mL 
of liquid LB. 0.5 mL of this culture was then mixed with 0.5 mL of sterile 80% (v/v) 
glycerol. Samples were placed in cryo vials, flash-frozen in liquid nitrogen and stored 
at -80°C. 
 
 
2.2.4 Preparation of competent cells 
 
The selected cell line was streaked from the glycerol stock and was grown on a solid 
medium overnight in the presence of the appropriate antibiotic. A single colony was 
then selected to inoculate the liquid LB “pre-culture”. After the overnight growth, this 
culture was then used to inoculate (1:100; v/v) 250 mL of LB supplemented with 20 
mM MgSO4 and appropriate antibiotic. It was incubated at 37°C with shaking at 180 
rpm until an optical density (OD600nm) of between 0.4 and 0.6 was reached. 
 
Cells were pelleted by centrifugation at 4500 x g for 10 min (Beckman JA-14 rotor), 
and gently resuspended in 100 mL ice cold TFB1 buffer (30 mM potassium acetate, 
10 mM calcium chloride, 50 mM manganese chloride, 100 mM rubidium chloride, 
15% (v/v) glycerol, pH 5.8), incubated on ice for 5 min and then centrifuged at 4500 
x g for 5 min (Beckman JA-14 rotor). The pellet was then resuspended in 10 mL 
TFB2 buffer (10 mM MOPS, pH 6.5, 75 mM calcium chloride, 10 mM rubidium 
chloride, 15% (v/v) glycerol) and incubated on ice for 1 hour. 50 µL aliquots of 
competent cells were then flash frozen in liquid nitrogen and stored at -20oC.  
 
 
2.2.5 Plasmids isolation, quantification and storage 
 
Genetic vectors were isolated using Qiaprep Spin plasmid isolation kit (Qiagen) 
according to the manufacturer instruction. 1.5 µL samples were quantified using a 
NanoDrop ND-1000 spectrophotometer (Thermo Scientific) with elution buffer used 
as a blank solution. Isolated plasmids were stored at -20°C. 
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2.2.6 Transformation of E. coli cells 
 
50 µL aliquots of competent cells were thawed on ice, and 1 µL of the appropriate 
plasmid was added (10-100 ng total DNA). Cells were incubated for further 30 min 
on ice and then heat-shocked at 42°C for 45 s using a water bath. Heat shock was 
followed by a 2 min incubation on ice. 250 µL of SOC media was added, and the cells 
were incubated at 37°C for 60 min with shaking at 180 rpm. 100 µL of the transformed 
cells were plated onto LB-agar plates containing the appropriate antibiotic and were 
incubated at 37°C overnight without shaking. 
 
 
2.3  Protein analysis and quantification 
 
 
2.3.1 Bradford total protein concentration assay 
 
Proteins purified without detergent were quantified using the Bradford colourimetric 
assay (BioRad) at 595 nm. 2 μL of the protein sample was added to 1 mL of the 
Bradford working solution and mixed in a plastic semi-micro cuvette. After 5 min 
incubation, absorbance at 595 nm was measured using a Jenway 6306 UV-vis 
spectrophotometer. A standard curve was prepared with serial dilutions of bovine 
serum albumin in the range between 0.1-2 mg/mL. Reading were taken in triplicates 
and samples were diluted if the concentration was exceeding the standard curve range. 
 
 
2.3.2 BCA total protein concentration assay 
 
Expressed and purified proteins were quantified using the bicinchoninic acid (BCA) 
assay (ThermoFisher). This method was selected due to its compatibility with 
detergents used for membrane proteins solubilisation. The assay was carried out at 1 
mL format according to the manufacturer instruction. Absorbance at 562 nm was 
measured with Jenway 6306 spectrophotometer. Protein concentration was 
determined based on the standard curve prepared with serial dilutions of bovine serum 
albumin in the range between 0.1-2 mg/mL (Figure 2.1).  
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Figure 2.1: Exemplary results of the BCA assay to determine E. coli PBP1b concentration.  
 
 
2.3.3 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Protein-containing extracts were separated and visualised using SDS-PAGE in the 
Tris-glycine buffer. A 4 mL resolving gel (375 mM Tris pH 8.8, 0.4% (w/v) SDS, 
10% acrylamide:bis-acrylamide (29:1 AccuGel, National Diagnostics)) was cast using 
the Hoffer MightySmall or BioRad MiniProteanTetra gel casting kit and polymerised 
with 100 μL 10% (w/v) APS (ammonium persulfate) and 10 μL N,N,N',N'-
Tetramethylethylenediamine (TEMED). The gel was set under a layer of 100% (v/v) 
ethanol to ensure an even set. 
 
After the resolving gel was set, ethanol was removed and a 2 mL stacking gel (125 
mM Tris pH 6.8, 0.4% (w/v) SDS, 4% acrylamide:bis-acrylamide (29:1)) polymerised 
with 50 μL 10% (w/v) APS and 10 µL TEMED, was poured on top and a plastic 
comb was inserted to form sample reservoirs.  
 
Samples containing 20 µg of total protein (or a maximum volume of 25 µL) were 
mixed with 6 x loading buffer (63.5 mM Tris pH 6.8, 0.4% (w/v) SDS, 5% (v/v) β-
mercaptoethanol, 20% (v/v) glycerol, 2.5% (w/v) bromophenol blue) at 5:1 ratio. 
ColorPlus prestained protein ladder (10-230 kDa, New England Biolabs) was used as 
a size reference. Samples were heat-denatured at 95°C for 10 min using an Eppendorf 
Mastercycler Gradient thermocycler. After a brief centrifugation, samples were 
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transferred into the wells, and the gel was run in SDS-PAGE running buffer (25 mM 
Tris pH 8.3, 0.19 M glycine, 0.1% (w/v) SDS) at 180 V for 50 min or until 
bromophenol blue reached the bottom of the gel. The gel was washed with distilled 
water, transferred to a plastic container and stained for 30 min using Instant Blue stain 
(Expedeon). Excess dye was removed, the gel was washed in distilled in water and 
imaged using Syngene GeneSnap G:Box analysis system. 
 
 
2.3.4 Western blot 
 
Western blotting was used to detect a proper expression of polyhistidine-tagged 
proteins. His-tagged protein marker (BenchMark His-tagged protein standard, 
Invitrogen) was used as a positive control and as a size reference. 
 
Purified proteins and a His-tagged marker were resolved in 10% SDS-PAA gel, as 
described in the paragraph 2.3.2. The proteins were transferred from the gel onto the 
blotting membrane using a semi-dry transfer method. After the gel was fully resolved 
and washed, the blotting sandwich was assembled using the TransBlot Turbo Mini 
PVDF transfer pack (Biorad). If a single gel was analysed, TransBlot Turbo transfer 
system (Biorad) was set for a quick transfer protocol: 3 minutes at 1.3 A and 25 V. 
After the transfer, PVDF membrane was blocked by placing in 50 mL of 10% milk 
powder solution in TBS buffer supplemented with 0.1% Tween-20 (TBS-T) and 
rocked for 2 hours at ambient temperature before an overnight incubation at 4oC.  
 
The blocking solution was then removed, and the membrane was washed three times 
with 50 mL of TBS-T for 15 minutes. 0.2 μg of the primary antibody (anti-His IgG 
monoclonal mouse antibody, Roche, Cat No. 1922416) was diluted in 20 mL of TBS-
T with 5% milk powder, and the membrane was incubated in this solution for one 
hour at ambient temperature. The antibody solution was then removed, and the 
membrane was washed three times with 50 mL of TBS-T for 15 minutes. This step 
was followed by the membrane incubation with the secondary antibody (10 µL of anti-
mouse IgG derived from sheep, conjugated to horseradish peroxidase, Sigma, A5906) 
in 20 mL of TBS-T with 5% milk powder for two hours. Three wash steps were then 
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applied as before, and an additional wash was carried out overnight to reduce 
unspecific interactions. 
 
The blotting result was imaged on an X-ray sensitive film using a chemiluminescent 
development method. At first solutions A and B of the EZ ECL western blotting 
detection reagent (GE Healthcare) were mixed at 1:1 ratio and incubated with the 
membrane for 2 min in the dark. The membrane was then removed from the solution 
and excess placed in a development cassette with the x-ray sensitive film (Super-RX 
NIF, Fujifilm). The film was exposed for chemiluminescence for 15 to 90 seconds. 
The film was then developed in the Agfa CP automatic development machine.  
 
 
2.4  Protein expression and purification 
 
Multiple batches of proteins were used during the project. Part of the E. coli PBP1b 
was prepared by Mrs Anita Catherwood and Dr Dom Bellini. Soluble E. coli LpoB 
was purified by Dr Dean Rea and Mrs Anita Catherwood. 
 
 
2.4.1 E. coli PBP1b expression trials 
 
Five E. coli cell lines were transformed, as described in the paragraph 2.2.6, with the 
E. coli PBP1b construct (pDML924, courtesy of Prof. W. Vollmer, Newcastle 
University) to identify optimal host cells for the protein expression. Transformed cells 
were cultured in 50 mL of LB at 37oC with shaking at 180 rpm until the OD600 reached 
between 0.5 and 0.6 and the expression was induced by the addition of 1 mM 
isopropyl-β-D-thiogalactopyranoside (IPTG). For each cell line, a non-induced 
control was cultured. The cells were grown overnight and harvested the following 
morning by centrifugation at 10,000 x g and lysed. Total protein content in the 
membrane fraction was quantified with the Bradford assay. 25 µg of proteins from 
each sample was resolved in the SDS-PAA gel as described in the paragraph 2.3.3. 
Another gel prepared the same way was used for western blotting as described in the 
paragraph 2.3.4. SDS-PAGE and western blot results (Figure 2.2) indicated that C43 
cell line expressed the highest yield of uniform protein. Although the bands 
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representing recombinant E. coli PBP1b in C41 and C43R had similar intensities, they 
were not uniform, suggesting partial proteolysis or expression of an additional isoform 
of the protein. C43 cells were therefore selected for larger scale expression of the 
protein.   
 
 
 
 
Figure 2.2: Expression trials of E. coli PBP1b from the pDML924 construct. The top panel shows 
SDS-PAGE separation of the membrane fraction proteins in selected cell lines. The red band on the 
protein marker (Color Plus, New England BioLabs) lane marks a position of the 80 kDa standard. 
Bands representing E. coli PBP1b can be seen at a similar height. The bottom panel shows the results 
of the western blot with anti-polyHis primary antibody.  
 
 
2.4.2 Recombinant E. coli PBP1b expression  
 
C43 E. coli cells were transformed with the pDML924 plasmid and grown overnight 
on a solid LB agar medium supplemented with 50 µg/ mL kanamycin. A single colony 
was then transferred into LB supplemented with 50 µg/ mL kanamycin and grown 
overnight at 37oC with shaking at 180 rpm. One L of LB in a two-litre baffled flask 
was supplemented with 0.2% glucose and 50 µg/mL and kanamycin and inoculated 
with 5 mL of the overnight culture. Six to twelve L of LB was used for every batch of 
the protein. Flasks were incubated at 37oC with shaking at 180 rpm, and OD600 was 
measured regularly. When it reached the range between 0.5 and 0.6, the expression 
was induced by addition of 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG). The 
culture was then incubated for further 12-16 hours at 25oC with shaking at 180 rpm. 
Cell culture was then decanted into centrifuge flasks, and bacterial pellet was harvested 
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by centrifugation at 10,000 x g for 15 minutes at 4oC using Beckman JLA-8.100 rotor. 
The collected pellet was processed immediately or stored at -20oC for up to two weeks.  
 
2.4.3 Preparation of cell lysate 
 
The bacterial pellet was weighed and resuspended in the resuspension buffer (3 mL 
per gram of pellet) composed of 25 mM Tris-HCl pH 7.5, 10 mM MgCl2, 500 mM 
NaCl, 10% glycerol. 2.5 mg per millilitre of cell suspension of hen egg white lysozyme 
was then added along with 20 µg/ mL of DNAse I and EDTA-free protease inhibitor 
tablets (cOmplete, Roche). The suspension was incubated for 1 hour at 15oC with 
vigorous shaking. The cells were then homogenised using the continuous cell disruptor 
(Constant Cell Disruption Systems) at 30 kpsi at 4°C. The lysate was collected on ice 
and then centrifuged at 20,000 x g using a Beckman JA-25.50 rotor for 20 min at 4°C 
to sediment cell debris. 
 
 
2.4.4 Isolation and solubilisation of bacterial membranes 
 
The supernatant resulting from the previous step was then used to extract the 
membrane fraction of the cell lysate. This was achieved by centrifugation at approx. 
120,000 x g for 90 min at 4°C, using the Beckman Coulter Optima L-90K 
ultracentrifuge equipped with the Ti-45rotor. The supernatant containing the 
cytosolic fraction was decanted, and pelleted membranes were recovered from the tube 
and resuspended in the resuspension buffer. The pellet was homogenised manually 
using a glass homogeniser (Jencon, 2 mL).  
 
The resuspended membrane fraction was then supplemented with 1-2% of Triton X-
100 and solubilised by gentle rocking for 2 h at 4°C. The solution was centrifuged at 
approx. 120,000 x g using the Beckman Coulter Optima L-90K ultracentrifuge 
equipped with the Ti-45 rotor to pellet any insoluble material. The resulting 
supernatant was used in the next step 
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2.4.5 PBP1b purification  
 
His-tagged E. coli PBP1b was extracted from solubilised membranes using 
immobilised metal affinity chromatography. Fast-flow Sepharose beads charged with 
Ni2+ ions were washed with the resuspension buffer supplemented with 5 mM 
imidazole and subsequently added to the membranes solution (approx. 3 mL per 50 
mL of the suspension) and incubated for 2 h at 4 °C on a tube rocker. The slurry was 
decanted into a 10 mL syringe barrel with glass wool at the bottom to stop the beads 
from leaking out. A column formed this way was at first washed twice with 20 mL of 
the resuspension buffer + 15 mM imidazole. The protein was then eluted by washing 
the column with 5 mL aliquots of resuspension buffer supplemented with the 
following concentrations of imidazole: 50, 100, 150, 200, 250, 300, 350, 400 mM. 
The fractions were collected, and 10 µL of each fraction was then resolved on the 
SDS-PAA gel (Figure 2.3) to identify fraction containing the overexpressed protein. 
The protein normally eluted in fractions containing between 50 and 150 mM 
imidazole. Collected fraction were dialysed overnight against the protein storage 
buffer (25 mM Tris-HCl pH 7.5, 10 mM MgCl2, 300 mM NaCl, 10% glycerol, 0.2% 
Triton X-100) to remove imidazole. Dialysed protein was concentrated using Vivaspin 
centrifugal concentrator (Sartorius) and kept at -20oC.  
 
 
Figure 2.3: Purification of E. coli PBP1b in a gradient of imidazole. The figure shows SDS-PAGE of 
fractions collected during the IMAC purification of the protein. The red band on the protein marker 
(Color Plus, New England BioLabs) lane marks a position of the 80 kDa standard.  
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2.4.6 In-gel bocillin FL assay 
 
The correctness of penicillin-binding proteins fold can be partially assessed by the in-
gel bocillin FL assay. Bocillin FL is a conjugate of penicillin V with a fluorescent dye, 
bodipy (Zhao et al., 1999). Protein samples were incubated with 10 x molar excess of 
bocillin FL for 30 minutes at room temperature and then analysed by SDS-PAGE. 
Heat-denaturation of samples was omitted. Bocillin was visualised in the gel using the 
G:box gel documentation system (Syngene) fitted with a short pass filter.  
 
 
2.5  Synthesis of peptidoglycan intermediates 
 
UDP-MurNac-pentapeptide substrate and its dansylated variant were synthesised by 
Anita Catherwood and Julie Tod of BaCWAN facility at the University of Warwick. 
The compounds were then used for the synthesis of further intermediates.   
 
 
2.5.1 UDP-MurNAc-pentapeptide desalting 
 
For use in further steps, UDP-MurNAc-pentapeptide had to be purified from the 
contaminating ammonium acetate. This was achieved by anion exchange 
chromatography. Up to 20 mg of the pentapeptide was loaded onto the Q Sepharose 
hi-load column and purified in a gradient of sodium bicarbonate between 100 mM, 
and 1 M. 5 mL fraction were collected. Absorbance at 254 and 280 nm was monitored 
to identify fractions containing UDP-MurNAc-pentapeptide. 
 
Collected fractions were tested for the ammonium content using the Nessler’s reagent. 
Samples were mixed with Nessler’s reagent at 1:1 volume ratio and the absorbance at 
452 nm was measured using a Jenway 6306 spectrophotometer. Ammonium 
concentration was determined using a standard curve. All collected fractions had 
marginal ammonium content and were pooled together and freeze-dried. 
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2.5.2 Biotinylation of MurNAc-DAP-pentapeptide 
 
Biotin moiety was introduced into  MurNAc-DAP-pentapeptide by the reaction 
between ε-amine of position three diaminopimelic acid and biotin N-
hydroxysuccinimide ester (biotin-NHS). 10 x molar excess of biotin NHS was 
dissolved in 100% dimethyl sulfoxide (DMSO) and mixed with an equal volume of 
MurNAc-DAP-pentapeptide in water. The reaction was incubated overnight at 
ambient temperature in the dark. Unreacted biotin-NHS was neutralised by the 
addition of 10 x molar excess of tris(hydroxymethyl)aminomethane (Tris) pH 9.  The 
reaction was carried out for 1 h at room temperature.  
 
 
2.5.3 Purification of biotinylated MurNAc-DAP-pentapeptide 
 
Biotinylated MurNAc-DAP-pentapeptide resulting from the reaction described in 
the previous paragraph was purified by anion exchange chromatography. Source 30Q 
column was equilibrated with 100 mM ammonium acetate, pH 7.6, and the reaction 
mixture (approx. 50 mL) was loaded onto the column directly through the pump inlet. 
The sample was then subjected to a 100 mM- 1 M gradient of ammonium acetate 
over 90 minutes. Absorbance at 254 and 280 nm was monitored to identify fractions 
containing UDP-MurNAc-pentapeptide. Two peaks were observed (Figure 2.4) and 
eluted at the conductivity of 20.4 and 28.5 mS.cm-1 respectively. Samples were then 
freeze dried multiple times to remove the excess of ammonium acetate. Ammonium 
content in the in the samples was determined by Nessler’s reagent assay. 
 
With the aid of mass spectrometry (see Appendix 1), the first peak was found to 
contain unreacted UDP-MurNAc-DAP-pentapeptide, and the other contained its 
biotinylated variant. The unconverted substrate was recovered, and biotinylation 
procedure was repeated.  
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Figure 2.4: Chromatogram of post-reaction purification of biotinylated MurNAc-DAP-pentapeptide 
by anion exchange chromatography. Source 30Q resin. Peak 1- UDP-MurNAc-DAP-pentapeptide, 
elution at conductivity of 20.4 mS.cm-1; Peak 2- biotinylated-UDP-MurNAc-DAP-pentapeptide, 
elution at conductivity of 28.5 mS.cm-1 Blue trace- absorbance at 280 nm, red trace- absorbance at 254 
nm, brown trace- conductivity.  
 
 
2.5.4 Quantification of pentapeptide products 
 
UDP-MurNAc-Pentapeptide substrates were quantified by measuring absorbance at 
260 nm using a Jenway 6306 spectrophotometer. Uracil extinction coefficient of 
10,000 M-1cm-1 was used to calculate the concentration.  
 
 
2.5.5 Lipid II synthesis 
 
Multiple batches of lipid II were synthesised for this project including native lipid II 
–lysine and –DAP as well as biotinylated and dansylated variants of lipid II-DAP. All 
substrates contained undecaprenyl lipid tail (C55).  Lipid II variants were synthesised 
using a method adapted from Breukink et al. (2003). 
 
The enzymatic synthesis was carried out by enzymes from Micrococcus flavus 
membrane extract. The reaction mix contained 48 µmol UDP-GlcNAc, 12 µmol 
Purification	and	characterisation of	UDP-MurN Ac-hexapeptides (Gln,	Ala)(A,B)	and	(Gln,	Ser)(C,D)	by	
anion	exchange	chromatography
(Source30Q	resin)	and	negative	ion	mass	spectrometry.	A:	Purification	of	UDP-MurNAc-L-Ala-γ-D-Gln-L-
Lys(L-Ala)-D-Ala-D-Ala (elution	at	10.9	mS.cm-1	(A(ii)).
(A(i))	is	a	peak	of	organic	reagents	used	in	the	coupling	reaction.	Red:	A254nm;	blue:	A280nm,	black:	
conductivity.	B:	Negative	ion	electrospray	time-of-flight	mass	spectra
of	UDP-MurNAc-L-Ala-γ-D-Gln-L-Lys(L-Ala)-D-Ala-D-Ala.	[M-H]-expected	1218.3977,	observed	1218.4017,	
[M-2H]2- expected	608.6954	observed	608.6997.	C:	The
purification	of	UDP-MurNAc-L-Ala-γ-D-Gln-L-Lys(L-Ser)-D-Ala-D-Ala (elution	at	13.5	mS.cm-1	(C(ii)).	(C(i))	is	
a	peak	of	organic	reagents	used	in	the	coupling
reaction.	Red:	A254nm;	blue:	A280nm,	black:	conductivity	B:	Negative	ion	electrospray	time-of-flight	
mass	spectra	of	UDP-MurNAc-L-Ala-γ-D-Gln-L-Lys(L-Ser)-D-Ala-DAla.
m/z:	[M-H]-expected	1234.3926	observed	1234.4128,	[M-2H]2- expected	616.6928	observed	616.6984.
1
2
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UDP-MurNAc-pentapeptide, native or modified, and 4.8 µmol undecaprenyl 
phosphate. The reaction was carried out in the total volume of 3.5 mL in a glass vial. 
The reaction buffer was composed of 100 mM Tris.HCl pH 8, 5 mM MgCl2, 1% 
(v/v) Triton X-100. Reagents were incubated for 3 hours at 37°C. 
 
Lipid II was then extracted with 1:1 mixture of 6 M pyridine-acetate pH 4.2 and n-
butanol. Phases were separated by centrifugation at 4,500 x g for 10 minutes. The top 
phase of n-butanol was collected and washed with an equal volume of water. After 
another centrifugation, the top phase was collected, and rotary evaporated. The 
product was then stored at -80°C. 
 
 
2.5.6 Lipid II purification 
 
Lipid was purified by anion exchange chromatography using DEAE-Sephacel resin. 
A chromatography column was assembled by transferring 5 mL of the resin into glass 
pipette with glass wool at the bottom. The column was washed with five column 
volumes (CV) of 1 M ammonium acetate, 5 CV of water and 5 CV of solvent A (2:3:1 
(v/v) mix of chloroform, methanol and water). A thawed sample of lipid II was 
resuspended in 6 mL of solvent A and transferred onto the resin. It was then washed 
with 4 CV of solvent A. Elution was carried out by washing the column with 8 mL 
aliquots of 2:3:1 (v/v) mix of chloroform, methanol, ammonium bicarbonate. 
Ammonium bicarbonate concentration was stepwise increased from 50 mM to 1 M. 
Fractions were collected to separate glass vials. Biotinylated and dansylated lipid II 
required two additional washes with the most concentrated ammonium bicarbonate 
to ensure complete elution.  
 
 
2.5.7 Thin layer chromatography (TLC) analysis of lipid II 
 
400 µL samples of each fraction collected during the Sephacel anion exchange were 
vacuum dried and resuspended in 25 µL of solvent A (2:3:1 (v/v) mix of chloroform, 
methanol and water). Sample loading spots were marked 2 cm apart on a silica TLC 
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plate, and the plate was preheated at 60oC to increase solvent evaporation rate. 
Samples were loaded onto the plate in 5 µL aliquots and air-dried.  
 
 
 
Figure 2.5: Thin layer chromatography of fractions collected during the anion exchange purification 
of lysine-lipid II. Fractions were eluted in the gradient of ammonium bicarbonate (AB). Silica gel TLC 
was resolved with an 88:48:10:1 mix of chloroform, methanol, water, ammonia and stained with iodine 
vapours. Arrow indicates migration direction. The dashed rectangle indicates fractions where lipid II 
was eluted. 
 
The running buffer (88:48:10:1 (v/v) mix of chloroform, methanol, water, ammonia) 
was poured into a glass tank up to 1 cm depth, and the TLC plate was vertically 
positioned in the tank. Chromatography was run at room temperature for 
approximately 3 hours. The plate was then placed in a sealed container with iodine 
crystals, and it was stained with iodine vapour. The plate was then scanned to digitise 
the TLC results (Figure 2.5).  
 
 
2.5.8 Lipid II quantification 
 
Upon acid hydrolysis, lipid II releases inorganic pyrophosphate. This can be then 
quantified with the purine nucleoside phosphorylase (PNP) assay. Inorganic 
1							2						3							4						5							6						7						8							9					10				
1. Flow-through
2. Solvent	A
3. 50	mM AB
4. 100	mM AB
5. 150	mM AB
6. 200	mM AB
7. 250	mM AB
8. 300	mM AB
9. 500	mM AB
10.1M	AB
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pyrophosphatase (IPP) releases inorganic phosphate (Pi) from the pyrophosphate. 
This process can be coupled with an enzymatic conversion of 7-methyl-6-guanosine 
(MESG) to ribose-1-phosphate and 7-methyl-6-guanine catalysed by PNP in a Pi 
dependent manner. The reaction is monitored by measuring absorbance at 360 nm.  
 
50 µL of lipid II in solvent A (2:3:1 (v/v) mix of chloroform, methanol and water) and 
a control sample containing just solvent A were dried down under nitrogen flow and 
resuspended in 50 µL of buffer composed of 50 mM HEPES, 10 mM MgCl2, 30 mM 
KCl, 1.5% (w/v) CHAPS, pH 7.6. An equal volume of 1 M HCl was added, and both 
samples were hydrolysed by incubation at 95°C for 20 min using an Eppendorf 
Mastercycler Gradient thermocycler. After cooling down and centrifugation at 3,000 
x g for 2 minutes, samples were neutralised with 1 M NaOH to pH 7.6. 
 
1 unit of PNP and 1 unit of IPP were mixed with 200 µM of MESG and the reaction 
buffer containing 50 mM HEPES pH 7.6 and 10 mM MgCl2. The total reaction 
volume was 200 µL. The reaction mix was incubated in a Carry UV-VIS 
spectrophotometer at 37o C until A360 reached a stable baseline. The reaction was then 
initiated by the addition of 10 µL of the hydrolysed and neutralised lipid II (or control) 
sample. The lipid II content is then calculated based on A360 change, assuming 
extinction coefficient of 10,000 M-1cm-1 and release of two Pi molecules from each 
lipid II molecule. 
 
 
2.5.9 Lipid II storage and preparation for enzymatic assays 
 
Quantified lipid II, dissolved in solvent A (2:3:1 (v/v) mix of chloroform, methanol 
and water), was stored in glass vials secured with parafilm at -80oC. Prior to use in 
enzymatic assays, the required amount of lipid II was transferred into a new glass vial 
and dried out under nitrogen flow. Lipid II was then resuspended in 0.1% (v/v) Triton 
X-100. 
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2.5.10 Mass spectrometry of peptidoglycan intermediates 
 
Peptidoglycan intermediates synthesised for this project were analysed with mass 
spectrometry by Dr Adrian Lloyd. Mass to charge ratio was determined by negative 
ion electrospray ionisation mass spectrometry (ESI-MS).  
 
 
2.6  In vitro enzymatic synthesis and in-gel analysis of peptidoglycan 
 
Products of in vitro peptidoglycan transglycosylation can be analysed by SDS-PAGE 
as described in research by Barret and colleagues (2007). The principle is that instead 
of using native lipid II, its dansylated variant is used. It prevents from transpeptidation 
(if the reaction is carried out by the bifunctional PBPs) and allows to separate 
peptidoglycan products by their sizes and image them by detecting dansyl 
fluorescence. The original method was modified for the purpose of this project. 
 
50 nM E. coli PBP1b was used in absence or presence of different concentrations of 
LpoB.  In the total volume of 20 µL, 10 µM dansylated-DAP-lipid II was mixed with 
50 mM Bis-Tris propane pH 8.5, 10 mM MgCl2, 0.05% (v/v) Triton X-100, 1% (v/v) 
glycerol. The reaction was initiated by the addition E. coli PBP1b and, optionally, 
LpoB. A negative control sample was prepared by the addition of 10 µM 
moenomycin. The reaction was incubated in a plastic tube for 90 minutes (unless 
stated otherwise) at room temperature. Transglycosylation was then stopped by 
enzyme heat-inactivation at 95°C for 3 min using an Eppendorf Mastercycler 
Gradient thermocycler and samples were briefly centrifuged. 
 
The samples were then mixed with 4 µL of the 6 x loading buffer: 40% (v/v) glycerol, 
4% (w/v) SDS, 100 mM Tris pH 8.8 and loaded onto the SDS-PAGE gel. For 
improved separation, a precast Tris-Tricine 10-20% PAA gradient gel was used 
(BioRad). 
 
Peptidoglycan electrophoresis was carried out in anode buffer (0.1 M Tris, pH 8.8) 
and cathode buffer (0.1 M Tris, 0.1 M Tricine, 0.1% (w/v) SDS, pH 8.25) at 120 V 
and 50 mA for 1 h. The bands were then imaged using G:Box (Syngene) or 
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ImageQuant LAS 4000 (GE Healthcare) gel documentation systems under UV 
transillumination (Figure 2.6). 
 
 
 
Figure 2.6: An example of in-gel analysis of transglycosylation products. Images of PAA gels show the 
time-dependent conversion of dansylated-DAP-lipid II into peptidoglycan polymers in the presence 
(A) and absence (B) of LpoB.  50 nM E. coli PBP1b, optional and variable E. coli LpoB, 10 µM dansyl-
DAP-lipid II, 50 mM Bis-Tris propane pH 8.5, 10 mM MgCl2, 0.05% (v/v) Triton X-100, 1% (v/v) 
glycerol 
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CHAPTER 3: Development of the high-throughput transpeptidation 
assay based on D-alanine release and screening for penicillin-binding 
proteins inhibitors 
 
 
 
3.1  Introduction 
 
The final step of bacterial peptidoglycan synthesis is transpeptidation (TP). In this 
process, strands of polymerised lipid II are cross-linked to improve cell wall integrity. 
This two-stage reaction occurs at a variable frequency between stem peptides of lipid 
II. (Waxman & Strominger, 1983; de Pedro & Schwarz, 1981). First, the donor 
subunit releases the C-terminal D-Alanine upon formation of an intermediate 
substrate-enzyme complex.  Subsequently, a crosslink is formed through the 
nucleophilic attack of the free acceptor ε-amino group of either an-Lysyl or 
Diaminopimelyl residue within the donor stem peptide. The process is catalysed 
exclusively by transpeptidase domains of class A and B penicillin-binding proteins and 
can be inhibited by β- lactam antibiotics due to the structural resemblance of the 
lactam ring and the C-terminal D-alanyl-D-alanine of the donor stem peptide 
(Waxman & Strominger, 1983). In certain conditions, transpeptidases can use 
substances other than lipid II as a TP acceptor. For example, PBPs can use a water 
molecule in place of a regular acceptor. This type of reaction is known as 
carboxypeptidation (Egan et al., 2015). 
 
Historically, peptidoglycan transpeptidation was detected via incorporation of 
radiolabelled D-amino acids (Tsuruoka et al., 1984; Lupoli et al., 2011). This approach 
allowed discrimination between carboxypeptidation and transpeptidation but is not 
practical as a high throughput method. 
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3.1.1 Assay design 
 
The transpeptidation assay presented here was developed at the University of Warwick 
by Dr Adrian Lloyd. This method is based on the liberation of D-Alanine from the 
TP donor molecule, but the selection of reagents and conditions ensures that any 
residual carboxypeptidation activity has a negligible effect on the reaction output. The 
reaction occurs between Lys-lipid II and DAP-MurNAc-pentapeptide. The former, 
being a peptidoglycan intermediate unique to Gram-positive bacteria, serves as a 
substrate for transglycosylation in the presence of E. coli PBP1b but is a poor 
transpeptidation acceptor for this enzyme. Consequently, DAP-MurNAc-
pentapeptide serves as the only available TP acceptor. 
 
 
 
 
Figure 3.1: Cascade of biochemical reaction in the course of the assay. Courtesy of Dr Adrian Lloyd. 
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D-Alanine residues released in the process are detected via the short cascade of 
subsequent enzymatic transformations illustrated in figure 3.1. First D-amino acid 
oxidase oxidises released D-Alanine. Apart from pyruvate, ammonia and hydrogen 
peroxide are produced. That last product is reduced to water in a redox reaction 
catalysed by horseradish peroxidase. At the same time, fluorogenic Amplex Red is 
oxidised to its coloured derivative, resorufin. This transformation is reflected in the 
change of absorbance at 555 nm or fluorescence of excitation and emission 
wavelengths of 545 and 585 nm respectively. 
 
 
3.2  Experimental aims 
 
• To change the assay reading mode from spectrophotometric to fluorometric 
measurement  
• To explore method characteristics and potential limitations 
• To optimise the assay for the high throughput drug screening  
• To screen AstraZeneca’s chemical library against the assay 
 
 
3.3  Assay transition into high throughput format 
 
The assay was originally designed as a cuvette-based spectrophotometric method to 
investigate enzymatic properties of bacterial transpeptidases. As such it provides high-
quality time-course data, but its high reaction volume and instrument limitations make 
it unsuitable for high throughput purposes. The aim of this work was to develop a 
more cost-efficient protocol by miniaturising the reaction to low-microliter volume 
range in a microplate format. To achieve that, we exploited the fluorogenic rather than 
the chromogenic properties of Amplex Red. Measuring fluorescence rather than 
absorbance arising from the D-Alanine release was a preferred method for 
development of the high throughput screening assay since it allowed for a greater 
reduction in assay volume. The following work of assay reformatting, optimisation, 
validation and screening, was done in the laboratories of the Astra Zeneca Global 
High Throughput Screening Centre in Alderley Park, UK, with support from high 
throughput scientists Helen Plant, Marian Preston and Clare Stacey. 
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Table 3.1: Composition of the spectrophotometric TP assay. Total reaction volume is 200 µL. 
 
 
3.3.1 Continuous and discontinuous fluorescent assays 
 
Initial method development experiments were carried out in 384-well microtiter plate 
format at either 10 or 20 µL. Depending on the experimental aim, fluorescence-based 
TP assays could be run in two ways as illustrated in figure 3.2. To record a continuous 
reaction progress over time, the assay was assembled in a way similar to the 
spectrophotometric method- all reagents including coupling enzymes were mixed, and 
the reaction was started by addition of E. coli PBP1b. In practice, to facilitate liquid 
handling, the enzyme was added as its 2x concentrated solution in the PBP buffer. 
 
Taking multiple fluorescence measurements at regular time intervals limits the 
experiment throughput. In fact, collecting continuous data is neither required nor 
recommended for high throughput screening for enzyme inhibitors, and therefore a 
discontinuous protocol was developed. In this set-up, transpeptidation was also started 
Comments Reagent Stock conc. Final conc. Volume (μl) 
Dilution 
factor 
 Bis-Tris Propane pH 8.5 0.5 M 50 mM 20 10 
 MgCl2 2M 20 mM 2 100 
 Triton X-100 10% (v/v) 0.10% (v/v)| 2 100 
*including the 
volume of PBP 
added 
PBP Dilution buffer (25 
mM Tris, 0.2 % (v/v) 
Triton X-100, 10% (v/v) 
glycerol pH 7.5) 
1x  20 * 10 
(MW=22.5 kDa) 1 mg/ml LPOB 1 mg/ml (44.4 μM) 
0.04 mg/ml 
(1.78 μM) 8 25 
 Lipid II-Lys 0.2 mM 20 μM 20 10 
 MurNAc-DAP-5P 0.2 mM 5 μM 5 40 
 E.coli PBP1b 0.83 mg/ml (8.8 μM) variable   
(His)6 
Rhodotorula 
gracilis enzyme, 
2891.5 umol D-
Ala oxidised 
/min/ml 
DAAO   2.5 80 
1482.3 H2O2 
oxidised/min/ml HRP   2 100 
 AmplexRed 10 mM 50 μM 1 200 
 Water   up to 200 μl= 117.5  
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by mixing reagents with the enzyme solution, but with the omission of coupling 
enzymes and Amplex Red. These were added before completion of the reaction steady 
state, and only then resorufin fluorescence was measured. This allowed work with 
multiple microplates at the same time as each of them needs to be measured only once. 
When testing inhibitory properties of compounds in chemical collections, it is 
important to prevent further accumulation of D-alanine as it may take place in case of 
incomplete inhibition. High molar excess (34 mM) of ampicillin served as a stopping 
agent and enabled discrimination between weak inhibitors and non-inhibitors. 
 
 
 
Figure 3.2: Conceptual workflows of the continuous and discontinuous TP experiments. 
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3.4  High throughput screening assays quality criteria 
 
Methods employed in high throughput screening campaigns require rigorous 
validation. Apart from biological relevance, the robustness of assay performance 
should be thoroughly assessed. The goal of the assay optimisation was to meet 
following quality criteria, advised by scientists from the Astra Zeneca Global High 
Throughput Screening Centre: 
• Signal stability of at least 1 h at room temperature 
• Signal to background or positive control to negative control ratio >3 
• Z-factor > 0.5 where the parameter is calculated using the following equation: 
 
Equation 3.1: 
 
 
where:  𝜕𝑝 – standard deviation of positive control 𝜕𝑛
	
– standard deviation of negative control
 𝜇𝑝– mean of positive control 𝜇n – mean of negative control 
 
• Plate variation coefficient <10% 
• High day-to-day reproducibility 
• Sensitivity to known transpeptidase inhibitors 
• DMSO compatibility 
 
 
3.5  Development of the fluorimetric TP assay 
 
 
3.5.1 Sensitivity and stability of D-Alanine detection 
 
The performance of the TP assay relied on the capability of coupling enzymes to detect 
free D-amino acids. To establish the sensitivity of the DAAO-HRP-Amplex Red 
system in the microplate format, reagents required for transpeptidation were replaced 
by the buffers these components were delivered in and exogenous free D-Alanine at 
𝑍( = 1 − 3(𝜕𝑝 + 𝜕𝑛)𝜇𝑝	 − 𝜇n  
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defined concentrations was added. The plate was then incubated for 10 min at room 
temperature and transferred into the Pherastar plate reader equipped with a 540-
20/590-20 optical module. Focal height and gain value were adjusted for the well of 
the highest expected signal (highest D-Ala concentration) with the gain goal value of 
80%. Focal height was set at 11.6 mm and gain value at 39. The plate reader was 
programmed to take seven measurements in 30 min intervals (total time= 3 h). Signal 
intensity was then plotted against D-alanine concentration for each time point (only 
one plot shown here for clarity).  
 
Data showed a correlation between D-Alanine concentration and fluorescence 
intensity within tested range of 0.5 to 15 µM (Figure 3.3). A high background 
fluorescence was observed in the negative control where D-Alanine was absent. This 
may be due to the unspecific oxidation of AmplexRed or DAAO-independent 
generation of hydrogen peroxide.  
 
The time-course experiment (Figure 3.4) demonstrated that fluorescence intensity 
fluctuated to some degree. Samples of high D-Alanine concentration tended to reduce 
their signal while low D-Alanine samples and negative control undergo a minor 
increase in signal. This trend may negatively affect the dynamic range of the assay, 
however overall signal stability was sufficient for high throughput practice. Data 
indicated the best incubation time for the D-Alanine detection system to be between 
10 and 70 min. 
 
 
 
Figure 3.3: Relation between fluorescence intensity and D-Alanine concentration. Data collected after 
70 min incubation. Data points represent mean +/- standard deviation of 3 replicates. The dotted line 
represents second order polynomial regression (R2= 0.996) fitted with GraphPad Prism. 
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Figure 3.4: Signal stability over time. Data points represent individual replicates (n=3). 
 
 
3.5.2 Enzyme concentration effect in the continuous assay 
 
This experiment was designed to ensure that the TP fluorescence assay can be used to 
monitor TP reaction progress in real-time, similarly to the original spectrophotometric 
assay. Another goal was to determine an effect of the enzyme concentration on the 
reaction rate and assay window. Additionally, a range of negative control reactions was 
set up to assess the rate of unspecific signal development. In most assay development 
experiments, the negative control sample was prepared by adding 10 µM moenomycin 
to the reaction mix. 
 
Data analysis (Figure 3.5) revealed that the fluorescence-based assay could be 
successfully applied in a continuous manner, however all reactions, including negative 
controls, showed high initial fluorescence suggesting that resorufin might be generated 
independently from the enzymatic cascade of the assay or Amplex Red might be 
contaminated with resorufin. Unspecific oxidation seems to occur also during the 
reaction as all curves had significant positive slopes and positive control never reached 
a stable plateau. From the analytical perspective, high background signal may pose a 
challenge in HTS development as it affects assay window and negatively influences 
the method’s Z-factor. 
 
As predicted, a plate-based assay executed in this fashion did not provide good 
enzymatic data. Because of the time required for the assay assembly and measurement 
delays between particular samples, initial parts of kinetic curves could not be recorded, 
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and a precise relationship between enzyme concentration and initial reaction rate could 
not be established. 
 
 
Figure 3.5: E. coli PBP1b effect on the transpeptidation rate. Variable concentration of E. coli PBP 1b 
in the presence of 1.78 µM LpoB, 20 µM lipid II-Lys and 5 µM MurNAc-DAP-5P, 50 mM Bis-Tris 
propane pH 8.5, 20 mM MgCl2 , 0.1% (v/v) Triton X-100. Continuous data collection in the presence 
of detection reagents. Progress curves represent the average rate of five replicates. Data collected every 
2 minutes. Data points omitted for clarity. 
 
 
3.5.3 Influence of detergent quality on the background signal 
 
Investigation of the source of the background signal led to the discovery that laboratory 
grade Triton X-100 (Sigma-Aldrich) is commonly contaminated with hydrogen 
peroxide. It is used in PBP1b solubilisation and storage buffers (2% (v/v) and 0.2% 
(v/v) respectively) and at 0.1% as a solvent for lipid II utilised in the assay.  At a total 
concentration of 0.13%, it was likely it might contribute to the unspecific background 
noise. 
 
To assess the impact of hydrogen peroxide contamination, laboratory grade Triton X-
100 was compared with commercially available peroxide-free Triton X-100 (Surfact-
Amps, Thermo Fisher). 50 μM Amplex Red reagent was used as a hydrogen peroxide 
detection method. Resorufin fluorescence was measured after 1 h of incubation. The 
data showed that regular, laboratory-grade Triton X-100 indeed contained hydrogen 
peroxide as it led to the generation of a fluorescent signal proportional to its 
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concentration. Peroxide-free Triton X-100 did not demonstrate such relation yet still 
all samples showed significant fluorescence (Figure 3.6). 
 
Extrapolation of linear curves of both sample groups showed that at 0.13% (v/v) 
regular Triton X-100 had over twofold higher fluorescence intensity that the peroxide-
free batch (16 984.31 and 8134.24 units respectively). This finding suggests that using 
peroxide-free detergent may reduce the background fluorescence of the assay. 
 
 
 
Figure 3.6: Unspecific background fluorescence due to sample contamination with hydrogen peroxide. 
The plot compares two batches of Triton X-100 with respect to their effect on the Amplex Red 
fluorescence intensity. Data points represent mean +/- standard deviation of five replicates. 
 
 
3.5.4 Reagent stability test 
 
In the discontinuous TP assay designed for the screening of chemical libraries, 
transpeptidation and signal development are not concurrent. These two steps occur 
sequentially, and separate reagent mixes need to be prepared. Screening thousands of 
chemical compounds a day requires assay reagents to remain stable for prolonged 
periods. To assess the practicality of the discontinuous assay, both reagent mixes were 
tested for the impact of up to 1 h incubation on the assay signal.  
 
To determine the stability of the transpeptidation mix, all reagents excluding E. coli 
PBP1b (Bis-tris propane, MgCl2, Triton X-100, E. coli LpoB, Lysine-lipid II, 
MurNAc-DAP-pentapeptide, H2O) were combined and kept at ambient 
temperature. The reaction was initiated by adding E. coli PBP1b (or E. coli PBP1b 
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preincubated with moenomycin for the negative control) at four time points: 0, 20, 40 
and 60 minutes. After 40 minutes of incubation, freshly prepared detection mix was 
added to develop the fluorescent signal. Collected data demonstrate that storage of the 
transpeptidation mix for up to 60 minutes prior to reaction initiation has negligible 
influence on the final signal intensity (Figure 3.7, upper panel). 
 
 
 
 
Figure 3.7: Influence of reagents stability on signal intensity. Top chart illustrates the effect of 
prolonged storage of TP reaction mix on the final fluorescence intensity. The bottom chart shows the 
effect of prolonged storage of detection reagents mix on the final signal. Data bars show average value 
of eight replicates and error bars show standard deviation.  
 
Detection reagents’ stability was tested in a similar manner. All ingredients (Bis-tris 
propane, Ampicillin, Rhodotorula gracalis DAAO, HRP, Amplex Red, H20) were 
prepared 0, 20, 40 and 60 minutes prior to addition to a TP reaction mix after 40 
minutes of incubation. Unlike the previous experiment, prolonged storage of the 
detection mix at ambient temperature caused the increase of the fluorescent signal for 
both positive and negative control of the transpeptidation (Figure 3.7, lower panel). 
This observation was consistent with the previously noted gradual increase of the 
background 585 nm fluorescence in negative control samples. Increasing fluorescence 
intensity of the negative control had an adverse effect on the assay quality. Signal-to- 
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background ratio fell from 1.65 to 1.35 and Z-factor decreased from 0.44 to 0.42 when 
compared freshly made detection mix with one stored for 60 min. This result was 
taken into consideration when planning the library screening workflow. 
 
 
3.5.5 Importance of lipid II concentration 
 
In the described technique, signal intensity is dependent on the amount of released 
D-Alanine, therefore remains a function of the substrate concentration. Compared to 
the absorbance-based method, the fluorometric assay showed a high background 
signal which negatively affected assay robustness. Insufficient signal-to-noise ratio 
observed in early experiments was addressed by optimisation of lipid II content.  
 
In the lipid II titration experiment (Figure 3.8) signal-to-noise ratios and Z-factor 
values were calculated for each data series. Although samples with 58.9 µM lipid II 
showed the highest signal-to-noise ratio, it caused only small improvement of the Z’ 
when compared to 40 µM lipid II (0.73 and 0.71 respectively after 45 min TP reaction, 
continuous readout at 5 min intervals).  
 
 
Figure 3.8: Dependency of E. coli PBP1b transpeptidation rate on the donor concentration  
10 nM E. coli PBP 1b in presence of 1.78 µM LpoB, variable lipid II-Lys and 20 µM MurNAc-DAP-
5P, 50 mM Bis-Tris propane pH 8.5, 20 mM MgCl2 , 0.1% (v/v) Triton X-100. Continuous data 
collection in the presence of detection reagents. Data points represent mean +/- standard deviation of 
five replicates except for the 58.9 µM series where three replicates were used. 
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3.5.6 Optimisation of TP donor and acceptor 
 
To further explore the influence of substrate concentration on the assay robustness, 
both TP donor and acceptor were titrated in a single experiment.  As observed before, 
increased content of the TP donor had a positive effect on signal intensity. This effect 
was additionally enhanced by increasing concentration of the TP acceptor. In brief, 
doubling the concentration of both Lys-lipid II and MurNac-DAP-pentapeptide led 
to the overall improvement of the signal-to-noise ratio by 66.2%, from 1.66 to 2.76 
(Figure 3.9C). Despite failing to meet the original goal of threefold signal-to-noise 
ratio, method quality, especially observed Z-factor values,  at this stage of development 
was sufficient to progress into assay miniaturisation.  
 
 
 
Figure 3.9: Optimisation of TP donor and acceptor. Plot A demonstrates reaction progress in the 
original conditions used previously for the photometric assay. Plot B shows improved reaction rate after 
increasing TP donor and acceptor concentrations. Data points represent mean +/- standard deviation 
of eight replicates for positive and six replicates for negative control. Plot C shows the effect of tested 
combinations of donor and acceptor concentrations on the signal-to-background ratio. The experiment 
was carried out at 10 nM E. coli PBP 1b in the presence of 1.78 µM LpoB, variable lipid II-Lys and 
MurNAc-DAP-5P, 50 mM Bis-Tris propane pH 8.5, 20 mM MgCl2, 0.1% Triton X-100. Continuous 
data collection in the presence of detection reagents. 
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3.5.7 Increase of plate density 
 
Following numerous optimisation steps carried out in a 384-well microplate format, 
at 10 or 20 µl, the assay was adapted for use with high density, 1536-well microplates. 
The goal of the assay reformat was to reduce future consumption of reagents and 
plasticware. As manual liquid handling at this plate density is not practicable, liquid 
dispensing of standard assay reagents was done with a BioRaptr (Beckman) bulk liquid 
dispenser. Tested compounds or control reagents were transferred into the assay plate 
by acoustic dispensing using Echo 555 (Labcyte) liquid handler. 
 
Two assay volumes were considered: transpeptidation step occurring in the total 
volume of either 3 or 1.5 µl, followed by addition of equal volumes of detection 
reagents. Both formats were tested by measuring the fluorescence intensity of positive 
and negative samples (n=48) after 40 min transpeptidation and 15 min signal 
development steps.  
 
Volume reduction caused an increase in variation coefficient, particularly evident at 
the lowest tested volume where CV scored 4.03% and 5.83% for positive and negative 
controls respectively. Despite that, both formats showed sufficient Z-factor of 0.74 for 
3 µl reaction and 0.64 for 1.5 µl reaction. 
 
 
3.6  Final assay format and method workflow 
 
Optimisation experiments led to the establishment of the final assay formulation and 
screening procedure. Due to the instability of the detection reagent mix, a maximum 
number of assay plates in one batch was limited to 8. That allowed limitation of 
detection mix storage time to less than half an hour. All steps were carried out at 
ambient temperature. 
 
The procedure began with preparing the assay plate. Tested and control compounds 
were added into the plate with the aid of an acoustic dispenser. In the next step, 
Solution A, consisting of E. coli PBP1b in its proprietary buffer was prepared. 750 nL 
of it was then dispensed into the assay plates using a bulk liquid dispenser and pre-
 56 
incubated with potential inhibitors for half an hour. In the meantime, Solution B, 
consisting of Bis-Tris propane, MgCl2, Triton X-100, E. coli LpoB, Lysine-lipid II, 
MurNAc-DAP-pentapeptide and water, was prepared. 750 nL of it was then added 
to the assay wells to initiate PBP1b-mediated transpeptidation. 
 
The enzymatic reaction was carried out for 45 min before the last solution was added. 
To stop the transpeptidation and develop the fluorescent signal, 1.5 µl of solution C, 
made of Bis-Tris propane, Ampicillin, R. gracalis DAAO, HRP, Amplex Red and 
water, was used. After each dispensing step, assay plates were spun at 600 rpm and 
incubated on the bench, covered with an opaque lid. The signal was measured using 
PheraStar plate reader, using flying mode (single flash per cycle), 540-20 nm excitation 
filter, 590-20 nm emission filter, at a focal height of 7.8 mm and gain value of 200. 
 
 
3.7  Assay validation  
 
Optimised assay formulation and procedure underwent a validation according to the 
standards of the Astra Zeneca Global High Throughput Screening Centre. The goal 
of the validation was the assessment of assay performance at full, 1536-well format, 
under high throughput conditions. It included determination of assay reproducibility 
and variability across the assay plate as well as sensitivity to theoretical inhibitors and 
a small set of test compounds. 
 
The first attempt of assay validation resulted in a negative result. Data showed very 
low day-to-day reproducibility and high variation coefficient accompanied by a 
distinct pattern of data distribution across the plate: alternating rows of higher and 
lower fluorescence intensity. A number of control experiments were done to 
investigate the cause of the observed aberration. It was concluded that it resulted from 
a fault in the bulk liquid dispenser. As it could not be convincingly repaired, the 
BioRaptr (Beckman) dispenser was replaced with a Certus Flex (Gyger) 8-channel 
device, and the validation was resumed. 
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3.7.1 Full plate variability and Z-factor 
 
To assess Z-factor of a particular experiment, a number of wells for positive and 
negative control are usually selected in the central part of the plate as shown in figure 
3.10. Only that data is then used for calculations. Z-factor determined this way is a 
good descriptor of assay quality yet it does not account for global plate variability which 
plays a major role in identifying hit compounds based on their Z-scores. 
 
To evaluate global variability, the whole plate was filled with assay reagents in the 
absence of tested compounds, control inhibitors or compound vehicle (DMSO). Data 
collected from 3 plates showed the average coefficient of variation to be 13%. That 
was mostly attributed to an apparent edge effect- wells localised along the edges of the 
plate which produced a significantly lower fluorescent signal. 
 
The Z-factor was measured for six plates using a standard layout with positive (assay 
reagents in the presence of 1% (v/v) DMSO)  and negative (assay reagents in the 
presence of 10 µM moenomycin, 1% (v/v) DMSO) control. The average Z-factor was 
0.815.  
 
 
 
Figure 3.10: Standard plate layout. For validation and screening purposes, four central columns of assay 
plates were reserved for control samples. Green fields indicate the position of positive control wells, i.e. 
assay reagents in the presence of 1% DMSO (compounds solvent). Red fields indicate negative control 
wells, i.e. assay reagents in the presence of 10 µM moenomycin. 
 
 
3.7.2 Signal reproducibility 
 
Two sets of 1400 compounds were employed to test assay reproducibility. Core 
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at 100 µM. The experiment was repeated in the same manner on another occasion. 
Percent effect and Z-score were calculated for all tested compounds using the 
following equations: 
 
Equation 3.2: %	𝑒𝑓𝑓𝑒𝑐𝑡 = 𝑥𝜇𝑝	×	100 
 
Equation 3.3: 𝑍 = 𝑥 − 𝜇𝜕  
where: 𝑥 – signal of the given sample 𝜇𝑝 – mean value of positive control 𝜇 – mean of all tested compounds on a single plate  𝜕 – standard deviation of all tested compounds on a single plate 
 
To assess agreement between the results on two occasions, the difference between Z-
scores was calculated and presented on a Bland-Altman plot (Figure 3.11). The data 
showed a small number of outliers. Most of the observed outliers had a positive average 
Z-score suggesting that some compounds might interfere with the assay causing high 
fluorescence readout. Importantly, compounds of negative Z-score, potential 
inhibitors, demonstrated very good reproducibility. The median Z-score difference for 
core compounds was 5.3% and 2.07% for low molecular weight compounds. 
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Figure 3.11: Data reproducibility for core (A) and low molecular weight (B) compounds.  
Bland-Altman plots show the degree of agreement between two experiments for the same group of 
tested compounds. Data points indicate differences between Z-scores obtained on two occasions (Y-
axis) and the average Z-score (X-axis). Ideally, all data points should lay within the confidence interval 
marked by dashed lines. Data plotted by Helen Plant. 
 
 
3.7.3 Assay response to known inhibitors 
 
Liberation of D-Alanine, the principle of this assay, is a direct consequence of the 
activity of peptidoglycan transpeptidases. This process can be impeded by β-lactams 
that are natural inhibitors of penicillin binding proteins. Class A PBPs however, have 
another enzymatic activity: transglycosylation. The N-terminal domain of class A 
PBPs polymerises lipid II moieties into linear molecules. This activity precedes 
transpeptidation and is believed to be its prerequisite (see section 1.3). Class A PBPs 
cannot catalyse transpeptidation between singular lipid II molecules, therefore in the 
absence of peptidoglycan polymers, inhibition of transglycosylation prevents also from 
transpeptidation (Suzuki et al., 1980). 
A
B
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Figure 3.12: Dose-response curves of selected inhibitors of transglycosylation and transpeptidation. 
A: Cefazolin; B: Cefmetazole; C: Cefoperazone, D: Cefoxitin; E: Cefpiramide; F: Ceftazidime; G: 
Imipnenem; H: Latamoxef; I: Vancomycin; J: Moenomycin. Antibiotics were tested against 10 nM E. 
coli PBP 1b in presence of 1.78 µM LpoB at the following transpeptidation conditions: 40 µM lipid 
II-Lys, 40 µM MurNAc-DAP-5P, 50 mM Bis-Tris propane pH 8.5, 20 mM MgCl2 , 0.1% (v/v) 
Triton X-100, 40 min incubation at room temperature followed by addition of detection reagents. Plots 
A-I: n=1, plot J: n=16. Data plotted by Clare Stacey.  
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To test the sensitivity of this system to theoretical inhibitors, a number of antibiotics 
were selected. The assay was tested against the only well studied TG domain inhibitor- 
moenomycin, a lipid II-binding drug- vancomycin, and eight β-lactams: cefazolin, 
cefmetazole, cefoperazone, cefoxitin, cefpiramide, ceftazidime, imipenem and 
latamoxef.  
 
For moenomycin, dose response experiment was designed to include 12 data points 
with 16 replicates each. Other antibiotics were tested at 10 different concentrations 
without replicates. For tested β-lactams, data were normalised and fractional activity 
was plotted against inhibitor concentration. For moenomycin, fluorescence intensity 
was plotted against its concentration. Half maximal inhibitory concentration (IC50) 
was extracted from dose response curves presented in figure 3.12. 
 
As expected, the strongest potency (IC50 of 22.6 nM) was observed for moenomycin, 
a tight binder of the transglycosylation domain. The most potent of β-lactams, 
cefpiramide, had IC50 of 103 nM. Vancomycin had IC50 of 18 µM. This is consistent 
with the mode of action of this drug, which chelates lipid II, where the lipid II 
concentration in the assay (40 µM) is just over double the vancomycin IC50. 
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Table 3.2: Half maximal inhibitory concentration (IC50) of tested transglycosylation and 
transpeptidation inhibitors. IC50 values  were derived from response curves presented in figure 3.12. 
 
 
 
 
 
 
Tested	agent Structure IC50		(M) Class
Moenomycin 2.26E-08 Moenomycins
Cefazolin 6.03E-05 1st	generation	cephaolosporins
Cefmetazole >1.0E-4
2nd	generation	cephaolosporins	
(cephamycin)
Cefoperazone 3.85E-07 3rd	generation	cephalosporins
Cefoxitin >5.0E-5
2nd	generation	cephaolosporins	
(cephamycin)
Cefpiramide 1.03E-07 3rd	generation	cephalosporins
Ceftazidime 2.71E-05 3rd	generation	cephalosporins
Imipenem >1.0E-4 Carbapenems
Latamoxef >1.0E-4
3rd	generation	cephalosporins	
(oxacephem)
Vancomycin 1.80E-05 Glycopeptides
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3.8  Screening 
 
The primary biochemical screen was designed to identify chemical compounds 
inhibiting either of E. coli PBP1b transglycosylase or transpeptidase activities. Assay 
reformat and optimisation allowed achievement of a throughput of over 6,000 test 
compounds per hour. Upon successful validation, the assay was used against a 
collection of 121,633 molecules selected from Astra Zeneca Global HTS Centre 
chemical library. Information included in this part of the chapter is limited due to the 
commercial value of the screening results. 
 
 
3.8.1 Library composition and experiment assembly 
 
Since the goal of this study was to discover and explore novel inhibitors of PBPs, 
compound sets were designed to ensure possibly high diversity. The library was 
composed of two major groups: core compounds and low molecular weight (LMW) 
compounds. Two groups of compounds differed by their molecular weight ranges. 
Core compounds had a molecular weight up to approximately 500 Da while LMW 
compounds had a molecular weight up to 300 Da.  
 
Prior to the experiment, tested compounds were dispensed into individual wells of 
assay plates using an Echo 555 acoustic liquid handler. Core compounds were tested 
at a final concentration of 10 µM and LMW compounds were tested at an elevated 
concentration of 100 µM to improve the hit rate (Wigglesworth et al., 2015). The 
screening set was divided into ten batches of eight and one batch of nine assay plates. 
 
 
3.8.2 Primary screening results 
 
Raw screening data were exported to be analysed in the GeneData Screener software 
package. Z-factor of each screening batch was calculated to assess data quality and 
varied between 0.77 and 0.88. 
 
Z-scores were then calculated for individual compounds, and those scoring (-4) or less 
were considered active inhibitors. Core compounds subset exhibited 1476 actives (hit 
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rate of 1.63%) while LMW subset included 926 actives (hit rate of 3.00%). The overall 
hit rate was 1.97%.  
 
 
3.8.3 Chemical triage of hit compounds 
 
Active compounds were then tested to exclude early-stage false positives. As 
determined by LC-MS, 628 of tested substances did not have required purity of 80%. 
All 2,402 active compounds were then tested against another, unrelated assay using 
HRP-AmplexRed detection system.  This experiment demonstrated 504 compounds 
were active in both assays, suggesting that they might interfere with the detection 
system rather than the primary enzymatic step. The remaining compounds were then 
re-tested using the transpeptidation assay in a concentration-response mode. 
Compounds of insufficient potency or poor curve fit were removed from further 
analysis. The final number of remaining actives was 397. 
 
 
3.9  Discussion 
 
 
3.9.1 D-Alanine release assay and existing methods to study transpeptidation 
 
Difficulties in obtaining pure and active PBPs and sufficient amounts of pure 
peptidoglycan intermediates limited development of research techniques for studying 
peptidoglycan synthetases. Most of the experimental systems used to study 
transpeptidation are based on the introduction of radiolabelled substrate e.g. D-amino 
acid serving as a TP acceptor. This approach was used in methods based on paper and 
high-performance liquid chromatography and scintillation proximity measurements 
(Tsuruoka et al., 1984; Lupoli et al., 2011). 
 
The method developed by Dr Adrian Lloyd is the first quantitative, continuous assay 
of transpeptidation activity using non-radioactive substrates. Presented here, the D-
alanine release paradigm provides the way for real-time data collection and can be 
utilised for enzyme kinetics. As demonstrated here it can also be adapted to a 
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microplate format and still deliver high-quality data. It makes it a suitable tool for high 
throughput, and potentially ultra-high throughput, target-based drug screening.   
 
 
3.9.2 Limitations of the D-alanine release TP assay 
 
In certain conditions, e.g. favourable pH or lack of suitable acceptor, some 
transpeptidases including E. coli PBP1b can catalyse a reaction between peptidoglycan 
and a water molecule. It results in trimming peptidoglycan pentapeptide stem to 
tetrapeptide and release of terminal D-alanine. This type of catalysis is called 
carboxypeptidation (Sauvage et al., 2008). Due to this phenomenon, quantification of 
D-alanine might not be a definitive measure of transpeptidation. 
 
This issue was overcome at an earlier stage of assay development by careful selection 
of efficient transpeptidation substrates and reaction conditions. Using MurNAc-
DAP-pentapeptide as a highly effective transpeptidation acceptor effectively 
suppressed the relative background lipid II Lys carboxypeptidation rate to marginal 
levels. This solution was successful for E. coli PBP1b yet might not be applicable for 
other enzymes. Therefore, the assay might have limited scope of use. 
 
Another potential downside of the used assay is related to its complexity. Development 
of the photometric/ fluorimetric assay came at a price of employing two coupling 
enzymes. In the drug screening setup, this poses a significant issue of increasing the 
number of false actives. The reaction mixture contained four isolated proteins in total, 
three of which are enzymes. Observed signal reduction may have resulted from 
compound interference with D-amino acid oxidase or horseradish peroxidase. Such 
incidents are undesired as they give false positive results and relevant triage procedure 
should be devised. 
 
To identify compounds that hinder the detection system, all primary hits could be 
tested in an experiment where all transpeptidation reagents were replaced with D-
alanine. In presented work, this step was carried out by testing primary hits against 
another biochemical assay based on the DAAO-HRP-AmplexRed system. This 
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experiment revealed 504 compounds, yet it did not address the issue of potential 
DAAO inhibitors.  
 
 
3.9.3 General observations from the assay development process 
 
This chapter describes the process of adaptation of a single channel, 
spectrophotometric, biochemical assay into the high-throughput method used for 
target-based drug screening. This seemingly straightforward task proved to be 
challenging in several respects. 
 
The original design was thoroughly tested and very well characterised by Dr Lloyd. 
Nonetheless, reduction of the reaction volume and switching from the photometric to 
the fluorimetric mode of data collection caused a clear disparity. TP reaction rates did 
not behave the same way over time, and a number of factors had to be optimised again 
mostly to address decreased signal to noise ratio of the fluorimetric assay. Optimised 
HTS-ready TP assay required twice as much of the enzyme and donor and 8-times 
more of the acceptor when compared to the original formulation. This significant 
increase in reagents consumption was mitigated by the 133-fold decrease in the assay 
volume (TP step).  
 
Another aspect of this work worth emphasising is the reliability of the high 
throughput hardware. As all HTS assays must meet stringent quality criteria, highly 
reproducible performance of the used equipment, especially liquid handlers, played a 
critical role. As mentioned before, the assay failed to pass its first validation and might 
never have reached the screening stage. Only after careful investigation which revealed 
the underlying cause, the fault in the liquid dispenser that introduced high variability 
into collected data could the assay be further progressed. The primary method quality 
metric, Z-factor, is very sensitive to data variation as the equation triples standard 
deviations of the control groups. The issue was resolved by the employment of another 
dispensing device yet it vividly demonstrated the importance of excellent hardware 
performance.  
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3.9.4 Alternative solutions to address insufficient signal to background ratio 
 
As noted in the previous paragraph, the greatest challenge in the process of adapting 
the D-alanine release method into the HTS assay was achieving a sufficient signal to 
background ratio. Apart from the attempts described in the results, two other solutions 
were considered. 
 
Optimisation of the spectrophotometric assay revealed that the TP reaction rate and 
signal magnitude was dependent on the detergent used to solubilise E. coli PBP1b and 
lipid II. Using hexaethylene glycol dodecyl ether instead of Triton X-100 improved 
the assay performance (personal communication with Dr Adrian Lloyd). When tested 
in the fluorimetric, microplate assay no significant difference between the two 
detergents was observed. 
 
Another tested modification regarded the hydrogen peroxide detection method. 
Fluorogenic Amplex Red was replaced by the chemiluminescent reagent HyPerBlue 
(Lumigen). Claimed great sensitivity, stability and peroxidase independence offered 
by this method were promising, but tests demonstrated it is not suitable for coupling 
with the D-alanine release. Observed signal to background ratio was much lower than 
when Amplex Red was used (1.68 and 2.76 respectively). Additionally, measured 
luminescent signal was highly variable with variation coefficient scoring 7.74% and 
15.02% for the positive and the negative control group (n=16) respectively. 
 
 
3.9.5 Potency of tested inhibitors 
The only well described active site inhibitor of bacterial glycosyltransferases, 
moenomycin, is a natural product mimicking dimeric lipid II. Moenomycin A forms 
up to 10 hydrogen bonds with the TG domain of E. coli PBP1b (Sung et al., 2009) 
Although its in vivo potency against Gram-negative bacteria is poor, it exhibits a 
strong in vitro inhibition of isolated enzymes. It is considered to be a tight binder. The 
KD of its fluorescent derivative determined by fluorescence anisotropy experiment was 
54 nM (Cheng et al., 2008). Inhibitor kinetic experiments with fluorescently labelled 
derivatives of lipid II presented in another study reported the  inhibitor dissociation 
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constant (Ki) to be 1.1 +/- 0.4 nM and 1.2 +/- 0.2 nM (Huang et al., 2013). This work 
generally confirms the high potency of moenomycin against E. coli PBP1b with IC50 
in the presence of 10 nM enzyme of 22.6 nM. 
 
Due to the lack of functional assays for peptidoglycan transpeptidation, information 
on β-lactam in vitro potency is limited to that obtained from the interaction of PBPs 
with β-lactams in the absence of natural substrates. The effect of newly developed β-
lactam antibiotics can be assessed by measuring the relative affinity of selected PBPs 
for the particular agent. Traditionally, this was achieved by penicillin displacement 
assays, where C14 –labelled benzylpenicillin would compete for binding site occupancy 
with the tested agent (Curtis et al., 1979; Ohya et al., 1982). The affinity would be 
expressed as a concentration of the molecule that reduces benzylpenicillin binding by 
50 or 90%. Information on absolute affinities of β-lactams to E. coli PBP1b is also 
limited. 
 
Here we tested in vitro potency of eight β-lactams and found exact half-inhibitory 
concentrations of four of them. The remaining four antibiotics demonstrated 
reduction of enzyme activity, yet their dose-response curves had a poor fit or 
insufficient data points within tested concentration range, and their IC50 values could 
not be derived. Notably, two of the tested 3rd generation cephalosporins, cefoperazone 
and cefpiramide, showed significantly higher potency than other β-lactam drugs, 
characterised by IC50 values of 385 and 103 nM respectively. The assay presented here 
demonstrates therefore that it may provide an excellent tool for quantification of the 
molecular effects of transpeptidation inhibitors and exploring structure-activity 
relationships. 
 
The only glycopeptide antibiotic tested here, vancomycin was also the only one whose 
mode of action was not directed towards active sites of the enzyme. Vancomycin is a 
lipid II binder that acts by forming 5- hydrogen bond interactions with the D-alanine-
D-alanyl moiety of the lipid II peptide stem (Chen et al., 2003). Given that, in theory, 
it may sequester both TP donor and acceptor used in the reaction. 
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Interestingly, the vancomycin IC50 (18 µM) was 4.44 times lower than combined 
concentration of D-Ala-D-Ala containing substrates (80 µM) when theoretically it 
should not be lower than half of it. This might suggest that vancomycin specifically 
targets lipid II Lys, not the acceptor substrate used in the reaction. 
 
The exact model of de novo peptidoglycan synthesis by the bifunctional PBPs is not 
known however it is believed that TG domain needs to generate short lipid II polymers 
before transpeptidation can occur. If vancomycin can prevent PBP1b from 
synthesising long enough polymers and arrest it at the stage of transglycosylation, it 
might exhibit stronger TP inhibitory effect than it could be postulated based on the 
simple 1:1 stoichiometry.  
 
 
3.10 Future work 
 
 
3.10.1 Orthogonal assay design 
 
All primary hits identified within the tested library were subjected to a chemical triage 
that led to reduction of the number of putative inhibitors by 83.5%, from 2,402 to 397 
compounds. To fully confirm their inhibitory properties, we propose to develop an 
MS-based assay. PBP1b catalyses formation of the covalent linkage between the 
uncrosslinked polymer of lipid II-Lys (TP donor molecule) and MurNAc-DAP-
pentapeptide (TP acceptor molecule). Treatment of the resulting molecule with 
muramidase releases transpeptidation prodcuts- fragments formed by MurNAc-
DAP-pentatpetide and GlcNAc-MurNAc-Lys-tetrapeptide. Quantitation of these 
molecules by mass spectrometry should give a definitve evidence of the reaction 
outcome.  
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3.10.2 Elucidation of the mode of inhibition 
 
Although the assay described in this chapter was primarily designed to study 
peptidoglycan transpeptidation, it is in theory sensitive to four types of inhibitors. True 
hits might inhibit the reaction by: 
 
a) Interference with the PBP1b TP domain active site 
b) Interference with the PBP1b TG domain active site 
c) Lipid II sequestration 
d) Impediment to the PBP1b-LpoB interaction. 
 
Repeating dose response experiments at different concentration of the target enzyme 
and substrate might imply the general nature of the inhibitor, yet to investigate 
mechanisms of inhibition more precisely, additional assays must be devised.  
 
Compounds binding to the TP domain active site could be potentially examined with 
modified β-lactams serving as molecular probes. Bocillin FL, a fluorescent penicillin, 
is an example of such molecule (Zhao et al., 1999). It allows probing TP domain site 
and is used in competitive binding experiments. Binding of bocillin to transpeptidases 
can be observed by measuring fluorescence anisotropy which allows developing a 
relatively simple, microplate-based protocol (Shapiro et al., 2013). 
 
As demonstrated by the example of moenomycin, inhibition of transglycosylation 
halts D-alanine release and signal development. TG-inhibiting compounds should be 
identified as hits. There is several functional transglycosylation assays described in 
literature (Schwartz et al., 2002; Huang et al., 2013; King et al., 2017) that could be 
used to confirm this mode of inhibition. We propose to use for that purpose a novel 
TG assay that is described in Chapter 4 of this work.  
 
In current conditions, the success of the transpeptidation reaction occurring in the 
assay depends entirely on presence of the lipoprotein cofactor, LpoB. Disruption of 
the PBP1b-LpoB interaction may suppress transpeptidation. This mechanism of 
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inhibition has not been reported to date but it can not be excluded that some chemical 
compounds might cause such effect.  
 
In 2016 Markovski and colleagues identified four variants of E. coli PBP1b that can 
bypass the LpoB requirement (Markovski et al., 2016). These proteins, all carrying 
single amino acid mutation, were shown to be significantly more active than the wild 
type enzyme in absence of LpoB. When used in the D-alanine release assay, these 
mutant proteins could help to identify compounds interfering with the enzyme-
cofactor interaction. Unlike three other kinds of inhibitors, these chemicals should not 
have any effect on the cofactor-bypass variants of PBP1b.  
 
 
3.10.3 Testing antimicrobial potency of hit compounds 
 
Confirmed hit compounds should be tested for their antimicrobial properties, 
primarily against the wild type E. coli. Since PBP1b is partially redundant and can be 
complemented by PBP1a, using the a knock-out ΔPBP1a strain might be a more 
sensitive way to demonstrate potential bactericidal effect of tested compounds.  
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CHAPTER 4: Development of a novel time-resolved FRET 
transglycosylation assay 
 
 
 
4.1 Introduction 
 
Peptidoglycan biosynthesis enzymatic machinery has proven to be a clinically 
important target for antibiotics. Cell wall integrity is essential for bacterial survival 
and proliferation. Interference with its synthesis process often leads to the 
development of an abnormal cell morphology and lysis. The most successful and 
prevalent class of antibiotics, β-lactams, inhibits the final step of peptidoglycan 
assembly, transpeptidation, carried out by penicillin-binding proteins. 
 
Relatively little effort has been put into the development of antibiotics targeting the 
preceding step of peptidoglycan synthesis, transglycosylation. The disaccharide units 
of the peptidoglycan precursor, lipid II, need to be converted into linear polymers to 
form peptidoglycan backbones. Formation of these strands determines the 
occurrence of transpeptidation. The process is carried out by either mono-functional 
transglycosylases or transglycosylation domains of the class A penicillin-binding 
proteins. 
 
The only nature-derived direct inhibitor of transglycosylases, moenomycin, was 
discovered in the 1960s and demonstrated strong bactericidal activity against Gram-
positive organisms. Although the substance used to be commonly used as a growth 
promoter in animal feed, moenomycin resistance is extremely infrequent (Gampe et 
al., 2013; Halliday et al., 2006). Unfortunately, due to its pharmacokinetics, namely 
poor oral bioavailability and long serum half-life moenomycin has never become a 
therapeutic agent and development of transglycosylation-inhibiting antibiotics 
remains an unmet need. 
 
In the recent years, a number of research groups revisited that issue and attempted to 
identify novel transglycosylation inhibitors (see paragraph 1.3.1.2). This was mostly 
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possible thanks to the improved understanding of peptidoglycan biology and better 
access to cell wall intermediates. Several assay techniques have been developed since 
the beginning of the 21st century and some of them were used for inhibitor discovery 
purposes. Here we propose a novel functional transglycosylation assay and 
demonstrate its application in the chemical library screening. 
 
 
4.2  Experimental aims 
 
• To develop a novel biochemical assay for transglycosylation activity of E. coli 
PBP1b using bespoke reagents and detection method  
• To explore method characteristics and potential limitations 
• To optimise the assay for the high throughput drug screening  
• To identify other potential applications of the developed technology 
 
 
4.3  Assay design 
 
Keeping in mind its desired application, screening of chemical libraries for enzyme 
inhibitors, we focused on detection methods considered suitable for high throughput 
screening. The ideal method would: 
• deliver high-quality data 
• be applicable in a microplate format 
• be economically viable 
• be easy to scale up and automate  
 
We propose a novel approach to detecting transglycosylation in vitro. The concept is 
based on replacement of the natural transglycosylation substrate, lipid II, with its 
singly biotinylated variant. This substitution was proposed before by Suzanne 
Walker Kahne (US patent US 6,461,829B1) as a way of capturing transglycosylation 
products with avidin-coated beads for further purification and analysis. Our concept 
uses biotin moieties as binding sites for fluorophores to provide a homogeneous, 
real-time readout. 
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The principle of this assay is an enzymatic conversion of a singular biotinylated lipid 
II molecules into polymeric peptidoglycan strands with multiple biotin groups. The 
resulting product can be labelled with streptavidin-conjugated fluorophores. 
Application of two fluorophores with overlapping emission and excitation spectra 
allows for the fluorescence resonance energy transfer (FRET) to occur whenever 
biotinylated lipid II is being polymerised. When in close proximity, energy emitted 
from the donor fluorophore excites acceptor fluorophore which leads to the emission 
of the specific fluorescence. The whole process is illustrated in figure 4.1. Energy 
transfer does not occur when lipid II molecules remain in a monomeric state. This 
allows for differentiation between a successful or impaired glycosyl transfer.  
 
 
 
Figure 4.1: Schematic illustration of the HTRF transglycosylation assay principle. Conversion of 
biotinylated lipid II into linear peptidoglycan chains by the E. coli PBP1b is followed by the labelling 
with two streptavidin-conjugated FRET dyes: Europium or Terbium cryptate serving as a FRET 
donor and a red-shifted FRET acceptor d2. Successful peptidoglycan synthesis gives rise to a red 
fluorescence of the FRET donor (665 nm). 
 
 
4.3.1 Lipid II modification 
 
Biotinylation of lipid II was achieved by the reaction between the primary amine of 
the position 3 amino acid of the peptide stem, lysine or diaminopimelic acid (DAP), 
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and a biotin N-hydroxysuccinimide ester (see paragraph 2.5.2). This conjugation 
method ensures site-specific, single biotinylation. Skeletal formula of the 
biotinylation product is shown in figure 4.2. Apart from providing the binding site 
for streptavidin conjugates of FRET fluorophores, biotinylation of lipid II plays 
another important role. Substitution of the ε-amine prevents the newly synthesised 
peptidoglycan from cross linking. Lack of the free amine group at position 3 of the 
stem peptide prohibits transpeptidation. This ensures that observed FRET results 
exclusively from the formation of linear molecules and makes the assay 
transglycosylation specific. 
 
 
Figure 4.2 Skeletal formula of biotinylated lipid II DAP with a C-55 tail. Courtesy of Dr Adrian 
Lloyd. 
 
 
4.3.2 Peptidoglycan labelling 
 
Biotinylated molecules can be decorated with molecular beacons attached to 
streptavidin. Biotin and streptavidin engage into one of the strongest non-covalent 
interactions known in nature. This allows for stable labelling, resistant to most 
experimental conditions. Our transglycosylation assay employs two streptavidin-
conjugated fluorophores, lanthanide (Europium or Terbium) cryptate (see Figure 
4.3) as a FRET donor molecule and a red emission FRET acceptor called d2. This 
labelling technology is marketed as HTRF (Homogenous Time Resolved 
Fluorescence) by CisBio. 
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Figure 4.3:  Structure of Europium cryptate tris-bipyridine. Adapted from Degorce et al. 2009. 
 
Using lanthanide cryptates with long emission half lives as FRET donors enables a 
time resolved data collection. This means that a 50-150 µs delay between excitation 
of the donor molecule and measurement of the acceptor emission can be applied. 
This allows reducing the contribution of the unspecific, background fluorescence 
which is often short-lived. (Degorce et al. 2009, Current Chemical Genomics). 
HTRF technology finds its application in drug screening projects where tested 
compounds often interfere with the regular fluorescence readout and increase the 
number of false positives or negatives.  
 
HTRF requires a fluorimeter capable of producing excitation wavelength of 340 nm 
and simultaneous measurement of fluorescence of 620 and 665 nm that are 
characteristic for FRET donor and acceptor respectively. Donor emission intensity is 
measured as an internal reference while acceptor fluorescence indicates the 
occurrence of biological reaction leading to FRET events. The final data output is 
calculated using the following equation: 
 
Equation 4.1:    HTRF= FI665/FI620*104 
 
Where: 
 FI- fluorescence intensity measured at emission wavelength shown in the subscript 
(nm) 
 
Ratiometric data analysis is thought to diminish well-to-well variability and 
quenching effects, especially arising from photophysical properties of assay reagents 
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and tested compounds. To our knowledge, transglycosylation assay described here is 
the first use of HTRF technology to detect formation of polymeric molecules.   
 
 
4.3.3 Assay formulation 
 
Reagent Final concentration 
Bis-Tris propane pH 8.5 50 mM 
NaCl 20 mM 
MgCl2 10 mM 
Triton X-100 0.03% 
Glycerol 1% 
HTRF donor (Eu3+ or Tb2+ cryptate) approx. 0.75- 1.33 nM (1x working solution) 
HTRF acceptor approx. 83.5 nM (1x working solution) 
KF 100 mM (only when using Eu3+ cryptate as HTRF 
donor) 
Biotinylated lipid II-DAP variable 
E. coli PBP1b variable 
E. coli LpoB optional, variable 
 
 
Table 4.1: Composition of the HTRF transglycosylation assay. 
 
 
The method was developed primarily for use with E. coli PBP1b. Class A PBPs 
activity is often dependent on the presence of bivalent metal ions. Due to the highly 
hydrophobic character of the substrate and presence of the transmembrane element 
in the enzyme, the reaction must occur in the micellar environment created by the 
addition of a detergent. To make this method compatible with the transpeptidation 
assay described in chapter 3, similar buffer composition is used. HTRF labelling mix 
is prepared accordingly to manufacturer instruction. FRET donor and acceptor are 
diluted, mixed together and added to the TG reaction mixture at 1:1 volume 
proportion. 
 
 
4.4 Measurement of the enzyme-substrate affinity 
 
Apart from the advantages described before, biotinylation of lipid II enables the 
immobilization of the molecule on streptavidin-coated surfaces. Immobilisation of 
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the substrate prevents enzymatic catalysis. This quality was used in bio-layer 
interferometry experiments to look at affinity between PBP1b and its substrate. The 
Octet Red instrument (Pall Forte-Bio) was used to carry out the experiment. High 
precision streptavidin-coated BLI fiber-optic sensors (SAX, Pall Forte-Bio) were 
saturated with lipid II and then dipped into a series of wells containing the enzyme 
at different concentrations. 
 
Collected data were analysed using the proprietary software (Pall Forte-Bio). No 
enzyme control was used to obtain a baseline that was then subtracted from other 
sensograms (see Figure 4.4). Dissociation constant was calculated using a global 
fitting model and it was found to be 14± 0.88 nM. 
 
 
 
Figure 4.4: Biolayer interferometry sensograms of biotinylated lipid II- PBP1b binding. Sensograms 
at different E. coli PBP1b concentrations. Y-axis shows wavelength shift (nm). Trace of 0 µM PBP 
sample is not shown. It was used as a baseline and subtracted from other sensograms.  
 
 
4.5  Proof-of-concept experiment using a two-step protocol 
 
In order to test the concept, a two-step experiment was designed in which 
transglycosylation and peptidoglycan labelling were carried out independently. The 
TG step was carried out in the total volume of 50 µl, using 200 nM of 6-His-tagged 
PBP1b and 1 µM biotinylated-lipid II-DAP. Transglycosylation was initiated by 
addition of the enzyme into the reaction mix. Three kinds of negative controls were 
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set up: native substrate control where biotinylated lipid II-DAP was replaced with its 
nonbiotinylated variant, no enzyme control where PBP1b was replaced with its 
dilution buffer and moenomycin inhibition control where 10 µM moenomycin A 
was added. 
 
Samples were incubated for 30 min at room temperature and heat treated (2 min 
incubation at 95oC in a Mastercycler Gradient thermocycler, Eppendorf) to 
inactivate the enzyme. After cooling, samples were transferred into a black, half-area, 
96-well plates (Greiner Bio-one) and  50 µl of FRET labelling reagents mix was 
added to the reaction. The signal was measured after 15 min incubation using 
Clariostar plate reader (BMG Labtech) equipped with HTRF-specific excitation 
and emission filters. The instrument was set as recommended by the HTRF dyes 
manufacturer, see table 4.2.  
 
Clariostar settings for HTRF with red-shifted acceptor 
Excitation filter 330 (80) nm 
Emission filter 1 620 (10) nm 
Emission filter 2 665 (10) nm 
Integration delay (lag time) 60 μs 
Integration time 400 μs 
Number of flashes 200 
Optimal focal height Volume and plate format dependent 
Gain 2600  with black plate 2400 with white plate 
 
Table 4.2: Plate reader settings recommended by CisBio for HTRF experiments using Clariostar 
plate reader. Numbers in brackets next to excitation wavelengths indicate filter bandwidths. 
 
 
Data analysis revealed the positive outcome of the proof of concept experiment 
(Figure 4.5). The HTRF signal of the transglycosylation sample was 4,044 units and 
was 5.3 and 6.9 times higher than in no enzyme and moenomycin-inhibited controls 
respectively. Native substrate samples had an HTRF signal of only 180.8, which 
equals 4.47% of the specific signal observed in the uninhibited transglycosylation 
sample. This finding suggests that observed FRET events depend vastly on the 
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specific interactions between biotinylated substrate and streptavidin-conjugated 
fluorophores. This observation was further reinforced by the experiment in which 
development of FRET signal was fully inhibited upon addition of free biotin (data 
not shown). 
 
 
 
Figure 4.5: HTRF signals observed in the proof-of-concept experiment. Columns represent mean 
values of 5 replicates. Error bars show standard deviations. Full reaction composition: 200 nM E. coli 
PBP1b, 1 µM biotin-DAP-lipid II, 1x HTRF labelling mixture (Europium), 50 mM Bis-Tris 
propane pH 8.5, 10 mM MgCl2, 20 mM NaCl, 100 mM KF,  0.03% Triton X-100, 1% glycerol. 10 
µM moenomycin A added to the appropriate control. 
 
 
4.6  Transglycosylation time-dependency observed in a two-step HTRF protocol 
 
A similar experiment was carried out to establish the time dependency of the 
transglycosylation in vitro. At this occasion, reaction volume was reduced to 25 µl. 
Samples for each incubation interval were set up in a reverse order and the reaction 
was stopped by heat inactivation of the enzyme. After cooling, samples were labelled 
with 25 µl of the HTRF reagents mix and transferred into a black, 384-well 
microtiter plate (Greiner Bio-one) 15 min before measuring the FRET signal. 
Collected data (Figure 4.6) demonstrated a clear positive relation between 
incubation time and FRET signal intensity suggesting an enzyme-driven character 
of the experiment outcome. 
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Figure 4.6: Time-course two-step transglycosylation assay.  Data points represent mean values of 5 
replicates. Error bars show standard deviations. Full reaction composition: 200 nM E. coli PBP1b, 1 
µM biotin-DAP-lipid II, 1x HTRF labelling mixture (Europium), 50 mM Bis-Tris propane pH 8.5, 
10 mM MgCl2, 20 mM NaCl, 100 mM KF,  0.03% Triton X-100, 1% glycerol 
 
 
 
4.7   Assay development 
 
 
4.7.1 Buffer optimisation 
 
Although previously published studies on class A PBPs included buffer containing 
sodium chloride at relatively high concentration e.g. 200 mM, (Schwartz et al., 
2002), our early findings suggested that it might have an adverse effect on enzyme 
activity. To assess that, a two step protocol was used where transglycosylation was 
halted by heat inactivation after a 10 min incubation, which was approximately the 
duration of the initial rate phase observed in the time-dependency experiment (see 
paragraph 4.5) Additionally, the effect of magnesium chloride was compared with 
two other bivalent metal salts, calcium chloride and nickel chloride. All salts except 
nickel chloride were tested between 0 and 500 mM. The maximal tested 
concentration of nickel chloride was 300 mM. Because of the composition of the 
enzyme storage buffer, additional 1 mM MgCl2 and 50 mM NaCl were present in all 
tested samples. The data collected in these experiments are presented in figure 4.7. 
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Figure 4.7: Effect of salts on the HTRF transglycosylation assay. 50 µl reaction. Charts show FRET 
intensities reached in the TG reaction after a 10 min incubation. Columns represent mean values of 5 
replicates. Error bars show standard deviations. Additional NaCl and MgCl2 from the enzyme storage 
buffer were accounted. Please note that all salts are tested in different dilution series.  
 
 
Salts titration experiments showed that high concentrations of tested substances had 
a negative effect on transglycosylation rate. NaCl above 112 mM diminished the 
FRET signal which highlights a difference between this method and other reported 
E. coli PBP1b assays. Additionally, tested bivalent metal ions showed the negative 
impact. Although MgCl2 is reported to be required for the enzyme purification and 
activity experiments, its presence above low-mid millimolar concentration is 
impeding transglycosylation. Nickel chloride, in particular, demonstrated a strong 
adverse effect. It had not only inhibitory effect on the enzyme but also, at high 
concentration, it affected fluorescence of FRET dyes, suppressing the signal of both 
donor and acceptor molecule. 
 
The observation of unfavourable influence of salts at high concentration motivated 
changes in assay composition. In further experiments, europium cryptate used as 
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FRET donor was replaced with terbium cryptate since the latter does not require the 
presence of potassium fluoride. 
 
 
4.7.2 Frequency of peptidoglycan labelling 
 
Labelling of peptidoglycan using streptavidin-conjugated dyes provides a relatively 
easy way to build a FRET-based assay yet it provokes numerous questions regarding 
molecular interactions occurring in vitro. First of all, the concentration of HTRF 
reagents, especially donor dye, is minuscule in comparison to biotinylated lipid II. 
Labelling of 1 µM lipid II accordingly to the protocol recommended by the 
manufacturer means that, at most, only every twelfth lipid II molecule gets 
decorated. In that population, only 1 in 111 or 1 in 63 would carry europium or 
terbium cryptate, respectively. This statistic theoretically diminishes the probability 
of FRET occurrence. 
 
To determine whether FRET signal can be improved, the regular labelling mix was 
compared with two others, where donor content was doubled and quadrupled. The 
experiment was carried out using a two-step protocol described in paragraph 4.5. 
Negative control samples were prepared by excluding PBP1b.  
 
 
Figure 4.8: Optimisation of the FRET donor content. Columns represent mean values of five 
replicates. Error bars show standard deviations. Asterisk indicates invalid data set. 50 µl reaction. Full 
reaction composition: 200 nM E. coli PBP1b, 1 µM biotin-DAP-lipid II, 1x HTRF acceptor, 
variable HTRF donor (Terbium), 50 mM Bis-Tris propane pH 8.5, 10 mM MgCl2, 20 mM NaCl,  
0.03% Triton X-100, 1% glycerol. 
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Collected data (Figure 4.8) showed that doubling the HTRF donor concentration 
has a marginally positive effect on signal magnitude. In fact, observed signal to 
background ratio scored 3.49 which was lower than in the case of the regular 
labelling mixture (4.35). Using quadrupled FRET donor, had a strong apparent 
effect on HTRF ratio. Closer analysis of raw fluorescence intensities, however, 
showed that at quadruple FRET dyes content the plate reader was oversaturated 
which renders these data invalid. Intensity of FRET donor reached its top value for 
most of the samples, therefore calculated HTRF ratio does not reflect true results. 
 
 
4.7.3 Influence of accessory lipoprotein LpoB 
 
In 2010 two research groups independently reported the discovery of accessory 
lipoproteins, associated with class A penicillin-binding proteins in some Gram-
negative bacteria (Pardis-Bleau et al., 2010; Typas et al., 2010). Anchored in the 
outer membrane, they span across periplasm to interact with regulatory domains of 
their cognate PBPs and enhance peptidoglycan synthesis. 
 
E. coli PBP1b interacts with the outer membrane protein LpoB. It was believed that 
this interaction acts primarily on the transpeptidation activity of the enzyme but 
studies demonstrated its clear influence on transglycosylation as well. 
 
 
4.7.3.1 Influence of LpoB on the transglycosylation rate  
 
To assess the influence of Lipoprotein B on transglycosylation rate, a two-step 
HTRF protocol was used. 50 nM E. coli PBP1b was tested in the presence and 
absence of 200 nM E. coli LpoB. Data were collected at five time points between 0 
and 60 min. Based on the plotted data (Figure 4.9), initial rate intervals were 
determined to be between 0-2 min and 0-10 min for samples in presence and 
absence of LpoB respectively. Change in HTRF ratio was calculated for these 
intervals. The addition of LpoB was found to cause a 20.6-fold increase of the initial 
reaction rate. 
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Figure 4.9: Effect of LpoB on transglycosylation rate. Data points represent individual replicates 
(n=3). 50 µl reaction. Full reaction composition: 50 nM E. coli PBP1b, optional 200 nM E. coli 
LpoB, 1 µM biotin-DAP-lipid II, 1x HTRF labelling mixture (Terbium), 50 mM Bis-Tris propane 
pH 8.5, 10 mM MgCl2, 20 mM NaCl,  0.03% Triton X-100, 1% glycerol. 
 
 
4.7.3.2 Influence of LpoB on the peptidoglycan chains length 
 
As reported by Paradis-Bleu and colleagues in their 2010 study, in the presence of its 
cofactor LpoB, E. coli PBP1b generated dramatically shorter peptidoglycan polymers 
(Pardis-Bleau et al., 2010). Use of LpoB in our assay system is desired as it increases 
enzymatic activity and might lead to an identification of a new inhibition 
mechanism. Nevertheless, shortening of poly-biotinylated peptidoglycan molecules 
might have an adverse effect on the assay signal as it diminishes the probability of 
FRET occurrence.  
 
When dansylated lipid II is used as a substrate, SDS-PAGE can be employed to 
analyse the size of in vitro synthesised peptidoglycan (Hellasa et al., 2010). Synthesis 
and purification of dansyl-DAP-lipid II, as well as the electrophoretic method for 
peptidoglycan analysis, were described in sections 2.5.5 and 2.6. To assess LpoB 
influence on PBP1b processivity, a series of single time point reactions were carried 
out with varying concentrations of the enzyme and its cofactor. The samples were 
incubated for 90 min and then mixed with the loading buffer and separated in a 
Tris-Tricine 10-20% gradient PAA gel (Section 2.6). 
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Figure 4.10: Effect of enzyme concentration and LpoB on peptidoglycan processivity of E. coli 
PBP1b. Left panel: Comparison of reaction products using a Tris-tricine PAGE. Reactions set up 
with 10 µM dansyl-DAP-lipid II. Right panel: Densitometric analysis of peptidoglycan chain length 
distribution. 
 
 
Distribution of dansylated species in the Tris-tricine SDS gel (Figure 4.10) allows 
assuming that in all samples, apart from the negative control (lane A) monomeric 
lipid II was completely converted into molecules of higher molecular weight. In the 
absence of LpoB, only very large peptidoglycan fragments could be observed and 
PBP1b concentration did not significantly affect product lengths distribution. The 
addition of the lipoprotein led to significant changes in the distribution pattern. 
Products were spread all across the lane and a characteristic ladder-like pattern of 
short polymers could be seen in the bottom half of the lanes. The effect of LpoB on 
polymer length was stronger at higher cofactor concentration.  
 
To visualise observed changes in a clearer way, collected picture was analysed 
densitometrically using Image J software (Abramoff et al., 2004). Pixel intensity 
histograms were generated for each individual lane. Characteristic peaks of short 
polymers can be seen for LpoB-including samples. Cofactor dose effect is more 
apparent as the peaks corresponding to high molecular weight material become 
broader with increasing LpoB concentration. Still, even in presence of LpoB at 8-
fold enzyme concentration, only a small fraction of dansylated lipid II is converted 
into short (dodecamer or shorter) polymers. This suggests that addition of the 
cofactor would not significantly interfere with the FRET-dependent assay. 
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Another in-gel peptidoglycan analysis was carried out to confirm the effect of LpoB 
on the transglycosylation rate. 100 nM PBP1b in absence or presence of 200 nM 
LpoB was used to catalyse the conversion of 10 µM dansyl-DAP lipid II into 
peptidoglycan polymers in a time-course experiment. Samples were incubated for 1, 
3, 5, 10, 20, 40 and 60 minutes before the reaction was halted by addition of 50 µM 
moenomycin. Reaction products were separated in a Tris-tricine SDS PAA gel as 
described in section 2.6. Gel pictures were analysed to determine the shortest 
interval required for turnover of all monomeric lipid II into polymers (see Figure 
2.6). For PBP1b on its own, it was 20 minutes while in presence of LpoB it was 5 
minutes which corresponds with other data presented here and in literature. 
 
 
4.7.3.3 Influence of LpoB on lipid II binding 
 
LpoB has been shown to have a substantial effect on the transglycosylation process. 
As shown in previous paragraphs, it affects reaction rate and the products size 
profile. To investigate the mechanism of LpoB influence, a bio-layer interferometry 
experiment was carried out (Figure 4.11), similarly as in paragraph 4.4. This time 
PBP1b was mixed with its cofactor at a 1:2 molar ratio. 
 
 
 
 
Figure 4.11: Biolayer interferometry sensograms of biotinylated lipid II- PBP1b binding in presence 
of LpoB. Sensograms at different E. coli PBP1b concentrations. LpoB concentration was 2-fold 
higher.  Y-axis shows wavelength shift (nm). Trace of 0 µM PBP and 0 µM LpoB was used as a 
baseline and subtracted from the other sensograms. 
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In the presence of LpoB, lipid II-PBP1b affinity, expressed as dissociation constant, 
was reduced from 14 nM to 26 nM. Kinetics of the interaction was also altered. The 
addition of LpoB resulted also in faster association and dissociation rate constants 
(Table 4.3).  
 
 
 
kon 
(M-1 s-1) kon error 
kdis 
(s-1) kdis error KD KD error 
PBP1b 1.18E+05 4.16E+03 1.66E-03 8.62E-05 1.40E-08 8.78E-10 
PBP1b+ LpoB 1.98E+05 5.13E+03 5.18E-03 7.32E-05 2.62E-08 7.76E-10 
 
Table 4.3: Kinetics and affinity of lipid II and PBP1b in absence and presence of LpoB 
 
 
4.8  Continuous TR-FRET transglycosylation assay 
 
Successful experiments with the two-step HTRF protocol lead to postulating the 
concept of the continuous transglycosylation assay. In this setup, transglycosylation 
and peptidoglycan labelling steps would not be separated. The enzymatic reaction 
would not require being terminated by heat inactivation prior to addition of the 
FRET dyes. Fluorescence intensities could be read almost continuously providing 
better time course data. This change would make the experiments easier to execute 
and also to adapt it into the high throughput format. 
 
To test the concept an experiment was carried out where transglycosylation occurred 
in presence of streptavidin-conjugated fluorophores. In fact, HTRF dyes were mixed 
with lipid II prior to initiating the reaction by addition of the PBP1b. In other 
words, the enzyme carried out peptidoglycan synthesis using partially pre-labeled 
substrate. 
 
Low volume, 384-well, white plates (Greiner Bio-one) were introduced in order to 
carry out 20 µl reactions. 100 and 50 nM E. coli PBP1b was tested in absence and 
presence of 2-fold LpoB. Moenomycin at 10 µM was added to 100 nM PBP1b and 
200 nM LpoB sample to serve as a negative control. The reaction occurred at 25oC 
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and data were collected every 2 minutes. Using the equation 4.1, HTRF ratio was 
calculated and plotted against time. Initial rates of FRET intensity change were 
calculated and compared between the samples, see table 4.4. 
 
The experiment demonstrated that HTRF transglycosylation assay concept can be 
successfully used in a continuous mode (Figure 4.12). In the absence of LpoB, 
however, the HTRF signal to background ratio reached only up to 3.23. Also, the 
stimulating effect of the lipoprotein B was not as strong as previously described in 
the paragraph 4.7.3.1, nevertheless these two experiments are not directly 
comparable. None of the tested samples seemed to reach a stable plateau phase. 
When PBP1b was tested on its own, 100 nM sample demonstrated 2.4 times faster 
signal change rate than 50 nM sample. Interestingly, in presence of LpoB, higher 
maximal magnitude and signal change rate were observed for 50 nM PBP1b than for 
100 nM.  
 
 
 
Figure 4.12: Demonstration of a continuous TR-FRET transglycosylation assay performance. Data 
points represent mean values of 3 replicates. Error bars show standard deviations. Continuous assay at 
20 µl format. Full reaction composition: variable E. coli PBP1b, optional E. coli LpoB at 2-fold PBP 
concentration, 1µM biotin-DAP-lipid II, 1x HTRF labelling mixture (Terbium), 50 mM Bis-Tris 
propane pH 8.5, 10 mM MgCl2, 20 mM NaCl, 0.03% Triton X-100, 1% glycerol. Negative control: 
100 nM PBP1b+ LpoB+ 10 µM moenomycin A.  
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 HTRF/min fold change 
100 nM PBP1b 58.12 
6.07 100 nM PBP1b +LpoB 352.66 
50 nM PBP1b 24.68 16.09 
50  nM PBP1b +LpoB 397.29 
100nM PBP1b +Moenomycin 11.70  
 
Table 4.4: Initial reaction rates measured in a continuous TR-FRET transglycosylation assay   
 
 
4.8.1 Determination of the substrate concentration working range 
 
To characterise enzymatic activity of PBP1b using the new assay, an experiment was 
designed to find the relation between substrate concentration and reaction rate. The 
ultimate goal was to find the saturating concentration of biotinylated lipid II and 
determine Michaelis-Menten constant of transglycosylation in assay conditions. 
Two fold dilutions of the substrate in the range between 5 µM and 312 nM were 
prepared. No-enzyme and no-substrate samples were used as negative controls. 
 
The experiment results were opposite to those expected: FRET signal magnitude 
was inversely proportional to the concentration of the substrate and there was no 
correlation between lipid II concentration and signal change rates (Figure 4.13). 
This observation might suggest that assay outcome depends strongly on the 
substrate-HTRF ratio. At constant FRET dyes concentration, an increase of 
substrate concentration reduces labelling frequency and thus FRET occurrence. This 
might explain a dramatic drop in signal magnitude. 
 
In another experiment, samples at various lipid II concentrations were mixed with 
proportional amounts of FRET dyes to maintain equal labelling ratio. 
Unfortunately, at quadruple HTRF concentration (mixed with 4 µM lipid II) the 
result was similar to that described in paragraph 4.7.2: high intensity of fluorescent 
signal caused plate reader oversaturation making the data unusable. Concentration of 
HTRF dyes recommended by the manufacturer was shown before to be optimal but 
it can be used only with a fairly narrow range of biotinylated lipid II concentration. 
The assay is therefore unsuitable for in-depth study of enzyme kinetics. 
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Figure 4.13: Effect of substrate concentration on the signal magnitude and apparent reaction rate. 
Data points represent mean values of 3 replicates. Error bars show standard deviations. Continuous 
assay at 20 µl format. Full reaction composition: 100 nM E. coli PBP1b, variable biotin-DAP-lipid II, 
1x HTRF labelling mixture (Terbium), 50 mM Bis-Tris propane pH 8.5, 10 mM MgCl2, 20 mM 
NaCl, 0.03% Triton X-100, 1% glycerol.  
 
 
4.9  Other tested bacterial transglycosylases 
 
Source 
organism 
Protein details Source Result 
Staphylococcus 
aureus 
MGT FL 
Dr Avinash 
Punekar 
High activity observed at ≥ 1 
µM 
Staphylococcus 
aureus 
MGT ΔTM 
rubredoxin chimera 
Dr Avinash 
Punekar 
High activity observed at ≥ 1 
µM 
Staphylococcus 
aureus 
MGT ΔTM NBD-
fused 
Dr Avinash 
Punekar 
High activity observed at ≥ 1 
µM 
Yersinia pestis PBP1b Ms Katie Smart 
Very high activity observed in 
absence and presence of Y.pestis 
LpoB 
Mycobacterium 
tuberculosis 
PonA Mr Daniel McFeely No activity observed 
Pseudomonas 
aeruginosa 
PBP1a 
Ms Carmina 
Micelli 
High, yet unstable activity 
observed at ≥ 1 µM 
Acinetobacter 
baumanii 
PBP1b 
Ms Carmina 
Micelli 
No activity observed 
 
Table 4.5: List of bacterial transglycosylases tested with the TR-FRET transglycosylation assay 
0:0
0
0:1
0
0:2
0
0:3
0
0:4
0
0:5
0
1:0
0
1:1
0
1:2
0
1:3
0
0
1000
2000
3000
Time
H
TR
F 
ra
tio
No enzyme
0 µM
5 µM
2.5 µM
1.25 µM
0.62 µM
0.31 µM
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In the course of the assay development process, a number of other class A PBPs and 
monofunctional transglycosylases were tested for their enzymatic activity using the 
TR-FRET method. These enzymes were expressed and purified by other laboratory 
members. Proteins were tested with biotinylated variants of their proprietary 
substrates. Staphylococcus aureus MGT was tested with lipid II-lysine, Mycobacterium 
tuberculosis PonA was tested with N-glycolylated lipid II-DAP and for other 
enzymes regular biotinylated lipid II-DAP was used. Trials results are summarised 
in table 4.5. 
 
 
4.10 Assay sensitivity to known inhibitors 
 
As described in paragraph 1.3.1.2, a number of new inhibitors of bacterial 
transglycosylases have been identified in the last decade. Some of them are putative 
inhibitors of the TG domain, others are reported to act via lipid II sequestration. 
Multiple natural product antibiotics have been shown to inhibit cell wall synthesis 
using the latter mechanism but only moenomycin can occupy the catalytic site of 
TG-ases. 
 
To further demonstrate the assay’s specificity, a number of cell wall-affecting 
antibiotics were tested for their potency. The list included moenomycin and seven 
lipid II binders: mersacidin, deoxyactagardine B (both provided by Novobiotics), 
vancomycin, nisin, ramoplanin as well as recently discovered teixobactin (courtesy of 
Kim Lewis) and tridecaptin (courtesy of John Vederas). Additionally, bacitracin and 
three β-lactams were added to serve as a negative control. All agents were tested at 
seven different concentrations being a series of two-fold dilutions. The tested range 
for moenomycin was 2 µM to 31 nM while all other antibiotics were tested at 10 
µM to 156 nM. 
 
A set of regular, 20 µL format experiments was carried out to determine half 
minimal inhibitory concentrations against 50 nM PBP1b in the presence of 100 nM 
LpoB. Data were collected in a continuous manner which allowed to calculate 
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HTRF signal change rate. The values were plotted against log-transformed 
antibiotics concentrations and IC50 values were derived using GraphPad Prism.  
As expected, moenomycin proved to be the most potent inhibitor with IC50 of 93.9 
nM which equals 1.87-fold of the enzyme concentration. This result correlates well 
with the data described in the paragraph 2.5.3 where IC50 of moenomycin 
determined with the D-alanine release transpeptidation assay was 2.26-fold higher 
than enzyme concentration (22.6 nM) (see Figure 4.14, left panel). 
 
Among tested lipid II-binding antibiotics, only vancomycin (Figure 4.14, right 
panel), deoxyactagardine B and nisin demonstrated inhibitory activity against 
transglycosylation. Their half minimal inhibitory concentrations were 908 nM, 1.97 
µM and 530 nM respectively. The potency of nisin, however, might be overrated. 
Due to unavailability of pure product, a 2.5% formulation of Lactococcus lactis nisin 
mixed with sodium chloride and denatured milk solids was used (Sigma Aldrich). As 
shown before, NaCl has a negative impact on the assay thus its presence might have 
contributed to the observed reduction in signal change rate. 
 
 
 
Figure 4.14: Dose response curves of transglycosylation inhibitors moenomycin and vancomycin. 
Data points represent mean values of 3 replicates. Error bars show standard deviations. Continuous 
assay at 20 µl format. Full reaction composition: 50 nM E. coli PBP1b, 100 nM E. coli LpoB, 1 µM 
biotin-DAP-lipid II, 1x HTRF labelling mixture (Terbium), 50 mM Bis-Tris propane pH 8.5, 10 
mM MgCl2, 20 mM NaCl, 0.03% Triton X-100, 1% glycerol.  
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The remaining antibiotics did not demonstrate dose-dependent effects. 
Nevertheless, closer analysis revealed that ramoplanin and teixobactin caused a shift 
in FRET signal at the onset of the reaction. FRET acceptor signal (665 nm) was 
elevated in these samples and their time course curves did not have the usual shape. 
This phenomenon was further investigated and described in the next paragraph.  
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4.11  Investigating lipid II binders 
 
The observation of an unusual signal magnitude at an early stage of the reaction in 
the presence of ramoplanin and teixobactin suggested that some of the tested 
antibiotics might give rise to non-enyzymatic driven FRET between individual 
molecules of lipid II. To test that, five lipid II binders were used in a TR-FRET 
transglycosylation assay in absence of the PBP1b enzyme that would polymerise lipid 
II. Two-fold serial dilutions of ramoplanin, teixobactin, deoxyactagardine B, 
mersacidin and vancomycin were prepared to cover the range between 0.5 and 32 
µM. E. coli PBP1b was replaced with its storage buffer. Samples were incubated at 
room temperature for 30 minutes and HTRF ratio was measured. Data are 
presented in figure 4.15. 
 
Deoxyactagardine B, mersacidin and vancomycin did not produce any significant 
change in the assay signal when compared to the background noise level. Samples 
with ramoplanin and teixobactin, however, showed a very strong increase in FRET 
signal confirming previous observations that these antibiotics appear to induce 
aggregation of lipid II. That effect was partially dose-dependent. At low 
concentration (≤ 1 µM) teixobactin had a weaker effect than ramoplanin. 
 
 
 
 
Figure 4.15: Development of enzyme-independent FRET signal in presence of lipid II-binding 
antibiotics.  Data points represent mean values of 3 replicates. Error bars show standard deviations. 
The dotted line shows background noise level. Single time point experiment at 20 µl format. Full 
reaction composition: 1 µM biotin-DAP-lipid II, 1x HTRF labelling mixture (Terbium), 50 mM 
Bis-Tris propane pH 8.5, 10 mM MgCl2, 20 mM NaCl, 0.03% Triton X-100, 1% glycerol. 
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4.12 TR-FRET assay for peptidoglycan hydrolysis 
 
Previous paragraphs demonstrated that labelling of lipid II with streptavidin-
conjugated FRET dyes is a viable method of assessing in vitro activity of bacterial 
transglycosylases. As the development of the specific FRET signal depends on 
polymerisation of the substrate, an opposite effect should be observed when labelled 
peptidoglycan is treated with hydrolases.  
 
To verify this hypothesis, 1 µM biotinylated DAP-lipid II was incubated with 100 
nM E. coli PBP1b for 90 minutes at room temperature in presence of HTRF dyes 
and then treated with 1 µL chicken egg white lysozyme solution (Sigma Aldrich). 
The final concentration of lysozyme in the samples was 0.15 and 0.02 mg/mL which 
corresponds with 10.5 and 1.4 µM. Hydrolysis reaction was carried out at 25oC in a 
384-well microplate in the total volume of 21 µL. TR-FRET data were collected 
every 70 seconds and plotted against incubation time (Figure 4.16). A sample with 
lysozyme dissolution buffer (25 mM Tris-HCl, pH 7.5) was used as a negative 
control. 
 
 
 
Figure 4.16: HTRF-based peptidoglycan hydrolysis assay. Data points represent mean values of 3 
replicates. Error bars show standard deviations. Peptidoglycan was presynthesisedin the following 
conditions: 50 nM E. coli PBP1b, 100 nM E. coli LpoB, 1 µM biotin-DAP-lipid II, 1x HTRF 
labelling mixture (Terbium), 50 mM Bis-Tris propane pH 8.5, 10 mM MgCl2, 20 mM NaCl, 0.03% 
Triton X-100, 1% glycerol. Reaction was incubated for 90 min at room temperature. 20 µL aliquots 
were then loaded into the microplate wells and 1 µL of chicken egg lysozyme was added to reach 
intended concentrations. Hydrolysis reaction was carried out at 25 oC.  
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As expected, samples, where peptidoglycan was treated with lysozyme, showed a 
dramatic signal loss over time and that effect occurred much faster at higher 
lysozyme concentration. In fact, the initial part of the signal curve of the 0.15 
mg/mL sample was not recorded due to the delay between adding the lysozyme and 
collecting the data of the first time point. The results imply that the TR-FRET 
transglycosylation method can be applied to study in vitro activity of peptidoglycan 
hydrolases.  
 
 
4.13 Discussion  
 
 
4.13.1 TR-FRET assay and other existing methods to study peptidoglycan 
transglycosylation 
 
Fifty years ago the discovery of moenomycin was thought to initiate a new class of 
very potent natural product antibiotics. Limited activity against Gram-negative 
bacteria combined with poor pharmacokinetics disproved that belief. No other 
natural products directly inhibiting bacterial transglycosylases have been discovered 
and this class of enzymes was abandoned as potential antibiotics targets. Limited 
knowledge on peptidoglycan biology and access to key chemical intermediates 
preserved this status quo until the early 21st century.  
 
The rising threat of multi-resistant bacteria intensified work on the discovery of new 
antibiotics and put some forgotten targets back in the focus of researchers. Bacterial 
transglycosylases received attention as potential targets and a number of research 
groups worked on assays to monitor their activity and screen for novel inhibitors (see 
paragraph 1.3.1.2). These methods are based on radiolabeling (Branstrom et al., 
2000; Kumar et al., 2014), direct peptidoglycan labelling with fluorophores 
(Schwartz et al., 2002; Huang et al., 2013), moenomycin displacement (Cheng et al., 
2008; Gampe et al., 2013) or use of anti-pyrophosphate antibody (King et al., 2017).  
In this work, we tested an alternative method of transglycosylation assay that 
combines substrate simplicity, lack of coupling enzymes, HTS-compatible detection 
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method and a great potential for miniaturisation. In our assay, the enzyme uses just 
one substrate that requires relatively simple, single modification. Successful 
application of HTRF dyes is advantageous in the prospect of the compound library 
screening. In the course of assay development, reactions were mostly carried out in 
the total volume of 20 µL yet lower volumes and higher plate density (1536-well) 
were tested with very good results. This further improves method’s cost efficiency. 
Importantly, the substrate synthesised for this assay system found two additional 
applications. Biotinylation allowed to use it in a straightforward BLI protocol to 
study enzyme binding and to develop the peptidoglycan hydrolysis assay. 
 
 
4.13.2 Assays limitations 
 
Despite its advantages, the described assay demonstrated several shortcomings. 
Firstly, although the final outcome of each experiment is presented as a ratio of 
fluorescence intensities of FRET acceptor and donor, which should, in theory, 
reduce variability, there were substantial differences in signal (HTRF ratio) 
magnitude observed between separate experiments. This might be caused by the 
inaccuracies in lipid II and HTRF dyes dosing. Both reagents are stored as very 
concentrated stock solutions and need to be diluted hundred (HTRF dyes) or several 
hundred times (lipid II) prior to the experiment setup. As shown in paragraph 4.8.1, 
alteration of lipid II-HTRF dyes ratio has a big impact on the signal magnitude. 
Since fresh working solutions of the reagents were prepared before most of the 
experiments, this cannot be excluded as a source of variability. Additionally, a 
number of assay formats were tested and they differed by reaction volume, plate type, 
preparation procedure and plate reader settings. This makes many of the experiments 
presented in this chapter to be not directly comparable. 
 
Another issue is also related to the lipid II-HTRF interplay. Paragraphs 4.7.2 and 
4.8.1 investigated working ranges of lipid II and FRET fluorophores concentrations. 
Lipid II-HTRF dyes ratio decides on the signal magnitude and working range. 
Increased concentration of the biotinylated substrate leads to a reduction in labelling 
frequency and signal decline. Theoretically, HTRF content in the reaction mix. 
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should be increased or decreased proportionally to the lipid II. Unfortunately, as 
shown in paragraph 4.7.2, HTRF dyes have very limited practicable concentration 
range. This makes it impossible to establish a relation between the substrate 
concentration and a reaction rate. Therefore, the assay presented here is not suitable 
for quantitative characterisation of enzymatic activity.  
 
 
4.13.3 Valency and spatial distribution of streptavidin-fluorophore conjugates 
 
Streptavidin from Streptomyces avidinii is a 52.8 kDa protein build of 4 identical 
subunits. Its wild type variant is a tetravalent biotin binder. Streptavidin multivalence 
might be undesired for the proposed assay concept. A single streptavidin-
fluorophore conjugate occupying more than one binding sites along the 
peptidoglycan chain might affect labelling frequency and reduce the chance of 
bringing the donor and acceptor dyes into proximity. Additionally, large globular 
molecule, like streptavidin, present on the peptidoglycan chain or lipid II molecule 
might hinder substrate binding by the enzyme.  
 
To get a clearer perception of how these interactions might look at a molecular level, 
the geometry of binding partners was inspected. To assess the distance between 
biotin binding pockets in neighbouring streptavidin subunits, a crystal model 
resolved by Le Trong and colleagues was used (Le Trong et al., 2011).  
 
     
 
Figure 4.17: Structure of biotin-binding interfaces of streptavidin. Biotin molecules are shown in red. 
Left panel illustrates top view on the biotin-binding clefts. The right panel depicts structural features 
separating two pockets and was produced by molecule rotation along the y axis. PDB entry: 3RY2. 
Reported resolution= 0.95 Å. 
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The structure (PDB entry: 3RY2) depicts two subunits in complex with two biotin 
molecules (Figure 4.17). Sulphur atoms of biotin were used as reference points. 
Using UCSF Chimera 1.11.2 software (Petersen et al., 2004), the shortest distance 
between them was found to be 21.193 Å. Although the binding clefts are exposed 
and relatively shallow, they are separated by two bulging beta sheets and a groove at 
the interface of the subunits. This makes the distance significantly longer. 
 
Experimental data on peptidoglycan structure is very limited. In 2006 Meroueh and 
colleagues, using NMR, resolved a structure of monomeric lipid II-Lys and used it 
to compute a model of an octamer. Their work included calculation of torsion angles 
along the polysaccharide backbone of peptidoglycan and suggested its geometry to be 
a right-handed helix of a three-fold symmetry. This simulation did not account, 
however, for any external interactions affecting the shape of the octamer thus it 
appears to be a straight and rigid molecule. 
 
The biggest peptidoglycan fragment of resolved structure is a hexamer analysed by 
solid state NMR by Shanda et al. in 2014. (PDB entry: 2MTZ). Their study shows 
an uncross-linked murein fragment in complex with Bacillus subtillis D-L-
transpeptidase Ldt (Figure 4.18). In contrast to the former publication, these data 
allow observing multi-directional flexibility of peptidoglycan induced by the 
interaction with the protein. The structure poses perhaps the best available example 
of peptidoglycan behaviour in a protein-enriched environment and, to some extent, 
allows to estimate distances between biotin moieties along the peptidoglycan 
synthesised in our assay.  
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Figure 4.18: Structure of the fragment of the hexameric lipid II chain resolved by solid-state NMR. 
The dotted line represents the distance between ε-amine groups of DAP residues of two 
neighbouring stem peptides.  
 
Since biotinylation of lipid II utilises ε-amine groups, they were used as reference 
points. Complex and irregular spatial setting of the hexamer induces variability into 
distances between neighbouring stem peptides. As measured with Protein Workshop 
4.2.0 (RCSB PDB), amino groups of DAP moieties were separated by 16.17 to 
31.98 Å (on average 25.32 ± 6.67 Å). 
 
Obtained distances imply that multivalent interaction between streptavidin and 
biotinylated peptidoglycan is possible yet might be difficult to involve neighbouring 
or closely situated stem peptides. Theoretically, this type of interplay might cause a 
formation of peptidoglycan ‘loops’. Significantly, influence of streptavidin valency on 
FRET occurrence might also depend on the length of peptidoglycan chains. 
  
A better understanding of the studied system would require at least complex 
simulations if not extensive structural characterisation. Data collected throughout 
this work do not clarify much about the intricacies of the peptidoglycan-streptavidin 
interplay. Successful implementation of the transglycosylation and hydrolysis assay 
concepts, however, suggest that discussed concerns regarding streptavidin spatial 
conformation might be unfounded.  
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4.13.4 Role of lipoprotein B 
 
In bacterial cells, class A PBPs interact with other proteins, often participating in 
large complexes (den Blaauwen et al., 2014). As these enzymes carry out two final 
stages of peptidoglycan synthesis, their activity must be precisely coordinated. From 
all binding partners of E. coli PBP1b, LpoB seems to be the most critical for its 
activity. The introduction of lipoprotein B into the assay formulation was an 
important milestone in the assay development. It allowed reducing enzyme 
concentration, especially in the continuous transglycosylation assay. 
 
Experiments carried out in this chapter clearly demonstrated the importance of the 
PBP1b-LpoB interaction and confirmed previously published findings. Using a 
novel transglycosylation assay, the strong stimulating effect of lipoprotein B was 
clearly demonstrated. Depending on the experiment design, the presence of LpoB 
caused 6 to 20-fold increase in the reaction rate. The observed effect was much 
stronger than the 1.5-fold activation previously reported by Paradis-Bleau and 
colleagues (Paradis-Bleau et al., 2010; supplementary information) or 8-fold 
stimulation reported by Egan and colleagues (Egan et al., 2014). 
 
Also, the impact of LpoB on the distribution of peptidoglycan chains length was 
confirmed with the aid of electrophoretic analysis of fluorescently labelled polymers. 
A study by Paradis-Bleau and colleagues, using a similar method, showed that 
addition of LpoB causes a shift in peptidoglycan size distribution. In this work 
(4.7.3.2) we improved methods resolution by the employment of gradient, rather 
than fixed percentage, SDS gels. This change allowed to clearly visualise bands 
representing polymers of uniform sizes. The characteristic ladder-like pattern could 
be seen only for very short peptidoglycan polymers though.  
 
Improved resolution revealed also that moenomycin does not completely inhibit lipid 
II polymerisation. In presence of the antibiotic two bands can be seen- a very 
intensive band of monomeric lipid II and a much fainter band of higher molecular 
weight, perhaps a dimeric form of the substrate, lipid IV. This observation is 
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consistent with the fact that moenomycin inhibits transglycosylases thanks to its 
resemblance to lipid IV rather than lipid II (Huang et al., 2012). 
 
In the attempt to further investigate the phenomenon of LpoB-driven stimulation of 
PBP1b enzymatic activity, substrate binding was analysed using bio-layer 
interferometry (see paragraph 4.7.3.3). Biotinylated lipid II synthesised for the 
purpose of assay development, proved to be applicable also as a molecular bait for 
measuring substrate-enzyme interactions. Binding of PBP1b to its substrate 
immobilised on a BLI chip was carried out in presence and absence of LpoB. The 
presence of the lipoprotein reduced affinity, expressed as an equilibrium dissociation 
constant, from 14 to 26.2 nM. This change should be attributed mostly to the faster 
dissociation rate. Altered substrate binding profile in presence of LpoB might be a 
result of a long-range allosteric effect hypothesised by Egan and colleagues (Egan et 
al., 2014). 
 
 
4.13.5 Testing the assay concept with other transglycosylases  
 
Class A PBPs are often challenging to work with. Being membrane proteins of high 
molecular weight, these enzymes are likely to produce low yields when 
overexpressed. Moreover, some of the constructs are unstable upon purification. 
Another difficulty is protein activity, successful overexpression and purification 
seldom guarantee in vitro activity. Isolated protein might bind β-lactams yet be 
unable to carry out its catalytic functions. 
 
E. coli PBP1b is perhaps the most studied class A PBP. Discovered in a model 
organism, it received a lot of interest over the decades. The enzyme can be produced 
in satisfying amounts in bacterial protein expression systems. It was also shown to be 
active in vitro in numerous studies (Suzuki et al., 1980; Terrak et al., 1999; Bertsche 
et al., 2005; Huang et al., 2013; Egan et al., 2015)  
 
The TR-FRET transglycosylation assay was developed for E. coli PBP1b but was 
also tested with several other class A PBPs and a monofunctional transglycosylase 
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that were isolated at the University of Warwick during the project. The best results 
were observed for Yersinia pestis PBP1b. This protein is 65.4% identical to its E. coli 
homologue and behaved similarly in transglycosylation activity tests. Additionally, Y. 
pestis produces lipoprotein B sharing 44.6% amino acid sequence identity with E. coli 
LpoB. It further stimulated in vitro transglycosylation rate. This observation 
suggests that presented method could be used with other close homologues of E. coli 
PBP1b, especially from bacteria expressing outer membrane PBP cofactors e.g. 
Klebsiella, Shigella and other genera of the Enterobacteriaceae family.  
 
In vitro glycosyl transfer was also demonstrated for full length Pseudomonas 
aeruginosa PBP1a and Staphylococcus aureus MGT. These proteins, however, require 
assay optimisation as the signal to background ratio was significantly lower than in 
the case of E. coli PBP1b. Additionally, P. aeruginosa PBP1a produced a signal that 
was gradually decaying after approximately 20 minutes of incubation.  
 
Interestingly, two soluble constructs of S. aureus MGT also gave positive results with 
the TR-FRET transglycosylation test. NBD-fused construct and rubredoxin-MGT 
chimera demonstrated TG activity and sensitivity to moenomycin in spite of the the 
lack of the transmembrane domain. As the reaction occurs in the micellar 
environment of Triton X-100, accessing the substrate should require some degree of 
hydrophobic attraction. It can not be excluded that the patch of hydrophobic 
residues conserved in transglycosylases (Bury et al., 2015; Heaslett et al., 2009) 
suffices to support this interaction. 
 
 
4.13.6 Dose response of tested inhibitors 
 
Unlike transpeptidases that are targets of numerous approved antibiotics, 
transglycosylases remain underexploited as therapeutic targets. A number of research 
projects were carried out in the recent years to address this issue, and many of them 
used moenomycin as a control molecule for validation of their discovery methods. 
Moenomycin, being an invaluable tool for development of transglycosylation assays, 
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was also tested in this work. Using the method presented in this chapter, a half 
inhibitory concentration of moenomycin was determined to be 93.9 nM. In the 
previous chapter moenomycin dose response experiment carried out with a D-
alanine release assay in presence of 10 nM enzyme showed the IC50 to be 22.6 nM.  
 
Without knowing assay conditions, IC50 is not a very informative measure of the 
inhibitor potency. Target and substrate concentrations should be clearly stated for 
the accurate assessment. Table 4.7 compares moenomycin potency against E. coli 
PBP1b reported in the literature using several existing techniques with regards to the 
enzyme concentration used in the experiment. Relative IC50 was introduced to 
express the ratio of reported half inhibitory concentration and enzyme content. 
 
Reference Method [PBP1b] 
Reported 
IC50 
Relative 
IC50 
This work TR-FRET TG assay 50 nM 93.9 nM 1.88 
This work D-alanine release assay 10 nM 22.6 nM 2.26 
Mesleh et al. 
2016 
Assay using dansylated lipid 
II described by Schwartz et 
al. (2002) 
80 nM 19 nM* 0.24 
King et al. 
2016 
Pyrophosphate sensing 
assay 
1 uM 64.3 nM 0.064 
Kumar et al. 
2014 
SPA using 14C-labelled lipid 
II 
n/a- E. coli 
membrane isolates 
used 
9 nM n/a 
Chen et al. 
2003 
Paper chromatography 
using 14C-labelled lipid II 
6 nM 30 nM** 0.2 
Table 4.7: Published moenomycin half inhibitory values against E. coli PBP1b *authors assume the 
enzyme used in the experiment to be partially inactive; **PBP1b concentration determined by 
moenomycin titration 
 
 
Data showed that both methods presented in this thesis have similar relative IC50 of 
1.88 and 2.26 for the TR-FRET TG assay and D-alanine release assay respectively. 
Theoretically, assuming 1:1 stoichiometry of inhibition, relative IC50 should be 
higher or equal to 0.5, yet other cited papers report it to be significantly lower. This 
puts in question genuineness of these findings. Mesleh and colleagues indicated that 
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fact and assumed their enzyme batch could be only partially active which, as 
mentioned before, is often the case when working with class A PBPs.  
 
Besides moenomycin, several other substances were tested for their 
transglycosylation-inhibiting properties. The focus was laid upon lipid II-binding 
natural products. From that group, only vancomycin, deoxyactagardin B and nisin 
demonstrated inhibition in experiment conditions. Their IC50 values were 0.9, 1.97 
and 0.53 µM respectively. The potency of nisin might be overestimated due to the 
product formulation since it could not be obtained in its pure form. Nisin from 
Lactococcus lactis is used as a preservative in the dairy industry, therefore, is often sold 
mixed with denatured milk solids and sodium chloride and this particular 
formulation was used in potency experiments. The presence of NaCl could have an 
adverse effect on enzyme activity. 
 
Unexpectedly, mersacidin, ramoplanin and teixobactin showed no apparent 
inhibition of transglycosylation. All three natural products were previously 
demonstrated to bind lipid II in vitro (Brötz et al., 1998; Fang et al., 2006; Ling et 
al., 2015). Closer analysis of data revealed that ramoplanin and teixobactin affected 
the FRET acceptor signal magnitude and caused the altered shape of the time course 
curve. This observation was followed by an experiment in absence of PBP1b. Both 
ramoplanin and teixobactin, when added to the TR-FRET transglycosylation assay 
mix, caused a dramatic increase of the HTRF signal suggesting that both natural 
products provide for FRET interaction to occur. This effect was dose dependent and 
did not occur in absence of lipid II so the unspecific interaction between tested 
antibiotics and streptavidin-fluorophore conjugates was excluded. 
 
Ramoplanin was shown to form homodimers (Hamburger et al., 2009). Both 
ramoplanin and teixobactin are thought to bind lipid II with 2:1 stoichiometry (Fang 
et al., 2006; Ling et al., 2015) suggesting that their active form is indeed dimeric. 
Observations from the TR-FRET experiments imply, however, that ramoplanin and 
teixobactin may form bigger molecular assemblies, perhaps higher order polymers or 
aggregates.  
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The TR-FRET assay was also used to test an antimicrobial lipopeptide, tridecaptin 
A1, shown recently to act via lipid II binding (Cochrane et al., 2016). It shows 
bactericidal activity specifically against Gram-negative bacteria and it was 
demonstrated to disrupt inner membrane by the interaction with lipid II. Using a 
combination of NMR and molecular docking, Cochrane and colleagues suggested 
that binding between tridecaptin and lipid II involves ε-carboxylate of DAP residue. 
Engagement of diaminopimelic acid in this interaction might explain why 
tridecaptin did not demonstrate transglycosylation inhibition in the TR-FRET 
assay. Presumably, biotinylation of DAP hinders tridecaptin binding. 
 
 
4.14 Future work 
 
 
4.14.1 Chemical library screening for novel transglycosylation inhibitors 
 
Given the success of the assay development stage, the next natural step would be to 
validate the assay in the real-life high throughput set-up and carry out the library 
screening. Ideally, the assay should be used to examine both diverse and selected 
focused compound libraries. As the majority of cell-wall affecting agents are nature-
derived, it would be advantageous to test collections of either purified natural 
products or cellular extracts.  
 
 
4.14.2 Optimisation of the assay for use with other bacterial transglycosylases 
 
The goal of this work was to test the concept of a new transglycosylation assay and 
optimise it for use with E. coli PBP1b. The method can be therefore used to screen 
for inhibitors of that enzyme or used as a secondary assay to help deconvolute the 
mode of action of compounds identified with a D-alanine release method described 
in chapter 3. Although the main focus was laid upon E. coli PBP1b, the TR-FRET 
transglycosylation assay was tested with several other enzymes generously provided 
by colleagues. Three of tested proteins gave positive outcomes, but only Y. pestis 
PBP1b produced data of good quality, similarly to its E. coli homologue. It is likely 
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that assay conditions could be improved to provide better results for other active 
enzymes.  
 
The concept was shown to work for different proteins and it might be worthwhile to 
express and purify a wider range of transglycosylases from bacteria species of clinical 
significance. Since soluble constructs of S. aureus MGT demonstrated in vitro 
activity, truncation of transmembrane domains seems to be a viable way to make this 
task more feasible. Having several enzymes compatible with the TR-FRET 
transglycosylation assay would allow determining multi-targeting of any potential 
hits arising from the screening.   
 
 
4.14.3 Strategies to confirm hits authenticity 
 
The assay in the presented form should theoretically be sensitive to substances of 
three distinct modes of inhibition. As demonstrated by examples of model inhibitors 
(see paragraph 4.10), moenomycin and some lipid II-binding natural products, TG 
activity of PBP1b can be impeded by either obstruction of the enzyme catalytic site 
or substrate sequestration. At current experimental conditions, however, enzymatic 
activity is strongly dependent on the PBP1b-LpoB interaction. This condition 
constitutes the third potential mode of inhibition. Substances interfering with the 
binding interface of either protein partner might be identified as hit compounds. 
This mechanism of inhibition has not been reported to date. 
 
Any hits arising from the primary screening should be confirmed using an 
orthogonal analytical method. We propose to test identified hit compounds with the 
aid of mass spectrometry. Each round of transglycosylation leads to the liberation of 
the lipidic tail from the monomeric substrate (see paragraph 1.2.3). As demonstrated 
by Mesleh and colleagues, (Mesleh et al., 2016) release of undecaprenyl 
pyrophosphate (C55PP) can be detected upon solid phase extraction. Authors used a 
high throughput mass spectrometry system yet even in absence of HT equipment, 
the method seems feasible for tens or hundreds of compounds. Most importantly it 
provides a definitive evidence for inhibition of transglycosylation. 
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4.14.4 Further investigation of ramoplanin and teixobactin mode of action 
 
Assay validation experiments delivered interesting observations regarding two of the 
tested lipid II-binding inhibitors. Ramoplanin and teixobactin when mixed with 
assay reagents in the absence of E. coli PBP1b lead to signal development. This 
suggests that they bind lipid II and form some sort of molecular assemblies that 
provide conditions for FRET to occur. Both antibiotics were shown before to bind 
lipid II in 2:1 ratio yet it does not explain observed effect. It is worth investigating, 
whether this phenomenon is an artefact caused by the assay methodology and used 
conditions or results from inherent properties of ramoplanin and teixobactin. 
 
We propose to test the formation of ramoplanin and teixobactin complexes with the 
aid of dynamic light scattering (DLS) or size exclusion chromatography followed by 
multi angle light scattering (SEC-MALS). If confirmed, this could shed a new light 
on the mode of action of these natural products. 
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CHAPTER 5: Implementation of the TR-FRET transglycosylation 
assay into high throughput screening. 
 
 
 
 
5.1  Introduction 
 
Chapter 4 presented development process of a novel transglycosylation assay. Single 
chemical modification made to the lipid II substrate and application of the 
commercially available FRET dyes pair enabled monitoring peptidoglycan 
polymerisation in a near real-time. The method was made compatible with high-
density microplates and validated with several known inhibitors. 
 
As shown in several studies in the recent years, small molecules inhibitors of 
transglycosylation can be identified within existing chemical libraries (Huang et al., 
2013; Gampe et al., 2013). Motivated by the success of the development process, we 
attempted to harness the newly established assay into high-throughput screening and 
identify hit compounds for future development.   
 
 
5.2  Experimental aims 
 
• To optimise the TR-FRET transglycosylation assay for use as a high-
throughput method 
• To screen a chemical library for small molecule transglycosylation 
inhibitors 
• To select hit compounds for further validation and development  
 
 
5.3  TR-FRET TG assay in a high throughput set-up  
 
 
5.3.1 CMCB high-throughput facility  
 
The work presented in this chapter was carried out mostly in the laboratories of the 
Centre for Microbial Chemical Biology (CMCB) at McMaster University in 
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Hamilton, Canada, where the chemical library and high-throughput facility could be 
accessed. Equipment set up, library screening and data processing were supported by 
the CMCB employees, Tracey Campbell, Cecilia Murphy and Fazmin Nizam. 
 
The assay was previously optimised for use with 384 and 1536-well microplates at 10 
and 5 µl total reaction volume respectively. Given the limited amount of available 
biotinylated DAP-lipid II, the latter format would allow screening twice as many 
compounds. This endeavour, however, proved to be unfeasible due to equipment 
limitations. Dispensing of the tested compounds into assay plates for the high 
throughput screening was planned to be carried out using the Biomek FXP liquid 
handling automation workstation (Beckman-Coulter). The device was compatible 
with microplates only up to 384 wells.  
 
 
5.3.2 Optimal duration of the TG step 
 
Similarly to the D-alanine release transpeptidation assay described in chapter 3, the 
TR-FRET transglycosylation assay was intended to be used as a single read 
screening method. To find the optimal readout time, three measures were taken into 
account: data noise over time, signal to background ratio and the reaction progress 
curve. 
 
Since the transglycosylation reaction cannot be initiated in all wells at the same time 
due to delays in reagents dispensing, well-to-well data variability must be expected. 
In an experiment where 152 wells were monitored, variation coefficient was shown 
to be particularly high (>15%) in the early stage of the reaction, but it stabilised at 
the level of approximately 5% after 30 minutes (Figure 5.2). 
 
To spot any potential diminution of activity, ideally, the reaction should be measured 
or stopped before reaching the steady state. As observed before, even at extended 
incubation time, HTRF signal curve seldom reached a plateau. Due to its shape, it is 
also difficult to define an interval of the initial reaction rate (Figure 5.1). 40 minutes 
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incubation time was found to be optimal as it provided a 10.5-fold signal to 
background ratio and a variation coefficient of 4.83%. 
 
 
 
 
Figure 5.1: Time dependency of the TR-FRET signal in the transglycosylation assay. Data points 
represent mean values of 16 replicates. Error bars show standard deviations. 10 µL reaction was 
carried out in the following conditions: 50 nM E. coli PBP1b, 100 nM E. coli LpoB, 1 µM biotin-
DAP-lipid II, 1x HTRF labelling mixture (Terbium), 50 mM Bis-Tris propane pH 8.5, 10 mM 
MgCl2, 20 mM NaCl, 0.03% (v/v) Triton X-100, 1% (v/v) glycerol. Negative control samples 
contained 10 µM moenomycin. The reaction was incubated for 90 min at room temperature. 
 
 
 
 
Figure 5.2: A relation between incubation time and variation coefficient. Data points show variation 
coefficient calculated based on 152 replicates of the positive control (uninhibited reaction). 10 µL 
reaction was carried out in the following conditions: 50 nM E. coli PBP1b, 100 nM E. coli LpoB, 1 
µM biotin-DAP-lipid II, 1x HTRF labelling mixture (Terbium), 50 mM Bis-Tris propane pH 8.5, 
10 mM MgCl2, 20 mM NaCl, 0.03% (v/v) Triton X-100, 1% (v/v)  glycerol. Negative control 
samples contained 10 µM moenomycin. The reaction was incubated for 90 min at room temperature. 
 
 
5.3.3 Compounds transfer method 
 
Additionally, due to the relatively low total assay volume, compound handling 
proved to be difficult. The robot was capable of transferring liquids from stock plates 
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to the assay plates in two ways, either with disposable tips on an eight-channel rail or 
using the slotted pin tool that could transfer 320 compounds at once. Favourable 
time- and cost-efficiency decided on choosing the pin tool as a transfer method. 
Figure 5.3 A shows exemplary pins used for liquid transfer. 
 
For this protocol 200 nL-slot, retractable pins were used. They were arranged into 
the 320-positions array matching 20 central columns of a standard 384-well plate. 
This dosing method relies solely on the surface tension of the transferred liquid, and 
specific volume depends on pins dipping depth. Several transfer protocols were 
tested to find settings with the most reproducible results. Optimal settings were 
shown in table 5.1. 
 
Using DMSO-solubilised fluorescein isothiocyanate (FITC), a standard curve was 
prepared, and an average pin transfer volume was found to be 303.99± 31.38 nL (see 
Figure 5.3 B). Adding this amount of 1 mM stock of chemical compounds into the 
10 µl reaction would result in the final screening concentration of 29.5 µM or 
between 26.5 and 32.4 µM including the error. To ensure complete transfer of 
compounds, destination wells should be prefilled with liquid. This requirement 
determined reagent handling and assay assembly.  
 
 
 
Figure 5.3:A:  Examples of liquid transfer pins and B: determination of the pin tool transfer volume. 
Figure A copyright: V&P Scientific. Figure B: Data points show average values and error bars show 
standard deviations. The standard curve prepared by dispensing different volumes of 10 mM FITC 
solutions with BioRaptor dispenser (Beckman-Coulter) into 10 µl H2O, n=6. Pin tool transfer carried 
out as described in table 5.1. Fluorescence intensity measured with EnVision 5103 plate reader 
(Perkin Elmer). 
 
 
0
10
0
20
0
30
0
40
0
50
0
60
0
0
1×106
2×106
3×106
4×106
FITC added volume (nL)
FI
Standard curve
Pin-tool average
A B
 115 
 Source plate Destination plate 
Cycles 3 3 
Depth well bottom well bottom 
Move down speed 20% 20% 20% 20% 
Move up speed 20% 20% 20% 20% 
Pause 10s 5s 
 
Table 5.1: Optimal settings of the Biomek FXP robot for compounds transfer using the slotted pin 
tool.  
 
 
5.3.4 DMSO tolerance 
 
E. coli PBP 1b was originally intended to be tested against 10 µM compounds.  
Selection of the pin tool as a compound transfer method forced an almost threefold 
increase in that concentration. Additionally, it introduced nearly 3% (v/v) DMSO 
into the reaction mix. To establish DMSO effect on the assay, it has been added to 
the reaction mix at a concentration ranging from 0 to 10% (v/v). 
 
The presence of DMSO significantly increased the TR-FRET signal magnitude in 
both positive and negative control samples. Up to 4%, however, this had no adverse 
effect on the Z-factor of the assay. At 6% and higher DMSO concentrations, a 
signal magnitude of the negative control was disproportionately elevated which 
caused a dramatic reduction of the Z-factor (see figure 5.4 C).  
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Figure 5.4: Dimethyl sulfoxide effect on the assay quality. A: Transglycosylation assay at 2% (v/v) 
DMSO; B:  Transglycosylation assay at 6% (v/v) DMSO; C: Z-factor of the assay at different 
DMSO concentrations.  A and B: Data points represent mean values of 16 replicates. C: Z-factor for 
16 replicates of positive and negative control samples. 10 µL reaction was carried out in the following 
conditions: 50 nM E. coli PBP1b, 100 nM E. coli LpoB, 1 µM biotin-DAP-lipid II, 1x HTRF 
labelling mixture (Terbium), 50 mM Bis-Tris propane pH 8.5, 10 mM MgCl2, 20 mM NaCl, 0.03% 
(v/v) Triton X-100, 1% (v/v) glycerol. Negative control samples contained 10 µM moenomycin. The 
reaction was incubated for 90 min at room temperature. 
 
 
5.3.5 Final assay format and workflow 
 
Optimisation experiments and available facilities influenced the final shape of the 
high throughput protocol. For screening purposes, the procedure began with 
dispensing control reagents. Each assay plate contained 64 control wells of two kinds 
arranged as shown in figure 5.5. 300 nL of moenomycin (DMSO solution) and 
DMSO were added to the control wells using the BioRaptr bulk dispenser 
(Beckman-Coulter). 
 
The same device was used in the next step, to dispense 8.5 µL of a mix of all TG 
reagents (see table 5.2) apart from the biotinylated lipid II-DAP. Then the assay 
plate could be transferred onto the Biomek robotic platform where tested 
compounds were added using the slotted pin tool. During the compounds transfer 
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procedure, the pin tool was washed in 70% (v/v) ethanol and dried on a blotting 
paper before and after each plate to avoid cross-contaminations.Reagents were mixed 
by plate agitation and incubated for 30 minutes at room temperature. After this step, 
transglycosylation was initiated by the addition of 1.5 µL of the biotinylated lipid II-
DAP solution. This was carried out with a bulk liquid dispenser. Plates were then 
incubated for further 40 minutes at room temparetaure and transferred into the 
Envision 5103 (Perkin-Elmer) plate reader to measure the HTRF-specific FRET 
signal in a time-resolved manner.  
 
 
 
Figure 5.5: Standard plate layout for the TR-FRET transglycosylation screen. For validation and 
screening purposes, control samples were located in columns 1, 2, 23 and 24. Green fields indicate the 
position of positive control wells- assay reagents in the presence of 3% (v/v) DMSO- compound 
vehicle. Red fields indicate negative control wells- assay reagents in the presence of 10 µM 
moenomycin and 3% (v/v) DMSO. 
 
 
Reagent Final concentration 
Bis-Tris propane pH 8.5 50 mM 
NaCl 20 mM 
MgCl2 10 mM 
Triton X-100 0.03% (v/v) 
Glycerol 1% (v/v) 
HTRF donor (Tb2+ cryptate) 1.33 nM (1x working solution) 
HTRF acceptor approx. 83.5 nM (1x working solution) 
E. coli PBP1b 50 nM 
E. coli LpoB 100 nM 
Tested compounds 29.5 µM 
Biotinylated lipid II-DAP* 1 µM 
 
 
Table 5.2: Composition of the HTRF transglycosylation assay. *Biotinylated lipid II-DAP added as 
the last reagent. 
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5.3.6 TR-FRET HTS transglycosylation assay data reproducibility 
 
To evaluate the reproducibility of the full high throughput protocol two sets of 320 
compounds were tested on two independent occasions following the instruction 
described in section 5.3.5. Collected data were compared in two ways. Raw HTRF 
ratios of each compound were used to generate replica plots (figure 5.6 A and B). 
Then Z-scores were calculated using equation 3.3. The difference between Z-scores 
observed on two occasions were plotted against their average value which was 
depicted on a Bland-Altman plot (figure 5.6 C and D). 
 
Data showed very good agreement between replicates. Bland-Altman analysis 
revealed 11 and 12 compounds outside the 95% confidence interval in set 1 and 2 
respectively, which constitutes for 3.4 and 3.7%. Median Z-score difference was 
0.081 and 0.085. High reproducibility justified single-point screening of the 
chemical library.  
 
 
 
Figure 5.6: Assay reproducibility of the 10 µL TR-FRET transglycosylation assay. Two sets of 320 
chemicals compounds were tested on two independent occasions. Upper panels are replica plots of 
raw HTRF signal observed for set 1 (A) and 2 (B). Lower panels show Bland-Altman plots of 
normalised effect (Z-score) of tested compounds for set 1 (C) and 2 (D). Data points indicate 
differences between Z-scores obtained on two occasions. Ideally, all data points should lay within the 
confidence interval marked by dashed lines 
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5.4  High-throughput screening  
 
 
5.4.1 Screening library composition 
 
Compound collection available at CMCB included over 400,000 positions. Reagent 
limitations allowed to test up to 30,000 of them. To ensure a good diversity level of 
tested chemicals, a screening library was designed to include the following subsets: 
 
• Bacillus subtillis whole-cell actives- 3,003 
 A set of drug-like compounds selected from the collection of the Ontario 
 Institute for Cancer Research. These chemicals were identified as growth 
 inhibitors of anengineered Bacillus subtillis strain in the 2014 study (Czarny et 
 al., 2014). 
 
• Bioactive compounds- 4,160 
The most structurally diverse subset including some FDA-approved 
medicines, natural products and chemotherapeutic agents. These substances 
are considered membrane-permeable. For most of them, bioactivity and 
safety  data are available in the literature. 
 
• Drug-like diverse compounds- 21,440 
 Canadian Compound Collection. A set of drug-like compounds supplied by 
 Maybridge and ChemBridge offering a high level of chemical diversity and 
 meeting Lipinski criteria of molecular weight ≤ 500 Da, ≤ 8 rotatable
 bonds, ≤ 10 hydrogen bond acceptors and ≤ 5 hydrogen bond donors 
 (Lipinski et al., 1997). 
 
• Natural extracts- 240 
A collection of cellular extracts of 80 unidentified species of Streptomyces 
bacteria grown in three different conditions. As the stock concentration of 
such complex mixture cannot be defined, extracts were added at the same 
volume ratio as other  tested agents: 300 nL into a 10 µL reaction mix.  
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5.4.2 Library screening and data processing 
 
The library was then organised into batches of 3,200 compounds (10 assay plates) 
and screened at the throughput of 1,800 compounds per hour. Z-factor was then 
calculated for each assay plate using the equation 3.1. The average Z-factor for the 
full primary screening was 0.82± 0.054, and it was in the range between 0.61 and 
0.90. 
 
In the next step, inhibitory effect on the HTRF signal magnitude was estimated in 
two ways. Residual activity was calculated using the equation 3.2 and presented as a 
percent effect. Equation 3.3 was used to calculate also the Z-score of all tested 
compounds. These data were then presented as plate heat maps and plots for an ease 
of visual hit identification (see figure 5.7). 
 
 
 
Figure 5.7: Examples of screening data visualised for a single test plate. Normalised activity in 
presence of individual compounds was presented in a form of a heat map and on a plot. Green fields 
on the heat map allow to easily identify potential inhibitors. Courtesy of Fazmin Nizam. 
 
 
5.4.3 Hit selection criteria and screening results 
 
After establishing the effect that each compound had on transglycosylation in assay 
conditions, hit selection criteria were determined. To account for variability between 
screening batches, two conditions had to be met to consider compound a primary 
hit: percent effect of -40% or lower and Z-score of -4 or lower. 346 compounds and 
4 natural extracts met these requirements which gave an overall hit rate of 1.21%. 
Detailed hits breakdown was presented in table 5.3. 
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Class Number of tested compounds Number of hits Hit ratio 
Bioactive compounds 4160 104 2.50% 
Bacillus subtillis whole-cell 
actives 3003 87 2.90% 
Drug-like diverse compounds 21440 155 0.72% 
Natural extracts 240 4 1.67% 
Overall 28843 350 1.21% 
 
Table 5.3: Summary of primary screening results. 
 
 
Interestingly, the hit list of the bioactive compounds subset included vancomycin 
and teicoplanin, two glycopeptide antibiotics binding D-alanine-D-alanyl group of 
lipid II, and biotin which presumably inhibited the reaction by disabling 
peptidoglycan labelling with streptavidin-fluorophore conjugates.  
 
 
5.4.4 Dose response profile 
 
Following the primary screening, all 346 hit compounds were tested for their half 
inhibitory activity (IC50). Primary hits were cherry-picked, and intermediate 
compounds plates were prepared. Each assay plate included dilution series of 
moenomycin for control purposes. The experiment was designed to generate a 9-
point dose response curve. Essentially, primary hits were tested in the range between 
29.5 µM and 3 nM. The experiment followed the usual assay protocol used 
previously for screening. Obtained data were then analysed with GraphPad Prism to 
generate response curves (variable slope-four parameters model) and derive IC50 
values.  
 
Vancomycin and teicoplanin showed IC50s of 4.48 and 3.64 µM respectively. Biotin 
turned out to be the most potent of all primary hits with the half inhibitory 
concentration of 52 nM. Dose-response curves could not be obtained for all of the 
tested compounds. Some of the hits did not confirm their percent effect observed in 
the primary screening and showed only a low level of inhibition leading to a shallow 
curve (figure 5.8 B). For some other compounds, the curve could not be converged 
due to poor fit (figure 5.8 C).  
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Figure 5.8: Examples of dose response curves obtained for primary hits revealed with the TR-FRET 
transglycosylation assay. Figures show curves of good (A) and poor (B and C) fit. 
 
 
5.4.5 Hits selection process 
 
 In 2010, Baell and Holloway identified some chemical substructures of screening 
compounds associated with their promiscuity (Baell & Holloway, 2010). They 
demonstrated that substances containing certain chemical groups are identified as 
hits in numerous unrelated biochemical screens. These authors coined the term of 
pan assay interference compounds and the PAINS acronym. Since the publication, 
substructure filters excluding these problematic compounds are commonly used in 
medicinal chemistry, and the original paper was cited over 900 times. Nonetheless, 
many medicines, including established or late-stage clinical trials antibiotics contain 
undesirable chemical functional groups and would not pass substructure filters 
mentioned above  (Blaskovich et al., 2017). 
 
PAINS filters were applied to reveal potentially promiscuous compounds from the 
list of primary hits. An online tool developed by Jeremy Young at the University of 
New Mexico (http://pasilla.health.unm.edu/tomcat/biocomp/smartsfilter) was used 
to facilitate this process. 69 hits were identified as pan interference compounds and 
excluded from further other tested. Remarkably, 45 of identified PAINS originated 
from the ‘bioactives' subset of screening library which was 43.3% of all hits from that 
collection.  
 
Another criterion in selecting copmounds was their dose response profile. As 
mentioned in the previous paragraph, not all tested agents demonstrated clear dose-
dependent effect on the transglycosylation outcome. Hits with an insufficient 
A CB
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inhibitory effect, an unusual dose-response curve as well as those for which the curve 
could not be converged were excluded.  
 
The hits were then ranked accordingly to their half inhibitory values and top 30 were 
selected for further studies. Since seven of these compounds could not be easily 
sourced from vendors, the final list included 23 substances, shown in figure 5.9. 
 
 
 
 
Figure 5.9: Structures of TR-FRET transglycosylation assay primary hits selected for future study. 
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5.4.6 Characteristics of putative transglycosylation inhibitors 
 
At the stage of compounds selection, data were analysed and managed using 
DataWarrior free software (Openmolecules.org). It was also used to calculate key 
physicochemical properties of the molecules that were listed in the table 5.4. Their 
calculated partition coefficient (cLogP) and polar surface area were compared with 
the remaining compounds of the subsets that these hits originated from, OICR and 
CCC, and presented on plots (Figure 5.10). The analysis implied that screening 
favoured more lipophilic compounds (higher cLogP).  
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MTI_1 15.04 348.41 3.57 7 3 105.29 0.39 OICR 
MTI_2 6.63 392.43 3.72 6 2 122.80 3.12 OICR 
MTI_3 8.63 429.48 4.04 5 0 110.03 -8.05 CCC 
MTI_4 9.10 388.36 4.36 4 0 91.22 -9.06 CCC 
MTI_5 9.16 265.27 2.99 5 1 89.00 -5.44 CCC 
MTI_6 9.53 421.29 4.37 5 0 84.27 -4.60 CCC 
MTI_7 8.29 325.21 3.83 4 1 86.90 -4.85 CCC 
MTI_8 9.38 361.42 4.48 5 1 84.51 1.58 CCC 
MTI_9 8.18 402.44 4.74 3 1 60.58 -1.90 CCC 
MTI_10 11.56 364.48 5.15 3 1 97.94 6.23 CCC 
MTI_11 13.60 323.19 4.88 3 1 70.23 2.97 CCC 
MTI_12 13.19 212.20 3.02 3 1 46.53 -1.08 CCC 
MTI_13 9.51 492.02 5.31 5 0 146.15 -11.95 CCC 
MTI_14 12.49 321.84 3.70 3 0 93.46 -0.97 CCC 
MTI_15 11.64 282.36 3.07 3 0 71.47 0.86 CCC 
MTI_16 23.37 283.30 0.13 6 1 90.08 -6.88 CCC 
MTI_17 40.10 352.33 4.42 4 1 83.37 -4.87 CCC 
MTI_18 7.53 286.41 3.96 2 0 90.22 -8.07 CCC 
MTI_19 12.35 315.55 3.00 4 1 55.13 0.08 OICR 
MTI_20 12.34 370.43 1.96 7 4 131.42 3.15 OICR 
MTI_21 16.41 316.16 3.50 4 2 57.78 -0.08 OICR 
MTI_22 10.24 243.69 2.83 3 2 54.70 -0.10 OICR 
MTI_23 40.18 437.89 3.95 7 1 119.17 0.56 OICR 
 
Table 5.4: Key physicochemical properties and potency of putative transglycosylation inhibitors 
identified with the TR-FRET assay. Hydrophilicity, polar surface area and druglikeness calculated 
with DataWarrior (Openmolecules.org). IC50 reported in µM. Polar surface area reported in Å2. 
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Figure 5.10: Comparison of physicochemical properties of putative transglycosylation inhibitors and 
remaining compounds of the screening library. Plots show distribution of molecular weight in 
relation to computed partition coefficient (plot A) and polar surface area (plot B). 
 
 
5.4.7 Testing dose response of repurchased compounds 
 
23 selected compounds were purchased for further testing from three suppliers: 
Maybridge, Enamine and Vitas Labs. They were then solubilised in DMSO and 
tested in a dose response mode against E. coli and Y. pestis PBP1b. Seven two-fold 
dilutions were prepared to obtain final compounds concentration between 40 µM 
and 625 nM. As the compounds were added by manual pipetting, assay volume was 
increased to 20 µL to maintain dosing accuracy. 
 
 
 
E. coli PBP1b Y. pestis PBP1b 
MTI_1 20.89 ~ 23.03 
MTI_2 6.538 ND 
MTI_3 ~ 11.12 ~ 11 
MTI_5 12.26 ND 
MTI_7 13.55 ND 
MTI_13 21.01 18.47 
MTI_14 9.084 17.25 
MTI_17 20.09 ND 
MTI_18 15.26 ND 
MTI_23 12.13 12.11 
 
Table 5.5: Half inhibitory concentrations (µM) of repurchased putative transglycosyaltion inhibitors.  
20 µL reaction was performed in triplicates in the following conditions: 50 nM  PBP1b, 100 nM  
LpoB, 1 µM biotin-DAP-lipid II, 1x HTRF labelling mixture (Terbium), 50 mM Bis-Tris propane 
pH 8.5, 10 mM MgCl2, 20 mM NaCl, 0.03% (v/v) Triton X-100, 1% (v/v)  glycerol. Compounds 
were pre-incubated with enzymes for 30 minutes, and the reaction was initiated by the substrate 
addition. HTRF ratio was measured after 40 minutes incubation and normalised against positive 
control to determine relative activity. ‘~’ symbol indicates compounds of ambiguous curve fit. 
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From all 23 compounds tested against E .coli PBP1b, only 10 confirmed their 
inhibitory properties. Five of them demonstrated activity also against the Y. pestis 
homologue. Their half inhibitory values were presented in table 5.5. 
 
To investigate lack of activity of 13 primary hits, all purchased compounds were 
tested to confirm their chemical identity and assess purity. With the aid of LC-MS, 
all compounds were detected with right molecular weight and molecular formula. 
The analysis was carried out by Dr Lijiang Song. 
 
 
5.5 Discussion 
 
 
5.5.1 Amenability of the TR-FRET method to the HTS set-up 
 
In the work presented here, we have harnessed the capacity of the newly developed 
TR-FRET assay to identification of the chemical matter inhibiting 
transglycosylation in vitro. The method showed very good dynamic range and data 
reproducibility. Although it could not be used at its full capacity due to technical 
limitations, the assay was optimised to reach throughput of 1,800 compounds an 
hour. 
 
A primary screen of nearly 29,000 chemical agents revealed 350 hits from which 23 
were picked for further studies. Among hits emerging from the collection of 
bioactive substances were vancomycin, teicoplanin and biotin which confirmed assay 
sensitivity to lipid II binders but also highlighted one possible mechanism of false 
positive hits. 
 
The HTS protocol would benefit from several changes. If tested compounds could 
be dispensed into empty assay plates, the screening method would resemble the 
original experimental design more closely. Using a pin tool to transfer compounds 
was also more liable to error caused by technical intricacies like source plate 
curvature. Application of acoustic dispensing, similarly to the screening campaign 
described in chapter 3, would very likely diminish observed dosing variability. It 
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would also allow to employ 1536-well assay plates and reach the maximal 
throughput.  
 
 
5.5.2 Characteristics of the selected hits 
 
A landmark study by Lipinski and colleagues (Lipinski et al., 1997) explored a 
correlation between drugs physicochemical properties and their oral availability in 
humans. Their research led to defining a physicochemical property space that 
theoretically enhances drug-likeness of new lead compounds. The findings, as a set 
of rules, have been broadly implemented into medicinal chemistry and design of new 
chemical collections. Antibacterials, unlike drugs used in other therapeutic areas, do 
not generally follow Lipinski rules as they are on average a bit larger and more 
hydrophilic (O’Shea & Moser; 2007; Brown et al., 2014; Tommasi et al., 2015). 
Modern libraries of synthetic compounds are often biased towards Lipinski-like 
molecules, and this has been emphasised as one of the challenges in discovery of new 
antibiotics (Payne et al., 2007). 
 
Properties of 23 compounds identified as putative inhibitors of transglycosylation 
were compared with 147 antibacterially active compounds, as selected by O’Shea and 
Moser in their study (see Appendix 2). Figure 5.11 A presents molecular weights 
and cLogP values for these two groups of chemicals. Selected TG hits were generally 
more lipophilic than established antibacterials, with only two compounds with 
cLogP lower than two. Unfortunately, two most hydrophilic TG hits, compounds 16 
and 20, did not confirm their activity upon repurchasing. The bias towards more 
lipophilic molecules implies that selected hits might not be very effective in whole-
cell assays, especially against Gram-negative bacteria species. 
 
As observed by O’Shea and Moser and illustrated in figure 5.11 B, the polar surface 
area of almost all antibacterials exceeds 70 Å2. All but four of putative TG inhibitors 
met this condition.  Although computed partition coefficient (cLogP) might give an 
indication on passive permeability across bacterial membranes, a distribution 
coefficient (cLogD) could be more informative as it takes into account compound 
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acidity constant (pKa) usually at a physiological pH of 7.4. It cannot be omitted that 
antibacterial agents are often subject to active efflux and a real effect can only be 
established experimentally.  
 
 
 
 
Figure 5.11: Comparison of physicochemical properties of putative transglycosylation inhibitors and 
established antibacterial agents. Plots show distribution of molecular weight in relation to computed 
partition coefficient (plot A) and polar surface area (plot B).  
 
 
5.5.3 Disparity in anti-TG activity between original and repurchased compounds 
 
Remarkably, only 10 out of 23 tested primary hits confirmed their inhibitory 
properties after a fresh batch was purchased from commercial vendors. LC-MS 
analysis confirmed chemical identity of the products. Unfortunately, it could not be 
done for the corresponding samples of the original library based at McMaster 
University. In the light of a lack of evidence, it can only be cautiously hypothesised 
that the disparity was caused by impurities in the initial screening set. 
 
As indicated in the literature and by chemical libraries providers, chemical 
compounds stored in DMSO have limited stability (Darvas et al., 2005; Blaxill et al., 
2009). This is an effect of hydrolysis, precipitation or both. It is additionally 
accelerated by freeze-thaw cycles. In extreme cases, 27.5% of compounds was 
reported to decompose in 25 freeze-thaw cycles (Kozikowski et al., 2003). Given that 
CMCB compound collections at the time of screening were several years old 
(dissolved between 2006 and 2011, current screening sets in use since between 2011 
and 2014), it cannot be excluded that observed inhibition was caused by hydrolysis 
products rather than intact molecules and thus could not be replicated upon 
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repurchasing of fresh compounds. Another possibility is a compound carry-over that 
is also observed in HTS practice (Matson et al., 2009). Although the pin tool used 
for compound administration was carefully washed between transfer cycles, it could 
potentially cross-contaminate the samples and skew the screening outcome.  
 
 
5.6  Future work 
 
 
5.6.1 Confirmatory experiments design 
 
Confirmation of the anti-TG activity of selected hits requires orthogonal assays. 
Although several biochemical methods have been described in the literature in recent 
years (Schwartz et al., 2002; Huang et al., 2013; King et al., 2017), we propose to test 
identified hit compounds with the aid of mass spectrometry. Each round of 
transglycosylation leads to the liberation of the lipidic tail from the monomeric 
substrate (see paragraph 1.2.3.). As demonstrated by Melesh and colleagues, (Mesleh 
et al., 2016) release of undecaprenyl pyrophosphate (C55PP) can be detected upon 
solid phase extraction. Authors used a high throughput mass spectrometry system 
yet even in the absence of HT equipment, the method seems feasible for tens of 
compounds. Most importantly it provides a definitive evidence for inhibition of 
transglycosylation.  
 
 
5.6.2 Antimicrobial potency testing 
 
If confirmed, identified TG inhibitors should be tested for their antibacterial 
properties. This can be achieved by whole-cell viability assays. Since the screening 
method was developed around E. coli PBP1b, this organism should be investigated in 
the first place. PBP1b, however, is not the only protein capable of peptidoglycan 
transglycosylation in E. coli and loss of its activity can be complemented by PBP1a 
and possibly by the monofunctional transglycosylase MGT. In case of compounds 
targeting specifically PBP1b, it might be required to use PBP1a and MGT mutant 
strains to see growth inhibition. 
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A common challenge in discovery of new antimicrobial compounds, especially 
against Gram-negative species, is their permeability across the cell envelope. 
Inhibitors identified in target-based approaches often poorly accumulates in the 
cytoplasm or periplasm either due to their low permeability or efflux. Demonstrating 
cellular effects of putative antibiotics might require using bacteria strains of higher 
permeability or lower activity of efflux pumps in addition to wild-type models. 
Putative TG inhibitors could be tested against E. coli strains of higher outer 
membrane permeability (e.g. N43, D22) or deficient in efflux pumps (e.g. ΔTolC).  
 
 
5.6.3 Elucidation of the inhibition mode 
 
The assay in the presented form should theoretically be sensitive to substances of 
three distinct modes of inhibition. As demonstrated previously by examples of model 
inhibitors (see paragraph 4.10), moenomycin and some lipid II-binding natural 
products, TG activity of PBP1b can be impeded by either obstruction of the enzyme 
catalytic site or substrate sequestration. Additionally, at current experimental 
conditions, enzymatic activity is strongly dependent on the PBP1b-LpoB 
interaction. This condition constitutes the third potential mode of inhibition. 
Substances interfering with the binding interface of either protein partner might be 
identified as hit compounds. This mechanism of inhibition has not been reported to 
date. 
 
Given the overlapping character of potential inhibition modes of TR-FRET 
transglycosylation assay and D-alanine release assay, a similar strategy can be applied 
to investigate mechanisms of inhibition, as described in the paragraph 3.8.2. This 
potentially includes moenomycin displacement assay to confirm direct interaction 
with the transglycosylase catalytic site and employment of cofactor-bypass mutant of 
PBP1b to identify molecules impeding LpoB binding. 
 
Additionally, lipid II binding by selected hits could be investigated with the aid of 
biophysical techniques like surface plasmon resonance (SPR) or bio-layer 
interferometry (BLI). Given that the substrate used in this screening is readily 
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biotinylated, implementation of SPR or BLI protocols seems feasible. In fact, BLI as 
a method to study lipid II binding has been validated and described in chapter 4 of 
this thesis.  
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CHAPTER 6: General conclusions and future directions 
 
 
 
 
The introduction of antibacterial chemotherapy was one of the greatest achievements 
of medicine in the 20th century. Since the 1930s antibiotics saved countless lives and 
made complicated procedures more feasible, accelerating the progress in many other 
therapeutic areas. Pathogenic bacteria, once believed to be defeated, have eventually 
shown that the victory was transient. Inevitable resistance to antibiotics has become 
increasingly common over the years. The spread of resistant strains was further 
accelerated by the selective pressure of antibiotics, their misuse and overuse. Currently, 
multidrug-resistant pathogens pose a major threat to health care, but also to the global 
economy. 
 
Initial successes in antibiotic discovery were followed by the 40-years innovation gap 
that has contributed to the severity of the problem. Lack of novel scaffolds in the 
development pipelines resulted in a situation where there are no antibiotics without 
reported cases of resistance. Successful development of an antibiotic from a lead 
compound is highly unlikely, therefore there is a high demand for a novel chemical 
matter, especially targeting well-validated and conserved targets. As research and 
development of antimicrobials is commercially less attractive than other classes of 
medicines, academics and not-for-profit research organisations need to take the 
initiative in finding solutions to AMR. 
 
 
6.1 The need for novel inhibitors of cell wall synthesis 
 
Enzymes involved in the final steps of cell wall synthesis are targets for some of the 
most successful and popular antibiotics. Although studied for decades, the biology of 
penicillin-binding proteins is not yet fully understood. β-lactams, that are known for 
almost 90 years, are nature-derived inhibitors of transpeptidases and remain the only 
class of direct PBPs inhibitors in clinical use. Recent advancements help to elucidate 
mechanisms of PBPs activity, regulation and inhibition. We aimed at employing this 
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knowledge to deliver methods facilitating discovery of new chemical matter inhibiting 
penicillin-binding proteins in vitro. In order to do so, we developed two functional, 
biochemical assays with the intention to employ them into the high-throughput 
screening.   
 
 
6.2 Development of target-based drug screening methods 
 
Chapter 3 of this thesis described a novel method to monitor peptidoglycan 
transpeptidation carried out by E. coli PBP1b in the presence of its inherent cofactor, 
lipoprotein B. The assay developed by Dr Adrian Lloyd takes advantage of D-alanine 
release as a consequence of transpeptidation. Originally designed as a 
spectrophotometric method, it has been adapted for use as a fluorescence-based assay. 
This change has made it possible to miniaturise it while maintaining high dynamic 
range required for the development of a robust high-throughput screening assay. 
During the development, the assay was thoroughly validated, and sensitivity to known 
pharmacology was demonstrated. A 133-fold reduction in assay volume made the 
method highly time- and cost-efficient. The major factor that made the assay 
practicable in this set-up was the inclusion of LpoB. It not only enhanced enzymatic 
activity, allowing to work at low enzyme concentration but also made it possible to 
exploit an additional mode of action of potential inhibitors.  
 
Over 122,000 of drug-like compounds were eventually tested against the D-alanine 
release assay. The original hit rate of 1.97% got reduced to 0.32% upon chemical triage 
of 2,402 primary hits. Chemical data generated in that screening is not available due 
to its commercial value, and it could not be analysed in this thesis. 
 
In chapter 4, another new assay for PBPs enzymatic activity was presented. Assay 
design required a single chemical modification of the lipid II substrate- the addition 
of biotin moiety to the position three amino acid of the stem pentapeptide. The 
substrate could be then labelled with streptavidin-conjugated dyes. Despite initial 
worries that the presence of streptavidin might hinder the enzyme, the assay principle 
was confirmed. This allowed tracking the progress of peptidoglycan polymerisation by 
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measuring FRET signal. The assay, although unsuitable for an in-depth 
characterisation of enzyme kinetics, provided a tool to assess the influence of different 
factors on transglycosylation rate. Unlike the D-alanine release assay, FRET assay did 
not detect transpeptidase activity of E. coli PBP1b. The method, in both discontinuous 
and continuous fashion, demonstrated excellent dynamic range offering a good 
prospect for the high-throughput screening. During the assay optimisation, several 
aspects of PBP1b regulation by LpoB were explored. Lipoprotein B was demonstrated 
to enhance transglycosylation rate and promote synthesis of short peptidoglycan 
polymers, as previously described in the literature. The assay was further validated by 
demonstrating the influence of known transglycosylation inhibitors. Interesting 
observations were made when assessing inhibitory properties of lipid II-binding 
natural products. Two of them, ramoplanin and teixobactin, were demonstrated to 
promote enzyme-independent FRET signal development suggesting that they form 
higher order structures in the presence of lipid II. 
 
Biotinylated lipid II, synthesised for the purpose of this assay was given two additional 
applications. It was demonstrated to work as a molecular bait in a biolayer 
interferometry assay allowing us to measure the enzyme-substrate affinity. Secondly, 
the original transglycosylation assay was turned into a method to monitor 
peptidoglycan hydrolysis. 
 
After the successful development and initial validation, the assay was optimised for 
high-throughput screening, and a collection of nearly 30,000 chemical compounds 
from the McMaster University collection was tested against it. The screening yielded 
350 active agents that were then analysed. Multi-step hit selection process and 
retesting reduced the number of putative transglycosylation inhibitors to 10. Based on 
analysis of computed biophysical properties of identified hits, it became apparent that 
the screen favoured compounds of higher lipophilicity. Although this observation 
might reflect the nature of the substrate and the enzyme, this might also indicate poor 
permeability of the hits across bacterial membranes. 
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Both optimisation and screening campaigns exposed common challenges of the high-
throughput screening. Although highly time- and cost-efficient, the HTS endeavour 
might be easily affected by malfunctioning or non-optimal equipment. Great care 
must be taken at every stage of the process. Similar remarks apply to chemical libraries. 
Identification of hits must always be followed by their careful analysis to rule out any 
artifactual effects. 
 
 
6.3  Future directions 
 
Both methods developed in this project were successfully brought to the stage of high-
throughput screening, and over 2,700 primary hits were identified, yet chemical 
formula of only 346 is known, and just 11 were selected for further work. These 
compounds await confirmation with the aid of orthogonal assays and evaluation of 
their antibacterial properties. Valuable hits could be then derivatised to study their 
structure-activity relationship. 
 
 Having both methods fully validated, it would be beneficial to screen another diverse 
chemical library with the D-alanine release assay, or both of them. As the primary 
assays are complimentary and orthogonal methods were devised, a screening platform 
could be designed, to facilitate discovery and confirmation of inhibitors as well as 
elucidation of their mechanism of action. 
 
To improve the chances of demonstrating a whole-cell effect, a focused library could 
be employed, including compounds of optimised diversity, fitting into property space 
characteristic for antimicrobials. Another interesting, focused library to test could be 
composed of peptides, peptidomimetic compounds or other putative protein-protein 
interaction inhibitors. This could allow investigating a possibility of the indirect 
mechanism of PBP1b inhibition by interfering with LpoB binding.  
 
An alternative approach could be taken where assays would be used to test chemical 
matter emerging from whole-cell viability experiments. Investigating the mode of 
action of whole-cell active, natural or synthetic, compounds is often a complex task. 
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With the aid of methods described here, agents affecting final steps of the cell wall 
assembly could be easily identified. 
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Appendix 1: Negative ion mass spectrometry of  UDP MurNAc DAP 
pentapeptide biotinylation products 
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B
Figure A1.1: Negative ion mass spectra of samples collected during anion exchange
purification of UDP MurNAc DAP pentapeptide biotinylation products. A: mass spectrum of
‘peak 1’ fraction identified as unconverted UDPMurNAc DAP pentapeptide; B: mass spectrum
of ‘peak2’ fraction identified as biotinylated UDPMurNAc DAP pentapeptide. Courtesy of Dr
Adrian Lloyd.
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Name clogD pH7.4ACD
clogP
ACD
MW
ACD
PSA
ACD, [Å2 ]
H-Donors
ACD
H-
Acceptors
ACD
ABT-492 -1.03 0.8 441 120 4 8
AMIKACIN -8.67 -3.3 586 332 17 18
AMOXICILLIN -2.73 0.6 365 158 5 8
AMPICILLIN -2 1.4 349 138 4 7
Arbekacin -10.43 -4.0 553 297 16 16
AZITHROMYCIN 1.4 3.3 749 180 5 14
AZLOCILLIN -4.06 -0.3 461 173 4 11
Aztreonam -5.47 -0.7 435 238 5 13
CARBENICILLIN -3.74 1.0 378 149 3 8
CEFACLOR -3.05 0.1 368 138 4 7
CEFADROXIL -3.92 -0.6 384 158 5 8
CEFAMANDOLE -2.19 1.5 463 201 3 11
CEFAZOLIN -2.58 1.1 455 235 2 12
CEFDINIR -4.34 -0.6 395 212 5 10
Cefditoren -2.29 1.5 507 242 4 11
Cefepime -1.07 -1.6 482 201 4 11
Cefetamet -2.5 1.2 397 201 4 10
Cefixime -3.78 1.0 453 238 5 12
CEFMETAZOLE -2.94 0.8 442 230 2 11
Cefoperazone -2.28 1.4 646 271 4 17
CEFOTAXIME -2.56 1.2 455 227 4 12
Cefotetan -3.03 1.7 546 312 5 14
CEFOXITIN -3.08 0.6 427 202 4 10
Cefpirome -1.5 -2.1 516 205 4 11
Cefpodoxime -2.8 0.9 427 210 4 11
Cefprozil -3.23 0.1 389 158 5 8
Ceftazidime -3.28 -2.8 548 242 5 13
CEFTIBUTEN -5.69 -1.0 410 216 5 10
Ceftizoxime -3.11 0.6 383 201 4 10
Ceftobiprole -5.86 -2.7 535 257 6 14
CEFTRIAXONE -4.14 -0.3 555 288 5 15
CEFUROXIME -2.91 0.8 424 199 4 12
CEPHALEXIN -2.67 0.7 347 138 4 7
CEPHALOTHIN -2.26 1.5 396 167 2 8
Cephradine -2.02 1.0 349 138 4 7
Cethromycin 4.51 5.2 766 163 2 13
CHLORAMPHENICOL 1.02 1.0 323 115 3 7
Chlorobiocin 2.52 5.3 697.13 186 5 13
CHLORTETRACYCLINE -3.56 -0.5 479 182 7 10
CIPROFLOXACIN -1.35 0.7 331 73 2 6
CLARITHROMYCIN 2.41 3.2 748 183 4 14
Clinafloxacin -1.25 1.0 366 87 3 6
CLINDAMYCIN 0.75 1.8 425 128 4 7
CLOXACILLIN -1.2 2.5 436 138 2 8
Appendix 2
Key biochemical properties of clinically approved antibiotics.
  Based on supplementary data of: O'Shea, R., & Moser, H. E. (2008). Physicochemical properties of antibacterial 
compounds: Implications for drug discovery. Journal of Medicinal Chemistry, 51(10), 2871–2878. 
http://doi.org/10.1021/jm700967e
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CLOXACILLIN -1.2 2.5 436 138 2 8
Name clogD pH7.4ACD
clogP
ACD
MW
ACD
PSA
ACD, [Å2 ]
H-Donors
ACD
H-
Acceptors
ACD
Dalbavancin -0.0261 2.8 1823 569 22 37
Dalfopristin -2.32 -0.8 691 185 2 13
Danofloxacin -0.94 1.2 357 64 1 6
Daptomycin -10.08 -5.1 1706 764 29 46
DEMECLOCYCLINE -4.1 -1.1 465 182 7 10
Dibekacin -8.66 -3.2 452 248 14 13
DICLOXACILLIN -0.71 3.0 470 138 2 8
Difloxacin 1.22 2.8 399 64 1 6
Dirithromycin 1.99 2.8 835 196 5 16
Doripenem -6.16 -3.7 421 196 6 10
DOXYCYCLINE -3.48 -0.5 444 182 7 10
DX-619 -1.3 0.8 419 96 3 7
Enoxacin -1.26 0.6 320 86 2 7
EP-13420 2.21 2.9 841 206 2 17
Ertapenem -4.66 -1.1 476 182 5 10
ERYTHROMYCIN 2.08 2.8 734 194 5 14
Faropenem -5.21 -2.3 267 87 2 6
Fleroxacin -0.63 1.7 369 64 1 6
Fosfomycin -6.86 -3.0 138 80 2 4
FUSIDIC ACID 3.21 6.4 517 104 3 6
Garenoxacin -0.0632 2.3 426 79 2 6
GATIFLOXACIN -1.06 1.2 375 82 2 7
Gemifloxacin -2.09 0.4 389 121 3 9
GENTAMICIN -7.66 -1.9 478 200 11 12
Gramicidin -3.97 0.1 1141 325 12 22
Grepafloxacin -0.43 1.6 359 73 2 6
Iclaprim 1.99 2.2 354 106 4 7
Imipenem -5.28 -2.8 299 139 4 7
Isepamicin -7.19 -2.5 570 298 15 17
KANAMYCIN A -6.83 -2.6 485 283 15 15
LEVOFLOXACIN -1.41 0.8 361 73 1 7
LINCOMYCIN -0.2 0.9 407 148 5 8
Linezolid 0.29 0.3 337 71 1 7
Lomefloxacin -0.74 1.7 351 73 2 6
Loracarbef -4.4 -1.1 350 113 4 7
MECLOCYCLINE -3.1 0.0 477 182 7 10
Meropenem -5.68 -3.1 383 135 3 8
METHACYCLINE -3.66 -0.7 442 182 7 10
METHICILLIN -2.46 1.3 380 130 2 8
Mezlocillin -4.91 -1.2 540 207 3 13
MINOCYCLINE -3.47 -0.7 457 165 6 10
MOXIFLOXACIN -0.91 1.6 401 82 2 7
Nadifloxacin 0.17 2.0 360 81 2 6
NAFCILLIN -0.67 3.1 414 121 2 7
Nalidixic Acid -0.49 1.2 232 71 1 5
NEOMYCIN -9.91 -3.7 615 353 19 19
netilmicin -6.85 -1.9 476 200 11 12
NORFLOXACIN -1.62 0.8 319 73 2 6
Novobiocin 0.12 2.9 612.62 196 6 13
Oritavancin 0.62 4.1 1793 561 22 36
OXACILLIN -1.67 2.1 401 138 2 8
OXYTETRACYCLINE -4.5 -1.5 460 202 8 11
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OXYTETRACYCLINE -4.5 -1.5 460 202 8 11
Name clogD pH7.4ACD
clogP
ACD
MW
ACD
PSA
ACD, [Å2 ]
H-Donors
ACD
H-
Acceptors
ACD
Paromomycin -8.49 -3.3 616 347 18 19
pefloxacin -0.82 1.5 333 64 1 6
PENICILLIN G -2.06 1.7 334 112 2 6
PENICILLIN V -1.85 1.9 350 121 2 7
PIPERACILLIN -1.85 1.9 518 182 3 12
Polymyxin B1 -9.8 -2.9 1203 491 23 29
Pseudomonic acid A 0.85 3.4 501 146 4 9
PTK-0796 -2.22 0.4 557 177 7 11
Quinupristin -2.18 0.4 1022 257 4 19
R-115685 -8 -5.0 538 218 7 13
Ranbezolid 0.73 0.8 461 124 1 11
Rifalazil 0.31 3.6 941 226 5 17
RIFAMPIN -1.43 1.1 823 220 6 16
Roxithromycin 2.98 3.7 837 217 5 17
Rufloxacin -0.69 1.5 363 89 1 6
Sisomicin -7.57 -2.7 448 214 12 12
Sitafloxacin -1.37 0.9 410 87 3 6
Sparfloxacin -0.51 1.2 392 99 4 7
STREPTOMYCIN -6.6 -2.7 566 311 15 18
SULFABENZAMIDE -0.73 1.2 276 98 3 5
SULFACETAMIDE -2.51 -1.0 214 98 3 5
SULFACHLORPYRIDAZINE 0.15 1.0 285 106 3 6
SULFADIAZINE -0.66 -0.1 250 106 3 6
SULFADIMETHOXINE 0.32 1.5 310 125 3 8
SULFAGUANIDINE -1.22 -1.2 214 130 6 6
SULFAMERAZINE -0.00553 0.3 264 106 3 6
SULFAMETER 0.0483 0.4 280 116 3 7
SULFAMETHAZINE 0.59 0.8 278 106 3 6
SULFAMETHIZOLE -0.61 0.5 270 135 3 6
SULFAMETHOXAZOLE -0.2 0.9 253 107 3 6
SULFAMETHOXYPYRIDAZINE 0.11 0.3 280 116 3 7
SULFAMONOMETHOXINE -0.45 0.0 280 116 3 7
SULFANITRAN 2.75 3.0 335 129 2 8
SULFAPHENAZOLE 1.39 1.5 314 98 3 6
SULFAPYRIDINE -0.00914 0.0 249 93 3 5
SULFAQUINOXALINE -0.48 0.6 300 106 3 6
SULFATHIAZOLE -0.26 0.0 255 122 3 5
SULFISOXAZOLE -0.22 1.0 267 107 3 6
T-91825 -0.82 -1.3 606 284 4 13
Teicoplanin -2.68 0.4 1880 662 25 42
Telavancin -2.37 0.6 1756 608 24 38
TELITHROMYCIN 2.85 3.6 812 172 1 15
Temafloxacin 0.52 2.7 417 73 2 6
TETRACYCLINE -4.37 -1.5 444 182 7 10
Ticarcillin -4.06 0.7 384 178 3 8
Tigecycline -3.98 -1.3 586 206 8 13
TOBRAMYCIN -8.72 -3.4 468 268 15 14
Triclosan 5.03 5.2 290 29 1 2
TRIMETHOPRIM 0.58 0.8 290 106 4 7
Trovafloxacin -1.18 1.0 416 100 3 7
Vancomycin -4.52 -1.4 1449 530 21 33
